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bc1 de Plasmodium falciparum” 
Data: 2012-2016 
 
Apesar dos intensos esforços para controlo da malária, esta  doença parasítica  
milenar permanece como uma das doenças infeciosas conducentes a maiores taxas de 
mortalidade no mundo. É transmitida pela picada de um mosquito infectado do género 
Anopheles (apenas a fémea transmite a doença) e causada por um parasita do género 
Plasmodium. P. falciparum é a mais prevalente de entre as cinco estirpes de Plasmodium 
que afectam o homem e é também a mais mortal, sendo responsável por cerca de 90% do 
número total de óbitos por malária registados anualmente. Actualmente, a Organização 
Mundial de Saúde estima que cerca de 40% da população mundial está em risco de 
contrair a infecção e que, anualmente, cerca de 600 000 pessoas morrem devido a esta 
doença. O rápido desenvolvimento de resistência por parte de P. falciparum a pelo menos 
um dos fármacos antimaláricos convencionais de primeira linha e a terapias baseadas em 
artemisinina e seus derivados, estimula enormemente a comunidade científica e médica, 
convocando-a para a investigação e desenvolvimento de novos fármacos antimaláricos 
eficazes, seguros, acessíveis e fáceis de administrar, preferencialmente direcionados para 
novos alvos terapêuticos. 
A combinação farmacológica designada por Malarone® foi lançada pela 
GlaxoSmithKline para o tratamento e prevenção de malária causada por estirpes multi-
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resistentes. Este medicamento resulta da combinação de dois fármacos antimaláricos: 
atovaquona e proguanil. A atovaquona é um competidor da ubiquinona, inibindo 
especificamente o complexo bc1 de P. falciparum através da sua ligação ao sítio Qo deste 
complexo. O complexo bc1 é essencialmente responsável pela transferência de electrões 
e translocação de protões ao longo da membrana mitocondrial, formando um potencial de 
membrana. A sua inibição leva à perda da função mitocondrial (relevante para o 
fornecimento de intermediários para a síntese de ATP e pirimidina), colapso do potencial 
electroquímico transmembranar e, finalmente, morte do parasita, validando este 
complexo como um potencial novo alvo terapêutico para o desenvolvimento de novos 
fármacos. 
Além de ser o local de ação da atovaquona, o sítio Qo é também conhecido como 
o local de ação da estigmatelina (composto natural) e da endoquina (um dos primeiros 
antimaláricos sintéticos). A endoquina serviu como modelo para o desenvolvimento de 
análogos (ELQ) que mantiveram o núcleo quinolínico na sua estrutura. 
Além da sua potencial utilização na quimioterapia da malária, a versatilidade do 
quimiotipo quinolona tem atraído intensa investigação, originando principalmente 4-oxo-
quinolinas com propriedades farmacológicas melhoradas e com potencial aplicação 
terapêutica noutras áreas, como no tratamento de cancro, hepatite B, hepatite C, SIDA, 
herpes, infeções fúngicas ou tuberculose. A utilização das quinolonas como agentes 
antibacterianos teve início em 1963 com a descoberta do ácido nalidíxico. Muitos outros 
derivados quinolínicos com propriedades farmacológicas foram entretanto sintetizados, 
destacando-se as fluoroquinolonas norfloxacina, ciprofloxacina e levofloxacina. 
 Nos últimos anos têm surgidos publicações que reportam uma grande variedade 
de compostos 4-oxo-quinolínicos com grupos éster em posição 3 que demonstram 
atividade antimalárica em concentrações que se situam na gama nanomolar baixa, 
atuando por inibição do complexo bc1 plasmodial. No entanto, devido à existência de 
algumas fragilidades nestes compostos, de que se destacam a fraca solubilidade em meio 
aquoso e baixa biodisponibilidade oral, esta classe de compostos requer optimização. 
O projecto de investigação descrito nesta tese foca-se no desenho, síntese e estudo 
estrutural de uma biblioteca de novas 3-etiléster-4-oxo-quinolinas (quinolonas), 
introduzindo diversidade química, essencialmente, nas posições 6 e/ou 7 da quinolona. 
Estudos de docking realizados in silico no sítio Qo do complexo bc1 (de levedura 
- yeast) sugerem um papel importante dos resíduos His182 e Glu272 no reconhecimento 
de potentes inibidores. Os mesmos estudos também indicam a importância da presença 
  
xiii 
do grupo carbonilo e do grupo N-H do núcleo quinolónico na formação de ligações por 
pontes de hidrogénio com os resíduos proteícos His182 e Glu272, respectivamente. Deste 
modo, a possibilidade de tautomerismo entre as formas 4-oxo-quinolina e 4-hidroxi-
quinolina não deve ser negligenciada, no contexto do desenvolvimento desta classe para 
terapia antimalárica. 
Esta tese está organizada em 5 capítulos. No capítulo 1 faz-se uma apresentação 
sobre a malária, bem como sobre os fármacos antimaláricos existentes, seu modo de ação 
e alvos terapêuticos moleculares. Os fármacos que atuam por inibição do complexo bc1 
plasmodial e o uso e síntese de quinolonas em química medicinal também são abordados 
nesta secção.  
No capítulo 2 são descritas as abordagens sintéticas e a otimização das condições 
reacionais seguidas no desenvolvimento de quinolonas selecionadas. De uma forma geral, 
ao longo deste projecto de doutoramento, as quinolonas foram sintetizadas utilizando a 
metodologia de Gould-Jacobs. De acordo com esta metodologia ocorre ciclização térmica 
de um composto α,β-insaturado, derivado de uma anilina. Alternativamente, em algumas 
situações recorreu-se a uma outra estratégia utilizando o oxicloreto de fósforo. 
No decorrer destas sínteses, mais especificamente na etapa de ciclização, por 
vezes obtiveram-se alguns produtos inesperados relacionados com o padrão de 
substituição aromática decorrente da ciclização térmica e com a possibilidade de 
tautomerismo ceto-enólico.  
A possibilidade de tautomerismo entre as formas 4-oxo-quinolina e 4-hidroxi-
quinolina suscitou questões do ponto de vista mecanístico e estrutural que são aqui 
especialmente relevantes, tendo em conta a sua eventual repercussão no perfil 
farmacodinâmico dos compostos. Assim, foi conduzida uma investigação estrutural 
detalhada em alguns compostos, de forma a melhor compreender a atividade e 
reactividade química de derivados de quinolonas, descrita no capítulo 3. Os resultados 
obtidos com base em estudos de cristalografia de raio X, espectroscopia FTIR acoplada 
com isolamento em matriz criogénica e cálculos teóricos são apresentados e discutidos, e 
indicam que, em derivados quinolínicos com um grupo éster em posição 3, a forma 
enólica (4-hidroxi-quinolina) é mais favorável do que a forma ceto (4-oxo-quinolina). 
O tautomerismo poderá traduzir-se em alterações nas propriedades químicas e 
físicas dos compostos, com possíveis implicações nos perfis farmacocinéticos e 
farmacodinâmicos dos mesmos. Os compostos sintetizados neste projecto foram testados 
in vitro contra estirpes sensíveis e resistentes de P. falciparum. Os resultados destes 
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estudos, juntamente com estudos de avaliação da lipofilicidade/solubilidade de alguns 
compostos, são descritos e discutidos no capítulo 4. 
Tendo em conta os resultados de atividade biológica obtidos para alguns 
compostos e o facto de alguns estudos demonstrarem que certas quinolonas conseguem 
ultrapassar, embora parcialmente, os fenómenos de resistência à atovaquona, neste 
projecto de investigação estudou-se a possibilidade de ligação de potenciais fármacos a 
sítios alternativos e diferentes do sítio Qo do complexo bc1. Assim, foram efectuados 
estudos de simulação por docking no sítio Qi do complexo bc1, estando os resultados 
também descritos e discutidos no capítulo 4. 
Adicionalmente, foram sintetizadas algumas quinolonas substituídas com grupos 
arilo nas posições 2 e 3 que foram testadas contra estirpes de Mycobacterium tuberculosis, 
o agente responsável pelo desenvolvimento da tuberculose, cuja infeção é muitas vezes 
concomitante com a infeção pelo parasita da malária. A descrição e discussão deste 
trabalho é apresentada no capítulo 5. 
Para finalizar, e numa secção à parte, serão apresentadas as conclusões e 
considerações finais sobre o trabalho desenvolvido bem como algumas perspectivas para 
trabalho futuro. 
 
Termos chave: malária, quimioterapia antimalárica, descoberta de fármacos, 
quinolonas, inibidores do complexo bc1 de P. falciparum, tautomeria 4-oxo-quinolina/4-
hidroxi-quinolina  
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Abstract 
 
Malaria remains one of the most deadly infectious diseases. The growing spread 
of resistance by P. falciparum, the most prevalent strain affecting mankind, against 
conventional antimalarial drugs, urges the search for novel chemotherapeutics directed to 
new targets. The approval of Malarone® (combination of atovaquone and proguanil) for 
treatment and prevention of multidrug resistant malaria validated the P. falciparum bc1 
complex as target for new antimalarials. Inhibition of bc1 leads to loss of mitochondrial 
function (relevant to provide intermediates for pyrimidine and ATP synthesis), 
collapse of the transmembrane electrochemical potential and, ultimately, parasite 
death. 
The versatility of the quinolone chemotype has attracted intense research, yielding 
mainly 4-oxo-quinolines with improved pharmacological properties, targeting a variety 
of applications, e.g., cancer, hepatitis, HIV, tuberculosis or malaria.  
Recent publications report on the high activity of some quinolone 3-esters against 
the plasmodial bc1 protein complex. However, due to some liabilities (e.g. poor solubility 
and low oral bioavailability), this class requires optimization. 
The research described within this thesis focus on the design, synthesis, structure 
and properties of a library of new 4-oxo-quinoline 3-esters substituted at positions 6 
and/or 7 of the quinolone pharmacophore. 
Chapter one presents an introduction to malaria and antimalarial drugs. Other 
topics in this chapter are the plasmodial bc1 protein complex, the use of quinolones as 
inhibitors of this drug target and the synthetic routes to quinolones. In chapter two, 
synthetic approaches and conditions followed in the preparation of our library of 
quinolones, are described. For a better understanding of chemical reactivity and 
activity, a detailed structural investigation was undertaken on selected compounds, 
described in chapter three. Compounds synthesized in this project have been tested 
in vitro against P. falciparum. The results are discussed in chapter four, jointly with 
studies of lipophilicity/solubility evaluation and docking simulations. Additionally, 
selected quinolones were prepared and tested against Mycobacterium tuberculosis 
(chapter five). Conclusions and prospects for future work are presented in a final 
section. 
  
xvi 
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Scope of this thesis 
 
Millions of cases of malaria occur annually and around 600 000 deaths are 
estimated annually. Great efforts have been undertaken to circumvent this problem, but 
the growing spread of resistance by P. falciparum to currently used antimalarial drugs, in 
most of the more than 100 countries where malaria is endemic, has compromised the 
common goal of malaria eradication or, at least, of its control. 
In this scenario, the design and development of new, effective and safe 
chemotherapeutic agents for fighting malaria remains a major priority.  
The aim of the research described within this is the design, synthesis and study 
the structure and properties of a chemically diverse library of new 4-oxo-quinoline 3-
esters, in view of facilitating the selection of leads with improved pharmacological profile 
for drug development. 
This PhD thesis includes five chapters: 
Chapter one provides an introduction about malaria (history, epidemiology, 
symptomatology, diagnosis), Plasmodium (characteristics, life cycle) and antimalarial 
drugs or other strategies employed in the therapy, prevention and control of malaria. 
The role of the plasmodial bc1 protein complex and the effects of its inhibition are 
also reviewed in this section, as well as some important aspects concerning the 
synthesis and uses of quinolone derivatives in medicinal chemistry.   
Chapter two presents the synthetic approaches and reaction conditions 
followed during the preparation of our library of selected quinolones.  
Chapter three provides results of a detailed structural investigation of 
representative compounds, aimed at a better understanding of their chemical reactivity 
and properties, including biological activity. The possibility of tautomerism was 
specifically addressed.  
Chapter four presents results of in vitro activity tests of the synthesized 
compounds, against sensitive and multidrug resistant strains of P. falciparum. In 
paralel, studies for lipophilicity/solubility evaluation and docking simulations are 
described and explored in this section. 
Chapter five comprises the design and synthesis of selected 2- and 3-
substituted quinolones with potential activity against Mycobacterium tuberculosis.  
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1.1. Malaria 
Malaria, a parasitic disease affecting mankind, remains one of the most deadly 
infectious diseases in the world. It is transmitted by the bitten of an infected mosquito 
(Anopheles female) and, in the human, it is caused by parasites belonging to the genus 
Plasmodium (from the species P. falciparum, P. vivax, P. malariae, P. ovale or P. 
knowlesi).1 
Considering the growing emergence of resistance, the development of adequate 
solutions to tackle the disease is a priority. Among the relevant approaches to this goal is 
the development of new, effective and safe antiplasmodial drugs. 
1.1.1. History 
Malaria has been for long a great social, economic and health problem, 
specifically in the tropical areas. It was (and is) responsible for the decline of nations, 
forced the migration of populations, prevented the economic development and, 
sometimes, caused more deaths than the wars. History of malaria and its effects is as 
ancient as the history of civilization. 
The first evidence of malaria parasites was found in mosquitoes from the 
Paleogene period preserved in amber, that are approximately 30-60 million years old. 2 
These parasites have evolved and adapted to different conditions and hosts (jumped onto 
humans from the great apes) and, presumably, a major impact in the mankind coincided 
with the start of agriculture during the Neolithic revolution (about 10 thousand years 
ago).3 
However, the first reports about malaria were found in the Chinese Canon of 
Medicine (malaria symptoms: “periodic fevers” and “enlarged spleens”), from 2700 BC. 
Sumerian clay tablets, Egyptian papyri and Hindu scriptures from 2000 BC to 700 BC 
also refer deadly “epidemic fevers” and splenomegaly, suggestive of malaria.4,5 
The recognition of this infectious disease in Greece dates from 850-400 BC, being 
Hippocratic corpus the first document that correlated this “intermittent fevers” or splenic 
change with marshy places.5 
From the first century BC, a number of Roman writers mentioned that swamps 
could be the cause for this disease. Considering this idea, the term “malaria” was 
introduced from the Italian “aria cattiva” or “mal aria” that means “bad air”.4,5 
With the improvement of knowledge about microbiology the search around 
malaria was intensified, but in 1879 it took a wrong turn with the isolation of a microbe 
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from the damp soil in malarious regions, named Bacillus malariae speculated as the cause 
of malaria, by Edwin Klebs and Corrado Tommasi-Crudeli. One year after, Charles Louis 
Alphonse Laveran (a student of Pasteur; awarded the Nobel Prize in 1907) identified the 
right malaria parasite, designating it by Oscillaria malariae (currently Plasmodium 
malariae). In 1884 appeared the denomination for the genus Plasmodium, by 
Marchiafava and Celli. Plasmodium vivax and Plasmodium falciparum, firstly named 
Haemamoeba vivax and Haematozoon falciparum, were identified in 1890 (by Grassi and 
Feletti) and in 1897 (by William Welch), respectively. The recognition of the last malaria 
parasite, Plasmodium ovale, occurred in 1922 by John. W. Stephens.4–6  
Since the ancient Hindus, the swamp theory had been questioned and, gradually, 
it started to crumble. Many ancient texts mentioned the possible link between malaria and 
mosquitoes. However, just in 1897, Ronald Ross (Nobel Prize for Medicine in 1902) 
found the malaria parasite while dissecting the stomach tissue of an Anopheles mosquito 
and he proved the role of this insect as vector in the transmission of malaria parasites in 
humans.4,6 
In 1899, Bignami and Bastianelli observed the complete cycle of P. vivax and 
Grassi joined these efforts and, all together, the same feat was accomplished with P. 
falciparum.6 
The genome sequences of Anopheles gambiae7 and Plasmodium falciparum8 were 
published in 2002, and those of P. vivax9 in 2008. 
1.1.2. Epidemiology 
Malaria and poverty are correlated, since the main focus of this disease coincides 
with the tropical and sub-tropical regions, affecting some of the poorest populations in 
the world. Besides Sub-Saharan Africa, some countries of Asia (Saudi Arabia, India, Sri 
Lanka, Thailand and Indonesia), Western Pacific and Latin America suffer from 
prevalence of malaria. Turkey, Armenia and Azerbaijan are Asian–European boundary 
countries where it is still possible to find malaria. Normally is not found in North 
America, Europe and Australia, unless the illness was contracted abroad.1,10 
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Figure 1.1 – Global status of mortality by malaria per 100 000 population in 2013.1 
Globally, World Health Organization (WHO) and current estimates place 3.2 
billion people (more than 40% of the global population) at risk of malarial infection and 
developing disease, with 1.2 billion at high risk. In 2013 occurred 198 million cases of 
malaria, leading to 584 thousand of deaths, 90% of them in the African region (see Figure 
1.1) and 78% in children aged under 5 years. Despite these dramatic estimates, the 
increase of malaria control efforts has saved more than 3 million lives, between 2000 and 
2013, and the global malaria mortality rates have been reduced by 47%. 
 There are other infections (for example tuberculosis and human 
immunodeficiency virus) that demonstrate similar global distributions to malaria, 
exacerbating the economic problems and interfering with the fight against malaria.1 
1.1.3. Transmission 
Malaria is a vector-borne illness and can be transmitted by the bite of female 
Anopheles mosquitoes. These insects are found worldwide, in except Antarctica, and of 
the approximately 430 Anopheles species known, around 40 transmit malaria, depending 
on the region and the environment. In Africa, Anopheles gambiae is the most important 
as malaria vector while in Latin America is A. darling. Environmental changes, including 
deforestation, migration, new agricultural practices and climate change, may influence 
vector behavior.4 
Others rare routes of transmission may be considered, as the exposure to infected 
blood or blood products, organ transplantation, use of shared infected needles and vertical 
transmission across the placenta (congenital infection).11 
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1.1.4. Apicomplexa, Sporozoa, Plasmodium 
Malaria parasites are protozoa members of the Phylum Apicomplexa, 
characterized by the presence of an unique organelle called apical complex (see Figure 
1.2).11–13 Plasmodium (genus) parasites, responsible for malaria, do not have organelles 
of locomotion (class Sporozoa) and because of 
this are obligatory endoparasitic protozoa.14 
Five species of Plasmodium are able to 
cause human malaria: P. falciparum, P. vivax, 
P. ovale, P. malariae and P. knowlesi. P. 
falciparum is the most lethal species 
(“malignant malaria”) and, at the same time, the 
most prevalent in the African continent and the 
one that develops most episodes of resistance to 
drugs, leading to important therapeutic 
problems.1 
P. vivax, P. ovale and P. malariae 
cause “benign malaria” cases that rarely are 
fatal. P. vivax is the most widely disseminated and the most prevalent parasite causing 
malaria in the world. However in Africa the risk of infection by P. vivax is quite low, 
essentially, because this species needs a protein to invade red blood cells that is codified 
by Duffy gene, and this gene is absence in many African populations. In many areas 
outside Africa, P. vivax infections are more common because P. vivax can survive at 
lower temperatures.1,14 
P. ovale (infection least common and severe) is found in West Africa and Asia, 
while P. malariae (leads to mild or benign disease and may also affect some primates) is 
found in most endemic areas.11 
A fifth species, P. knowlesi, a monkey form of malaria in macaques, is emerging 
as an important parasite able to cross from animals to humans (zoonosis) and infections 
in humans have been found in the forests of south-east Asia (especially Malaysian 
Borneo). Its morphology is similar to P. malariae, but it produces very high parasitaemias 
leading to severe or fatal pulmonary and hepatorenal symptoms.14 
 
 
 
Figure 1.2 - Plasmodium falciparum 
merozoite in an electron micrograph (a) and 
schematic (b) images; ap - apical prominence, 
d - dense granule, n - nucleus, r - rhoptry.13 
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1.1.5. Parasite life cycle 
Plasmodium, as most genera from the class Sporozoa, has a life cycle with both 
sexual (gametocyte production and sporogony) and asexual (schizogony) phases of 
reproduction (Figure 1.3).14 
 
Figure 1.3 - Plasmodium falciparum life cycle; female Anopheles mosquito-Human transmission. 
Adapted from Pasvol et al..15 
Apart from the different distributions, each Plasmodium species may be 
distinguished by their morphological characteristics and their specific life cycle, 
responsible for the different clinical courses of the disease (incubation period, 
pathophysiology, morbidity and mortality associated).12 
The complex life cycle of malaria parasites includes eight separate parasitic forms 
(or nine, if we consider hypnozoites in P. vivax and P. ovale) with different structures and 
metabolic processes. Then, an effective treatment, especially if acting against more than 
one parasite form, is difficult.6 
A. Asexual cycle – schizogony 
The asexual cycle begins with the bite of an infected female Anopheles mosquito 
(definitive host), when inoculation of infective 20-30 sporozoites and salivary 
anticoagulants (helping the inoculation of the parasites) from the mosquito to the human 
host takes place.14,15 
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 Primary exo-erythrocytic cycle: through the bloodstream this parasitic 
forms rapidly (within half an hour) reach the liver and invade hepatocytes. Each 
sporozoite can invade up to five hepatocytes, before setting one in which the maturation 
will occur. In this stage, the parasites reproduce intracellularly by asexual division and 
mature into schizonts (with many merozoites inside).  
This asymptomatic stage is completed with the rupture of the hepatic schizonts, 
releasing tens of thousands of merozoites able to invade other hepatocyte and restart the 
cycle. 
The time to complete this liver stage and the number of parasitic forms released 
depends on the Plasmodium species. P. falciparum species release about 40 000 parasites 
in 7 days, P. vivax release 10 000 merozoites in 6-8 days, P. malariae release 2000 
merozoites in around 12-16 days and P. ovale release 15 000 merozoites in 9 days.  
In P. vivax and P. ovale, a dormant parasitic form (hypnozoite) can persist in the 
liver, causing relapses by invading the bloodstream after weeks, months or even years 
later. In infections by P. falciparum and P. malariae, after the schizonts burst no parasites 
remain in the liver, and the liver infection ceases spontaneously in less than 4 weeks.11,14 
 Erythrocytic cycle: from the rupture of the infected hepatocytes, other 
merozoites are released to the liver blood vessels. Once in the erythrocytic cycle, 
Plasmodium species do not reinvade the liver cells. Through the apical complex of the 
protozoa, the action of some proteases (e.g. P. falciparum subtilisin-like serine protease 
1 and 2 – PfSUB1 and PfSUB2)16 and by invagination with the red blood cell membrane, 
the merozoites invade erythrocytes.  
While merozoites of P. falciparum are capable of infecting erythrocytes of all ages 
(exponential parasitaemia), those of P. vivax and P. ovale infect only reticulocytes and 
those of P. malariae just invade older red blood cells. 
The binding of merozoites of P. vivax to erythrocyte membranes requires the 
presence of the Duffy blood group antigens (absent in many West African populations, 
thus protected from P. vivax infection).  
In red blood cells, merozoites develop asexually forming trophozoites, which 
initially assume a characteristic “ring form” and then enlarge to become mature 
trophozoites or schizonts.11,14,15 
This stage is the feeding stage of the parasite and is highly metabolically active, 
consuming glucose and haemoglobin from the red blood cell. With the proteolysis of 
haemoglobin by proteases (e.g. cysteine protease falcipain-2 and aspartic protease 
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plasmepsin I, II and IV), in the acidic food vacuole, small globin peptides are generated 
and transported to the parasite cytosol where they are cleaved to obtain free amino acids 
for feeding parasites. At the same time, toxic products (e.g. haem) are released from the 
haemoglobin’s proteolysis. To detoxify the haem group, the parasite stores it as dimers 
within the food vacuole and, by polymerization, a malaria pigment is obtained – 
haemozoin.17 
By rupture, each erythrocytic schizont (in 48 hours after erythrocyte invasion in 
P. falciparum, P. vivax and P. ovale; or 72 hours for P. malariae) releases 16-32 
merozoites that invade other red blood cells and the cell rupture is continually repeated.  
Simultaneously, the contents of the parasitized erythrocyte are released into the 
circulation, initiating the production of cytokines that contribute to the clinical symptoms 
of malaria. 
A parasite derived P. falciparum erythrocyte membrane protein (PfEMP1) 
appears on the surface of the infected erythrocyte, causing agglutination, lysis and 
facilitating the attachment to the vascular endothelium. Parasitic forms sequestered in the 
microvasculature throughout the body, including the brain, viscera and placenta, avoid 
the destruction by the spleen and, at the same time, the vessels become blocked, causing 
damage of tissues (renal, pulmonary and cerebral anoxia).11,15 
B. Sexual cycle (gametocyte production and sporogonic cycle) 
Some merozoites (inside the erythrocytes and in a later stage of the infection) 
develop into microgametocytes and macrogametocytes (male and female gametocytes, 
respectively), by a process called gametocytogenesis. Gametocytes do not undergo 
further multiplication, but may survive in the peripheral blood for up to several weeks 
and do not cause clinical symptoms. 
The sporogonic cycle begins when during a subsequent bite by a female 
Anopheles, it takes some blood and gametocytes from the infected person to its midgut. 
The inoculation of salivary anticoagulants secreted by the mosquito help the suction of 
the human blood to the Anopheles. Micro and macro gametes (male and female, 
respectively) appear from the corresponding gametocytes, a motile and elongated zygote 
(ookinete) is generated through fertilization,  penetrates the mosquito gut wall and 
matures to an oocyst containing sporozoites.11,14 
Chapter 1 - Introduction 
 
 
10 
 Oocysts grow, rupture and the sporozoites are released from the oocyst and 
migrate through the mosquito lymph system to the salivary glands. Inoculation of the 
sporozoites into a new human host perpetuates the malaria life cycle. 
The vector phase takes 1 or 2 weeks to complete and can only occur where 
temperatures are maintained between 16°C and 33°C, and at altitudes below 2000 meters 
above sea level.11 
1.1.6. Immune response to Plasmodium 
After a bite by an infected Anopheles, the main first contact between the human 
and the parasite is in the liver stage (within half an hour of the bite). In the hepatocyte, 
the merozoites are undetected by the immune system because they can modify the biology 
of the liver cells. These parasitic forms induce the first step of apoptosis (infected cells 
detach from its neighbours to move freely in the liver) but, at the same time, prevent this 
death process by blocking the release of Ca2+ ions (calcium ions are a signal to phagocytes 
to engulf the dead cell). Then, the host immune system does not recognise the infected 
detached cell as ready to die.18 
Although rarely, parasites forms in the liver may be detected by the immune 
system. For that, several antigens specific to the liver stage of the Plasmodium have been 
identified and by presence on the surface of infected hepatocytes lead to a recognition by 
cytotoxic T lymphocytes (also called as CTL, CD8+ T or Killer T; kill infected cells) 
and/or a stimulation of natural killer cells (NK cells) and T helper cells (CD4+) to produce 
interferon  (triggers a cascade of reactions leading to the death of intracellular parasites).  
Inside red blood cells, the merozoites modify the cell surface of the infected 
erythrocyte by incorporation of parasite proteins and the exposition to these antigens leads 
to an immune response against Plasmodium. After erythrocyte rupture, in the 
bloodstream, the parasite induces a specific immune response (by antigens exposure) and 
stimulates the release of factors, which might play an important function, for example in 
the activation of the host’s monocytes, neutrophils, T cells and NK cells.  
The antigen exposition based on the surface of the infected erythrocyte (PfEMP1), 
on the surface of the merozoite and on the external proteins from the apical complex leads 
to antibody production that could neutralise the parasitic forms and to death of the 
Plasmodium by macrophages. Then, these white blood cells can control the infection by 
phagocytosis (antibody-dependent and independent) and by secretion of factors that are, 
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directly or indirectly, toxic to the parasite (e.g. interleukin 1, tumor necrosis factor or 
TNFα, reactive nitrogen and oxygen radicals).  
Interferon  is a macrophage-activating factor involved in the innate immune 
response to malaria. It is mainly produced by CD8+ and CD4+ T lymphocytes, and by 
NK cells, in a specific and non-specific immune response, respectively. Some studies 
demonstrated that it could be associated with protection against malaria reinfection in 
Africa. This cytokine may also help to induce IgG (Immunoglobulin G) and assist in 
antibody-dependent cellular inhibitory mechanisms, as well as to induce releasing of the 
factors by the macrophages activation.  
Haemozoin is an obstacle for the immune system because it affects the antigen 
processing and its accumulation inside macrophages interferes in their activation and 
function. 
The inflammatory response, induced by the released cytokines, to remove 
parasites, leads to considerable tissue damage and production of inflammatory cytokines, 
which can cause systemic effects.19 
There are also aspects in the host that inhibit or decrease the erythrocyte cycle, 
mainly by inherited disorders such as sickle-cell disease, thalassemia, absence of the 
Duffy antigen and glucose-6-phosphate dehydrogenase deficiency. In areas with higher 
transmission rate, babies can be protected from severe malaria by maternal antibodies.20 
1.1.7. Symptomatology 
Infection with malaria parasites may result in a wide variety and variability of 
symptoms, ranging from absent, very mild symptoms, severe disease and even death, 
depending of the Plasmodium species and the host’s immunity response. Then, malaria 
disease can be categorized as uncomplicated or severe (complicated).  
The liver stage is asymptomatic (non-pathogenic) and it is related with an 
incubation period from 7 to 30 days, depending on the Plasmodium species (shorter 
periods for P. falciparum and longer for P. malariae). Furthermore, antimalarial drugs 
taken for prophylaxis by travellers can delay the appearance of malaria symptoms by 
weeks or months. These long delays between exposure and symptoms can result in 
misdiagnosis or delayed diagnosis, especially in countries where malaria is 
uncommon.4,12 
This stage is followed by the erythrocytic cycle that produces the clinical 
symptoms of malaria (pathogenic stage). The regular, intermittent paroxysms of fever 
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caused by malaria infections were first clearly described by Hippocrates. However, other 
symptoms are associated to malaria disease, especially with the erythrocytic cycle and 
the release of parasites and other substances to the bloodstream.11 
The periodic release of merozoites, haemozoin and other toxic factors from red 
blood cells to human bloodstream (stimulating the production of cytokines, e.g. TNF) is 
responsible for the characteristic periodicity of the fever (the temperature may rise above 
41 ºC) in malaria. This process occurs in cycle, after 48 (P. falciparum, P. vivax or P. 
ovale) or 72-hours (P. malariae). In general, this paroxysm begins suddenly and is 
characterized by 10-15 minutes of shaking chills, followed by high fever from 2 to 6 hours 
or longer. The temperature returns to normal and the patient begins sweating profusely.  
More commonly, the patient presents a combination with other symptoms, such 
as: headaches; nausea, vomit and/or diarrhoea; body aches (back and joint aches) and 
myalgia; fatigue; cough; and general malaise. These symptoms can be easily confused 
with influenza, especially in countries where malaria is not frequent. Populations from 
areas where malaria is frequent, often recognize the symptoms as malaria and treat 
themselves before the diagnostic confirmation.4,14 
Usually, other symptoms like anemia, jaundice, splenomegaly and hepatomegaly 
also arise, which may be exacerbated in P. falciparum infections. 
Severe or complicated malaria is almost exclusively caused by P. falciparum 
(occasionally by P. vivax), it is associated with higher parasite burdens and with the 
presence of parasite protein PfEMP1 in infected red blood cells.12 
The manifestations of severe malaria include: 
 Severe anemia: the rupture of the infected red blood cells and the 
destruction of both infected and uninfected erythrocytes by the organism provides the 
progression to normochromic normocytic anemia;11 
 Splenomegaly and hepatomegaly: host responses to red-cell remnants and 
other parasitic debris lead to more erythrocyte lysis and erythrocyte’s clearance by the 
spleen, causing enlargement of the spleen and liver;14 
 Jaundice: the increased rate of hemolysis from the rupture of the red blood 
cells and the breakdown of the haem of the haemoglobin, lead to an increase of 
unconjugated bilirubin in the blood and its consequent deposition into various tissues;  
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 Haemoglobinuria: uncommonly, massive intravascular hemolysis may 
lead to “blackwater fever” with the passage of dark urine (presence of haemoglobin in the 
urine);  
 Thrombocytopenia: and other abnormalities in blood coagulation are 
commons and result from the increased splenic clearance;  
 Bone marrow suppression: contributes to anemia and may takes weeks to 
recover after infection;  
 Metabolic disorders: metabolic acidosis can be evidenced; hypoglycemia 
arises from the increased demand for glucose due to the metabolic demands of the illness 
and glucose consumption by the parasites; hepatic glycogen stores are rapidly depleted 
and gluconeogenesis fails;11 
 Tissue obstruction, organ failure, coma and death: infected erythrocytes, 
by PfEMP1, adhere to the vascular endothelium of blood vessel resulting in a 
microvascular obstruction and subsequent tissue hypoperfusion (hypoxia) of vital organs. 
It is the main factor leading to organ failure, such as, pulmonary or renal failure. When 
this sequestration occurs in the brain, cause cerebral malaria ensues, usually associated 
with neuronal degeneration, meninges inflammation, coma and death.12 
In pregnancy, the adherence of a large number of infected erythrocytes within the 
placenta in combination with maternal anemia result in placental insufficiency and 
intrauterine growth retardation, leading to stillbirth, low birth weight infants or perinatal 
mortality.11,12 
On rare occasions, P. vivax can cause rupture of the spleen and chronic P. 
malariae infection can be associated with nephrotic syndrome (kidney shows histological 
hypertrophy), caused by the deposition of immune complexes.4 
In P. vivax and P. ovale infections, the development of dormant parasitic forms 
(hypnozoites) allows the parasite to remain quiescent in the liver and then a new wave of 
merozoites can emerge from the hepatocytes, causing several additional attacks (relapses) 
after months or years. 
All Plasmodium species can induce a recurrence of symptoms of malaria in cases 
where the blood stages of malaria are maintained at very low levels after inadequate drug 
treatment or when parasites become drug resistant. Mixed infections (P. falciparum with 
one other species) are possible and the successful treatment of one species may be 
followed by symptoms due to the second species.12 
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1.1.8. Diagnosis 
When any person who lives, has lived or has passed through a malaria-endemic 
area presents febrile illness, malaria should be assumed until proven otherwise. Specially 
in travellers, an inadequate malaria prophylaxis may prolong the incubation time of 
infection (delay in the first symptoms).11 
A rapid and accurate diagnostic is crucial to the appropriate treatment and to the 
prevention of further spread of the infection in the world. Malaria suspicion is based on 
the patient’s travel history, symptoms and physical findings at examination.4 
In malaria suspicion, World Health Organization (WHO) recommends the 
diagnosis by microscopy and/or by rapid diagnosis test (RDT) to demonstrate the 
presence of malaria parasites, their components or metabolic products. The African 
region has seen the largest increase in the proportion of suspected malaria cases receiving 
a malaria diagnostic test (from 47% when WHO’s recommendation was introduced in 
2010 to 62% in 2013).1 
Microscopy is the standard malaria diagnosis test. Plasmodium sp. can be 
identified by microscope examination of a drop of the patient’s blood as a stained blood 
smear. The detection limit for malaria infection by examination is a parasitaemia of 
around 0.001% (approximately 50 parasites per μl blood).  
More parasites may be visible when blood is collected between paroxysms. The 
most common stain is Giemsa and it gives the parasite a distinctive appearance from the 
blood cells. Thin films allow calculation of the percentage of red blood cells containing 
parasites and the differentiation of Plasmodium sp.. The ring form, trophozoite, schizont 
and gametocyte stages may all be distinguished by microscopy, depending on the parasite 
species. By microscopy, ring forms of P. falciparum can be seen in peripheral blood, 
while trophozoites and schizonts are rarely identified due to the sequestration of these 
parasitic forms in the microcirculation (estimation of total parasite burden is unreliable). 
Sequestration does not occur in P. vivax, P. ovale and P. malariae, then all parasitic forms 
are seen in the peripheral blood smears.11 
Microscopy provides good sensitivity and specificity, but results depend on the 
handler and technical skills (quality of the reagents and microscope) that may be 
problematic especially in poor countries and/or where the disease is not endemic.12 
Consequently, different nonmicroscopic malaria-diagnostic methods have been 
developed from 1990, including antigen detection by RDT, molecular diagnostic and 
serology. 
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The measurement of circulating specific products derived from malaria parasites 
by RDT (immunochromatographic test) provides results in 2-15 minutes, decreasing the 
amount of time to determine if a patient is or is not infected with Plasmodium sp.. It is 
recommended that RDT are followed-up by microscopy to confirm the result and, if 
positive, to define which strain is responsible for the infection and to quantify the 
proportion of erythrocytes infected. This methodology may not detect early infections 
with low parasitaemia.4,14 
The antigens or metabolic products targeted with RDT include P. falciparum 
histidine-rich protein 2 (HRP-2), Plasmodium aldolase and Plasmodium lactate 
dehydrogenase (PLDH). HRP-2 is produced only by P. falciparum, plays a role in 
haemozoin formation and is released from erythrocytes at schizont rupture. It may persist 
for up to 4 weeks in the bloodstream after the resolution of an infection (not useful to 
monitor the treatment’s response neither to diagnostic re-infection). Plasmodium sp. use 
large amounts of glucose (by glycolysis) and the species of this parasite produce different 
isomers of PLDH (involved in the conversion of pyruvate to lactate) at high levels during 
the asexual erythrocytic cycle. This metabolite is thus useful for treatment’s monitoring 
because its levels may be correlated with the microscopic parasitaemia. Plasmodium 
aldolase intervenes in the glycolytic pathway of all Plasmodium species and its detection 
may be combined with the HRP-2 detection. 
Molecular diagnostic tests (nucleic acid-based tests) using polymerase chain 
reaction (PCR) may be significantly more sensitive than microscopy for the diagnosis of 
malaria infection and may be used for identification of Plasmodium species. However 
these tests are not widely available, because they are expensive and require technical 
expertise.11  
Serology detects antibodies against malaria parasites (using indirect 
immunofluorescence – IFA – or enzyme-linked immunosorbent assay – ELISA). 
However, because of the time required for development of antibodies and also their 
persistence in the blood, this methodology may not be useful to diagnose malaria but 
rather to measure past exposure.  
To complement the diagnostics of infection, drug resistance tests that must be 
performed, including in vitro tests and/or molecular characterization, to assess the 
susceptibility of parasites to antimalarial compounds.4  
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1.1.9. Preventing and control of malaria 
Prevention of malaria involves knowledge about the transmission risk, avoiding 
mosquito bites and undertaking chemoprophylaxis when appropriate. The risk of 
acquiring malaria varies according to the geographic area (e.g. Asia or Africa; urban or 
rural area), type of accommodation (e.g. air conditioned may be protective; camping is a 
risk), duration of stay, season (transmission may decrease during the colder or drier 
months) and altitude (malaria transmission is rare above 2000 meters).  
Besides the localization (often uncontrollable), any measures that reduce exposure 
to female Anopheles mosquito and avoid mosquito bites can reduce the risk of infection. 
Insecticide-impregnated bed nets (with pyrethroids), insect repellents containing DEET 
(N,N-diethyl-meta-toluamide), flying insect spray (such as dichloro-diphenyl-
trichloroethane – DDT) and appropriate clothing (long-sleeved shirts, long pants, boots 
and hat) may minimize transmission.4 
The use of bed nets impregnated with, for example, permethrin, represents an 
effective measure and it is safe for children and pregnant women. However, most of them 
require repeated re-impregnation to remain effective. Despite their benefits, bed nets are 
associated to cost and distribution barriers and there is evidence of development of 
resistance to pyrethroids by parasites in some areas.  
 The use of repellents with DEET should be localized and minimized (only to 
exposed skin or clothing from dusk to dawn; the malaria vector is most active in twilight 
periods), especially in pregnant women. Although with side-effects on pregnancy and 
lactation, DDT is very effective as insecticide for female Anopheles mosquitoes if used 
indoors, but its use in excess (especially in the beginning; indoors and outdoors) has 
facilitated the development of resistance by mosquitoes.11,12 
Other biological measures have been explored to control the mosquito population, 
including the drainage of breeding sites, the use of predators for insects (e.g. snails or 
lavivorous fish to control mosquitoes larvae), insect traps using pheromones and also the 
use of genetically modified mosquitoes, unable to be infected with Plasmodium.11 
Chemoprophylaxis of malaria is not truly a way to prevent infection because none 
of the drugs kill sporozoites (parasitic forms inoculated from the mosquitoes). However, 
it represents an effective strategy for prevention of the development of symptomatic 
malaria, since all effective chemoprophylatic agents kill erythrocytic parasites before they 
grow sufficiently in number to cause clinical disease. Considering the growing emergence 
of strains of Plasmodium resistant to conventional drugs and the evidence for toxicity of 
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some therapeutic regimens, the recommendations for the use of malaria prophylaxis have 
been made more rigorous and should be reserved for those at high risk. Advice on 
prophylaxis differs around the world, but WHO generally recommends that it should start 
about 1 week (or longer) before exposure or, if this is not possible, at the earliest up to 1 
or 2 days before exposure to ensure that the patient tolerates the drug. Also, it should 
continue throughout exposure and for, at least, 4 weeks after exposure (atovaquone-
proguanil, Malarone®, may be stopped one week after exposure). Based on the risk of 
infection and the susceptibility of Plasmodium strains, various prophylactic regimens 
may be adopted. Chloroquine can be taken in areas where P. falciparum is absent or still 
sensitive to this drug, and concomitantly with proguanil in areas with a risk of P. vivax 
and P. falciparum with information/risk of emerging resistance. Malarone®, mefloquine 
or doxycycline are recommended where there is a high risk of P. falciparum multidrug 
resistance. 
Considering the side-effects of the drugs for prophylaxis and the consequences of 
this parasitic disease, WHO also advises pregnant women, children and elderly to avoid 
travelling to areas where P. falciparum malaria is endemic. If it cannot be deferred, the 
use of an effective, safe and specific chemoprophylaxis regimen must be adopted.21,22 
Chemoprophylaxis of malaria is becoming increasingly problematic and the 
development of effective antiplasmodial vaccines remains a priority. Developed vaccines 
may be categorized into three main groups: against sporozoite antigens; directed to 
merozoite antigens; and targeting gametocyte and ookinete surface proteins.11,14 
Vaccines targeting sporozoites and liver stages (pre-erythrocytic forms) could 
prevent infection blocking the invasion of liver cells and/or destroying infected liver cells, 
preventing the release of parasites into the bloodstream. When the target for the vaccines 
are asexual erythrocytic stages (merozoite forms), a reduction of the blood-parasite 
density should be achieved and, consequently, a decrease in the severity and duration of 
the disease. Transmission-blocking vaccines consist in inoculation of antibodies in the 
human organism that act against the gamete and ookinete stage of the parasite, in the 
mosquito. The antibodies are to be taken by the mosquito during its blood meal and will 
block further parasite development in the mosquito, reducing the infectivity. A fourth 
vaccine group, acting against the toxins produced by the parasite could be considered. 
The best approach to effective vaccination against malaria is the administration of a multi-
antigen and multistage combination vaccine.21 
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Malaria vaccine trials have shown promising results against P. falciparum and P. 
vivax. However the technical and financial problems associated to production, 
distribution, storage and administration will be a great and costly barrier. 
None of the prevention measures are 100% effective, so a premature diagnostic 
and a quick treatment are essential in the control of the disease. Then, if symptoms of 
malaria occur, the patient should be able to identify them and seek immediate medical 
attention. Some countries where the risk of malaria is high may sell counterfeit drugs that 
may not be effective. WHO recommends that people travelling for these countries should 
consider carrying with them a full treatment course of malaria medicines for emergency 
self-treatment.4,21 
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1.2. Chemotherapy 
During the last 2 decades, the implementation of effective control measures led to 
the eradication of malaria from some of the endemic countries. However, following the 
rapid and recent emergence of the drug-resistance by Plasmodium and insecticide-
resistance by Anopheles, the disease has been reintroduced into controlled areas.14 
The fight to discover more effective chemotherapeutics agents led to promising 
leads, but their usefulness is sometimes limited by high cost and toxicity. The existence 
of different species of Plasmodium (some chemotherapeutic agents are not effective 
against all of strains) and various stages of the malaria life cycle complicates matters, 
further worsened by the fast development of drug resistance (most notably by P. 
falciparum). Furthermore, these potential drugs should act selectively in the parasite and 
not in the host, so a rational approach to antimalarial chemotherapy requires comparative 
biochemical and physiologic information of host and parasite. Then, three major types of 
potential drug targets can be considered: unique essential enzymes found only in the 
parasite; similar enzymes found in parasite and host but just indispensable for the first 
one; and common biochemical functions found in parasite and host but with different 
pharmacologic properties.23 
The treatment of malaria follows the strategies of a clinical cure and a radical cure. 
The first one aims to relieve the symptoms, but it does not necessarily mean that all the 
parasites are eradicated from the body. An elimination of all parasite forms from the body, 
including secondary tissue schizonts, is termed as radical cure. Patient variables, such as 
age, weight and sex (e.g. pregnancy status), may limit the available options for malaria 
cure.4,14 
There chemotherapy agents against Plasmodium (available drugs as well those 
under development) may be classified according to the pharmacophore structure and can 
be, mainly, grouped in: quinolines, peroxides, tetracyclines and lincosamides, biguanides 
and sulphonamides, dipeptides, naphthoquinones, pyridones, acridones, acridinediones 
and quinolones. 
In the context of the life cycle, three classes of antimalarial drugs are considered:  
 blood schizonticides – directed against asexual erythrocytic forms, treating 
or preventing clinically symptomatic malaria (clinical cure);  
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 tissue schizonticides - eliminate developing or dormant liver forms, 
preventing invasion of the blood cells, or useful as anti-relapse drugs to produce radical 
cures of P. vivax and P. ovale;  
 gametocidals - kill sexual stages, preventing transmission to the mosquito 
vector.  
Hypnozoite is not eradicated by most agents and no one available drug can 
eliminate both hepatic and erythrocytic stages that could coexist. None of the agents kills 
sporozoites (parasitic form inoculated from the mosquito).21–23 
Plasmodium offers a variety of possible drug targets associated with its various 
organelles (cytosol, apicoplast, mitochondria, parasite plasma membrane and lysosomal 
food vacuole), enabling the development of antimalarials directed to different targets and 
with different mechanisms of action (Figure 1.4). Therefore antimalarial agents can be 
divided into: haemozoin formation inhibitors; folate antagonists (nucleic acid 
biosynthesis inhibitors); protein synthesis inhibitors; precursors of free radicals (oxidative 
and alkylating activity); cysteine protease inhibitors; and mitochondrial electron transport 
chain inhibitors. 
 
Figure 1.4 - Diagram of a Plasmodium falciparum trophozoite residing in an erythrocyte, 
highlighting the targets of current antimalarials and of new targets that are under investigation.24 
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1.2.1. Inhibitors of haemozoin formation (quinolines) 
In acidic/food vacuoles, the trophozoite parasitic forms break down haemoglobin 
for protein synthesis and energy. From this proteolysis haem is released and it can be 
toxic to the parasite via oxidative damage to membranes. Then, the parasite converts haem 
into dimmers which subsequently polymerise to form haemozoin, a polymer non-toxic 
for the parasite. There are evidences that quinoline-like compounds (Cinchona alkaloids, 
their derivatives and synthetics analogues, described on this section) interfere with haem 
detoxification by binding to the porphyrin ring system of haem or by raising intravesicular 
pH, inhibiting haem polymerization. These compounds accumulate in high 
concentrations inside the parasite vacuole because the nitrogens atoms of the side chains 
of these drugs are protonated preventing them from passing back out through the vacuole 
membrane.14,22 
In the early 17th century Cinchona (Figure 1.5) was 
introduced into Europe, as a treatment for malaria by Jesuit 
priests returning from Peru. The main medicine responsible 
for this antimalarial activity is known as quinine (Figure 1.6) 
occurring naturally in the bark of Cinchona trees (quinidine, 
Figure 1.6, is also obtained from this natural source), 
originally found in the high hills of South America. Initially 
its therapeutic results were inconsistent due to the difficulty to 
distinguish Cinchona from other trees and because of the 
variety in quinine content in the different Cinchona species. 
Its popularity was such that in 18th century several species of 
Cinchona trees were becoming extinct.  
In the early 19th century, quinine was isolated as the 
active drug and replaced the crude bark in the malaria 
treatment. Nowadays, quinine and quinidine remain as alternative antimalarials in 
infections resistant to others drugs (e.g. chloroquine), although several side effects are 
known and related with their use. Due to its toxicity and short t1/2, quinine is not used for 
prophylaxis. This drug acts against asexual erythrocytic forms, is gametocidal for P. vivax 
and P. malariae and it has little effect on hepatic forms. Quinidine is more potent but 
more cardiotoxic than quinine.22,25 
The synthesis of quinine failed until 1944 but, from the efforts towards its 
investigation, by the end of the 19th century methylene blue (Figure 1.6) was synthesized 
Figure 1.5 - Sketch of 
Cinchona tree (by Mr. 
Pritchett).25 
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and used in humans, since it stained malaria parasites and was found to be toxic to 
Plasmodium spp. (inhibits glutathione reductase disturbing the redox homeostasis of the 
parasite). 
 
Figure 1.6 – Structural representation of quinine, quinidine and methylene blue. 
Pamaquine (plasmoquine), the first 8-aminoquinoline and the first compound 
useful to prevent relapses in P. vivax, was developed in 1925 and, in 1932, mepacrine 
(an acridine) showed be effective against P. falciparum (Figure 1.7). During World War 
II, these two compounds were widely used.25 
 
Figure 1.7 – Structural representation of pamaquine and mepacrine. 
Considering the high toxicity of quinine and the development of resistance by the 
parasite towards this drug, research to find a substitute for this natural compound became 
a priority. In 1934, the first synthesized 4-aminoquinoline (chloroquine; Figure 1.8) 
demonstrated to be highly effective against parasites, well-tolerated by human (less toxic 
and more effective than quinine) and relatively cheap. Hydroxychloroquine (Figure 1.8) 
is essentially equivalent to chloroquine against P. falciparum. In the liver, chloroquine is 
bio transformed in two active metabolites and, at the same time, inhibits CYP2D6, 
interacting with a variety of drugs.22,25 
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Figure 1.8 – Structural representation of chloroquine and hydroxychloroquine. 
Chloroquine provides a clinical cure but it does not treat latent hypnozoites from 
P. vivax and P. ovale, which may reactivate after months or years to cause recurrent 
clinical episodes of malaria. Its uncontrolled use led to the development of chloroquine-
resistant strains of P. falciparum (first cases detected in 1950), which are currently 
common in all endemic areas around the world. Despite those limitations, chloroquine is 
still used for prophylaxis and treatment in some African regions where Plasmodium 
remains sensitive to this drug.11,14,22,25 
Resistance of erythrocytic asexual forms of P. falciparum to antimalarial 
quinolines, especially chloroquine, has been ascribed to multiple mutations. Genetic 
alterations in the gene encoding a chloroquine resistance transporter (PfCRT), in 
multidrug resistance protein 1 (PfMDR1 or P-glycoprotein) and/or in other transporters, 
may induce a reduction in drug levels within the parasite food vacuole.11,22  
For example, in the presence of a mutant form for PfCRT, protonated chloroquine 
can move rapidly out of the food vacuole, reducing the concentration of this drug, while 
in the “wild-type” there are three basic residues that would repulse this passage, keeping 
the drug inside of the vacuole.26 
The efforts to the discovery of new antimalarial drugs, effective against 
chloroquine-resistance strains, resulted in the synthesis of various antimalarial 
compounds, represented in Figure 1.9: mefloquine (4-methanolquinoline used for 
prophylaxis and chemotherapy of infections due to drug-resistant P. falciparum and P. 
vivax); halofantrine, pyronaridine and lumefantrine (aryl amino alcohols); 
piperaquine (a bisquinoline used extensively in China and Indochina for prophylaxis and 
treatment); and more effective versions of 8-aminoquinolines (e.g. primaquine and 
tafenoquine) and 4-aminoquinolines (amodiaquine, isoquine). However, some of this 
new drugs have limitations, mainly due to side effects and cost: hepatotoxicity by 
amodiaquine; seizures, depressions, hallucinations and anxiety by mefloquine; 
cardiotoxicity by halofantrine; and haemolytic anemia in patients with glucose-6-
Chapter 1 - Introduction 
 
 
24 
phosphate dehydrogenase (G6PD) deficiency by primaquine. Furthermore, in some areas 
where malaria is endemic, development of resistance towards these drugs has been 
reported.14,22,25 
 
Figure 1.9 – Structural representation of the antimalarial drugs with historical and/or current 
importance. 
Chloroquine-resistant alleles of the CRT gene may confer increased sensitivity to 
mefloquine and the amplification of the PfMDR1 gene is associated with resistance to 
mefloquine and quinine. Mefloquine is a highly effective blood schizonticide  but has no 
activity against early hepatic stages and mature gametocytes of P. falciparum or latent 
tissue forms of P. vivax.22 
8-aminoquinolines (pamaquine, tafenoquine and primaquine) are also effective 
as gametocidal agents and acts on tissue stages in the liver. Since primaquine produces a 
radical cure for P. vivax and P. ovale, it is currently used as the second course of treatment 
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and for the terminal prophylaxis (initiated before or immediately after leaving an endemic 
area). The mechanism of antimalarial action of the 8-aminoquinolines is not very well 
defined, but some studies demonstrate that primaquine may be converted to electrophiles 
that act as oxidation-reduction mediators which might be toxic.11,14,22 
Lumefantrine is administered only in combination with an artemisinin derivative 
(artemether) for the treatment of acute uncomplicated malaria caused by P. falciparum 
(including for chloroquine-resistant strains). It has a relatively slow onset of action and, 
although its mode of efficacy is not fully understood, some studies suggest that this drug 
inhibits haemozoin formation and may also interfere with the nucleic acid and protein 
synthesis.21,27 
 
1.2.2. Folate antagonists 
Intracellular protozoa of the Phylum Apicomplexa such as Plasmodium must 
synthesize their own folates in order to survive (Figure 1.10). Folate derivatives are 
important cellular cofactors involved in the biosynthesis of methionine, purines and 
pyrimidines, which are essential for deoxyribose nucleic acid (DNA) generation and 
protein synthesis.23,28 
 
Figure 1.10 - Folate pathway in Plasmodium parasites, showing the target enzyme for two 
commonly used folate antagonists.29 
Para-amino benzoic acid (pABA) is a substrate for dihydropteroate synthase 
(DHPS), where it reacts with 7,8-dihydropterin pyrophosphate to give 7,8-
dihydropteroate (Figure 1.10). Sulphonamides (e.g. sulfadoxine; Figure 1.11) act as 
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competitive inhibitors of pABA. Dihydrofolate reductase (DHFR), another enzyme in the 
folate synthetic pathway, is responsible for the conversion of dihydrofolate into 
tetrahydrofolate (folic acid derivatives) and may be inhibited by biguanides (including 
proguanil; Figure 1.11) or by pyrimethamine (Figure 1.11; purine analogue). Proguanil 
was developed during World War II and served as a prototype for the development of 
pyrimethamine in 1950.23,25,29 
 
Figure 1.11 – Structural representation of the established folate antagonists. 
 Reports of resistance to these drugs have increased and are largely attributable to 
mutations in the sequences of the genes from P. falciparum dihydropteroate synthase and 
P. falciparum dihydrofolate reductase (PfDHPS and PfDHFR), rendering those enzymes 
less susceptible to the folate inhibitors. At the same time, pyrimethamine and sulfadoxine 
act more slowly than quinolines as blood schizonticides and their prolonged clearance 
encourages the selection of resistant parasites. 
Proguanil is well tolerated when administrated orally but has little antimalarial 
activity until oxidized in the body by CYP2C isoforms to the active metabolite 
(cycloguanil). This active metabolite exerts activity against both the primary liver stages 
and the asexual red cell stages. Pyrimethamine demonstrates a higher antimalarial 
potency than cycloguanil but its efficacy against hepatic forms is lower. At therapeutic 
doses, both drugs fail to eradicate the latent tissue forms of P. vivax or gametocytes of 
any species.22,23 
The use of proguanil is limited by the rapid development of resistance and by 
the too slow schizontocidal activity on erythrocytic forms. As such, this prodrug is 
administered in combination with atovaquone or chloroquine, for the treatment or 
prophylaxis of malaria.21 
Sulfadoxine and pyrimethamine, used in a synergistic combination (to inhibit 
two steps in folate synthesis pathway), were introduced in the mid-1970s, and this strategy 
has been effective in controlling malaria, especially some strains of chloroquine-resistant 
P. falciparum. Pyrimethamine inhibits PfDHFR at concentrations far lower than the 
required to inhibit the mammalian enzymes, so it causes little toxicity. However, the drug 
combination sulfadoxine-pyrimethamine is not recommended for prophylaxis due to 
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toxicity of the sulphonamide (including Stevens-Johnson’s syndrome, hepatotoxicity and 
myelosuppression).21–23 
1.2.3. Protein synthesis inhibitors 
Some antibiotics, such as tetracyclines and lincosamides, demonstrate 
antimalarial activity, possibly due to specific inhibition of the parasite’s plastid-like 
organelle, the apicoplast, where protein synthesis occurs. From the tetracycline family, 
tetracycline and doxycycline (Figure 1.12) are the most frequently used antibiotics in 
antimalarial therapy, but their relative slowness of action as blood schizonticides makes 
them ineffective as single agents. However, they are successfully applied in combination 
regimens, with quinine or artesunate. These two tetracyclinic antibiotics have marked 
activity against primary tissue schizonts of chloroquine-resistant P. falciparum. 
Clindamycin (lincosamide; Figure 1.12) in combination with quinine is effective to treat 
patients with falciparum malaria who could not take doxycycline. Doxycycline may be 
used by travellers for short-term prophylaxis of malaria by multidrug-resistance species.22 
 
Figure 1.12 – Structural representation of the antibiotics with antimalarial activity. 
1.2.4. Precursors of free radicals 
The Qinghao plant (Artemisia annua) was described for its anti-fever properties, 
in a Chinese medical treatise, during the second century BC. However, the isolation of its 
active ingredient (artemisinin; Figure 1.13) was reported only in 1971, and even raised 
some scepticism. After structure elucidation of this active pharmaceutical ingredient 
(API), many studies ensued to elucidate the pharmacophore, mode of action and to 
evaluate pharmacologic properties, for example. To improve the poor bioavailability of 
this sesquiterpene containing a 1,2,4-trioxolane, some semisynthetic derivatives, known 
as artemisinins (artenimol or dihydroartemisinin, artemether, arteether, artesunate 
and artelinic acid; Figure 1.13) have been developed from the manipulation of the 
lactone function. It was found that these derivatives are metabolized to 
dihydroartemisinin, which appears to be the main bioactive form of the artemisinin-based 
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drugs. The artemisinins are very potent and effective antimalarial drugs, widely used in 
our days, especially in combination regimens with other antimalarials.4 
 
Figure 1.13 – Structural representation of artemisinin and its derivatives (artemisinins). 
 Several studies have confirmed that the mechanism of action of these artemisinins 
involves the production of free radicals, which are toxic to the parasites. So, an 
endoperoxide moiety is required for antimalarial activity. It has been postulated that the 
endoperoxide bridge is cleaved within the parasite (through a process catalysed by the 
haem iron), forming oxigen-centered radicals that, after rearrangement, produce carbon-
centered radicals that alkylate and damage macromolecules in the parasite. Then, these 
drugs are active especially for the asexual erythrocytic stages of P. vivax and P. 
falciparum, and could evidence some gametocytocidal activity, but do not affect liver 
stages.  
Artemisinins are associated with a high level of parasite recrudescence when used 
alone and should not be used as prophylaxis due their rapid metabolism (short half-life). 
They are not cross-resistant with other drugs and, indeed, some studies have shown an 
increase in sensitivity to the artemisinins among chloroquine-resistant parasites. Then, 
artemisinin and its derivatives are being used widely in combination with other agents 
with different mode of action (artemisinin combination therapy – ACT), maximizing 
treatment efficiency and reducing the emergence of further drug resistance. However, 
despite these efforts resistance is still being seen to emerge in cases of P. falciparum 
infection.11,22 
The artemisinins enjoy a deserved reputation of safety. However, reports of mild 
gastrointestinal disturbance, haemolytic anaemia and bradycardia have emerged. Barriers 
to effective ACT programs include the relatively high cost, the difficulty in obtain large 
quantities of artemisinin and the counterfeit drugs. Combination treatments of artesunate 
with mefloquine, amodiaquine or pyrimethamine-sulfadoxine, and artemether with 
lumefantrine are examples of ACT regimens.11,21 
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Besides the antimalarial activity, artemisinin and its derivatives exhibit 
antiparasitic activity against other protozoa, including Leishmania major, Leishmania 
infantum30 and Toxoplasma gondii.22 
In addition to the artemisinin-derivatives described above, numerous 
semisynthetic derivatives have been studied for their antiparasitic properties, such as 
fluorinated dihydroartemisinin derivatives, fluoroaryl artemisinins, hybridized 
artemisinin derivatives and dimeric artemisinins.31 
The short supply of natural artemisinin and its difficult and costly total synthesis 
still make it unaffordable to most. So, the use of a microbial source (like engineered yeast) 
to obtain artemisinin or derivative has been investigated.32 
Another approach is based in the synthesis of fully synthetic endoperoxides 
(especially 1,2,4-trioxolanes and 1,2,4,5-tetraoxanes)33 without a artemisinin core. 
Among these, trioxolanes OZ277 (or arterolane) and OZ439 and tetraoxane RKA182 
(Figure 1.14) attained clinical trials. OZ277 shows potent antimalarial activity and, 
besides its clinical trials disappointing results (unstable in the plasma of malaria patients), 
the investigation of this drug in combination regimens continues in development. OZ439 
is now under a clinical development program to investigate its efficacy when 
administered alone or when co-administered (e.g. with piperaquine phosphate) to adults 
and children with uncomplicated P. falciparum malaria.34–37 
 
Figure 1.14 – Structural representation of OZ277 and OZ439 (1,2,4-trioxolanes) and RKA182 
(1,2,4,5-tetraoxane). 
Studies about endoperoxide stability have shown that 1,2,4,5-tetraoxanes have 
significantly higher stability than their 1,2,4-trioxolane counterparts. RKA182 
demonstrated superior properties to the semisynthetic artemisinins: better antimalarial 
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activity, stability, ADME (absorption, distribution, metabolism and excretion) properties 
and lower toxicity.  
1.2.5. Other approaches and emerging chemotherapeutic tools against 
malaria 
The development of resistance to available drugs by Plasmodium parasites 
continues growing, increasing the difficulty to control malaria. Many new approaches to 
antimalarial drug discovery are under development or in study, considering new scaffolds 
and new therapeutic targets.  
A. Protease inhibitors  
Proteases are required for the parasite survival, intervening in crucial processes 
such as the erythrocyte invasion (PfSUB1 and PfSUB2),16, the haemoglobin degradation 
and the erythrocyte rupture (cysteine proteases)38. These proteases are potential 
chemotherapeutic targets. 
The haemoglobin degradation has been explored in antimalarial drug design 
programmes, and most studies are directed to find inhibitors of the proteases acting in this 
pathway, with the aim of blocking the production of free amino acids by the parasites, for 
feeding purposes. Aspartic proteases plasmepsin I, II and IV (involved in initial cleavage 
of haemoglobin),39 cysteine protease falcipain-2 (involved in cleaving relatively large 
globin fragments)38 and metalloprotease falcilysin and histoaspartic protease (involved in 
cleavage of smaller peptides) are some of the proteases involved in the parasite’s feeding 
and, as such, suitable targets for antimalarial drug design.40 
B. Utilization of parasite-induced transport systems 
The cell membranes of the host (including of erythrocytes) contain many 
transporters responsible for the movement of molecules between the plasma and the cell 
cytosol. However, upon a malarial infection new permeation pathways are induced and 
have demonstrated functional characteristics that are quite different from those of the host 
transporters. Thus, one potential approach to fight malaria may consist in the 
administration of a parasiticidal agent that is not taken by host cells but is transported by 
the new permeation pathways, allowing its accumulation inside the infected erythrocyte 
and subsequent destruction of the parasite.41 
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C. Inhibitors of phospholipid and fatty acid synthesis 
In the erythrocytic phase, Plasmodium needs to synthesize its own components of 
parasite membranes, predominantly phospholipids. So, inhibition of the synthesis and/or 
transport of some precursors required for the synthesis of phospholipids, has shown to be 
a promising strategy for drug design.42 
Fatty acids play an important role to provide precursors of biological membranes 
and represent an important form of metabolic energy.  The human host synthesizes fatty 
acids using a type I fatty acid synthase (FAS-I). However, and differently, Plasmodium 
parasites use a type II system (FAS-II). Since the human host and the parasite synthesize 
fatty acids via different pathways, this could be an important intervention focus for the 
development of new antimalarials.43 
D. Inhibitors of protein farnesylation 
Protein prenylation or lipidation are processes of post-translational modification 
of proteins by the addition of hydrophobic moieties of 15 carbons (farnesyl group) or 20 
carbons (geranylgeranyl group). These groups facilitate attachment to membranes, as well 
as protein interactions. Protein farnesyl transferase (PFT) is one of the enzymes 
responsible for the protein prenylation and occurs in eukaryotic cells but also in a wide 
variety of pathogenic protozoa, including P. falciparum. Some studies have shown that 
PFT inhibitors are more toxic to cancer cells and parasites than to normal mammalian 
cells.44 
E. Inhibitors of heat-shock proteins  
Heat-shock proteins (HSP) have an important role in stress tolerance and in the 
folding, activation and assembly of many proteins, such as steroid hormones, protein 
kinases and molecules regulating the cell cycle. During host invasion, establishment and 
development, parasites are exposed to environmental stress and the parasitic heat-shock 
protein (expressed during the erythrocytic stages) has an important role in the parasite 
survival. HSP inhibition may affect the parasite’s progression from ring to trophozoite.45 
Furthermore, human host humoral response against parasite’s HSP has been observed, 
placing this protein as an important antigen target for the development of vaccines.46 
F. Protein kinase inhibitors 
Protein kinases are key regulators of cell cycle control. One family of kinases, the 
cyclin-dependent protein kinases (CDK), regulates directly the timely progression 
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through the cell cycle. Some CDK inhibitors effectively inhibit PfPK5 (P. falciparum 
protein kinase 5) and/or PfMRK (P. falciparum MO15-related protein kinase), two 
plasmodial CDK that are structurally different from the host’s CDK.47 
G. Inhibitors of glycolysis 
Plasmodium parasites do not have a functional Krebs cycle and hence rely 
extensively on ATP (adenosine triphosphate) generation via the anaerobic fermentation 
of glucose. Lactate dehydrogenase (LDH), the last enzyme in the glycolytic pathway, 
converts pyruvate to lactate with simultaneously conversion of NADH to NAD+ 
(nicotinamide adenine dinucleotide). Thus, inhibition of LDH is expected to stop 
production of ATP, with subsequent Plasmodium cell death.  
Structural and kinetical discrepancies between these malarial enzymes (PLDH) 
and the three human counterparts (HsLDH) suggest that specific and potent malarial 
inhibitors can be designed or identified.48 
H. Inhibitors of the shikimate pathway  
The shikimate pathway, known to exist in P. falciparum but not in mammals, leads 
to the biosynthesis of aromatic aminoacids. The inhibition of 5'-enolpyruvylshikimate 3-
phosphate synthase by glyphosate (Figure 1.15) was found to inhibit the growth of P. 
falciparum. However, it is not clear if biosynthesis of aromatic aminoacids plays an 
essential role in this parasite and if this compound inhibits growth of the parasite by 
inhibition of this enzyme of the shikimate pathway.23 
I. Inhibitors of isoretinoid biosynthesis  
A mevalonate-independent isoprenoid biosynthetic pathway was identified in P. 
falciparum and T. gondii, but not in humans. Inhibiting 1-deoxy-D-xylulose-5-phosphate 
isomerase by fosmidomycin (Figure 1.15), leads to an in vitro inhibition of the growth 
of P. falciparum. However, it has not been demonstrated that this pathway plays an 
indispensable role in this parasitic organism, neither that the inhibition of the parasites is 
due to inhibition of this particular enzyme.23 
 
Figure 1.15 – Structural representation of glyphosate and fosmidomycin.  
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1.3. Mitochondria – an essential organelle 
Mitochondria as an organelle emerged from a symbiotic arrangement is also 
characterized by loss and transfer of some genes from the mitochondria to the host 
genome.49–51 
The phylum Apicomplexa contains the smallest mitochondrial genome known 
and, despite the relatively low activity of the mitochondrial electron transport chain 
(mtETC), mitochondria plays a critical and essential role in the life cycle of the parasite 
as the primary source of the proton electrochemical gradient. The blood-stage of P. 
falciparum maintains an active mitochondrial electron transport chain to serve the 
regeneration of ubiquinone (CoQ).50,52 The molecular and functional differences between 
the human’s mitochondria and the parasite’s mitochondria highlight this organelle as a 
target for medicinal chemistry.53–55 
1.3.1. The mitochondrial electron transport chain of P. falciparum 
Conventionally, the mitochondria is viewed as the source of cellular energy in the 
form of ATP, but previous studies have demonstrated that glycolysis is the main source 
of ATP in the intraerythrocytic stage of Plasmodium, with little or no contribution from 
oxidative phosphorylation driven by the TCA (tricarboxylic acid) cycle and from 
respiratory chain.53,56 
However, mtETC continues to be the main generator of the proton electrochemical 
gradient which, while not appearing to power the mitochondrial ATP synthesis in blood 
stages of Plasmodium, is required to transport metabolites and proteins in and out of the 
mitochondria to fuel carbon metabolism in this organelle (Plasmodium parasites do not 
have a functional Krebs cycle).57,58 
Instead of the canonical multimeric complex I (NADH: dehydrogenase), found in 
mammalian mitochondria, the intraerythrocytic malaria parasites encode four 
dehydrogenases or oxidoreductases belonging to the mtETC (Figure 1.16): type II NADH 
ubiquinone oxidoreductase (PfNDH2), dihydroorotate dehydrogenase (PfDHODH), 
glycerol 3-phosphate dehydrogenase (GPDH) and malate quinone oxidoreductase 
(MQO). Some of these dehydrogenases act concomitantly with succinate ubiquinone 
oxidoreductase (Complex II or SDH) to reduce CoQ (ubiquinone) to ubiquinol 
(dihydroubiquinone or CoQH2), providing electrons to the other complexes involved in 
the mtETC: ubiquinol cytochrome c oxidoreductase (Complex III or cytochrome bc1), 
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cytochrome c oxidase (Complex IV) and ATP synthase (Complex V). Complex III is 
responsible for the reoxidation of CoQH2 to CoQ.
53 
 
Figure 1.16 – Representative diagram of Plasmodium mitochondrial electron transport chain.55 
PfNDH2 catalyses the oxidation of NADH with concomitant reduction of CoQ to 
CoQH2. While this mitochondrial enzyme is not involved in the vectorial transfer of 
protons across membranes, due to the absence of transmembrane domains, its activity 
may indirectly contribute to the formation of an electrochemical transmembrane 
potential. Similar type II NADH dehydrogenases may be found in other organisms, 
including plants, fungi and bacteria, such as Mycobacterium tuberculosis.55,59–61 
PfDHODH is involved in pyrimidine biosynthesis, essential for the formation of 
DNA, RNA (ribonucleic acid), glycoproteins and phospholipids, therefore crucial for the 
parasite survival. It is responsible for the conversion of dihydroorotate to orotate, where 
CoQ is the co-substrate electron acceptor being reduced to CoQH2.
50,55,57 
Mitochondrial GPDH plays a very important role in the bioenergetic metabolism, 
interfering with glycolysis, oxidative phosphorylation and fatty acid metabolism. This 
isoform catalyses the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate, 
with concurrent reduction of flavin adenine dinucleotide (FAD) to FADH2 and, via 
another independent protein domain, transference of electrons to CoQ, giving CoQH2 and 
FAD regeneration.62,63 
Chapter 1 - Introduction 
 
35 
MQO exists in multiple forms that differ in cofactor specificity and subcellular 
localization. Mitochondrial MQO catalyses the conversion of malate to oxaloacetate (for 
the biosynthesis of citrate) and the generation of NADH to feed the respiratory chain.58 
The Plasmodium Complex II is composed by four subunits, where a 
flavoprotein (Fp) and iron-sulphur (FeSp) subunits form a catalytic portion. The Fp 
subunit converts succinate to fumarate with oxidation of FADH2 to FAD. The FeSp 
subunit contains three iron-sulphur clusters [2Fe-2S], [4Fe-4S], and [3Fe-4S], and 
provides the reduction of CoQ to CoQH2 using the electrons derived from the succinate 
oxidation via FAD.56  
 With the reoxidation of CoQH2 to CoQ in Complex III, cytochrome c acts as 
electron carrier to Complex IV transferring the electrons to one oxygen molecule to get 
two molecules of water. In addition, protons are translocated across the membrane to the 
intermembrane space, helping to establish a transmembrane difference of the 
proton electrochemical potential that can be used by ATP synthase (Complex V) to 
synthesize ATP from ADP (adenosine diphosphate).53,55  
1.3.2. Cytochrome bc1 protein complex (Complex III) 
The cytochrome bc1 is a protein complex that should not be referred to as an 
enzyme. This homodimeric system is member of the larger family of bc-type complexes 
that spans the inner mitochondrial membrane. Each functional unit of the homodimeric 
complex is composed by ten polypeptide chains embedded with some haem units. The 
catalytic core contains three electron transfer subunits: cytochrome b; cytochrome c1; and 
an iron-sulphur protein known as the Rieske protein (ISP) – see Figure 1.17.64,65 The other 
seven subunits are not well understood, presuming that they are involved in the complex 
anchoring at the mitochondrial membrane.66 
Cytochrome b is a transmembrane protein in which two b-haem groups (low 
potential bL and high potential bH) form an electrical circuit across the subunit from the 
Qo site (or P), on the outer electropositive portion, to the Qi site (or N), on the inner 
electronegative portion. The ISP is anchored to the complex by a hydrophobic helix, at 
the N-terminal, and the C-terminal domain, that contains a [2Fe-2S] cluster, is located 
near the electropositive surface of the membrane. Cytochrome c1 is held to the complex 
by a hydrophobic helix at the C-terminal and the domain of the protein, that contains the 
haem, is accessible at the electropositive surface of the membrane, where it reacts with 
cytochrome c.64 
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1.3.2.1. Protonmotive Q-cycle 
The cytochrome bc1 complex transfers electrons from ubiquinol (CoQH2) to 
cytochrome c, regenerating ubiquinone (CoQ) and translocating protons across the 
membrane (from the matrix of mitochondria to the intermembrane space). This process, 
described by Mitchell’s Q-cycle hypothesis (Figure 1.17 and Figure 1.18), is designated 
protonmotive Q-cycle and maintains a membrane potential across the mitochondrial 
membrane, essential for some biological processes (pyrimidine and ATP synthesis).67–69 
In each complete cycle, two molecules of CoQH2 are oxidised to CoQ at Qo and 
four protons (H+) are translocated to the intermembrane space. At the same time, four 
electrons (e-) are released and, while two of them reduce one molecule of CoQ to CoQH2 
(at Qi), the other two move to the [2Fe-2S] cluster of the ISP. Upon reduction of ISP its 
cytoplasmic region changes, favouring the transfer of these two electrons to the haem 
group bound in cytochrome c1, which is then reoxidised by cytochrome c, that acts as 
electron carrier to Complex IV.68–71 
 
Figure 1.17 – Representative diagram of the reactions held in complex III (Protonmotive Q-
cycle), targeted by some drugs or drug candidates. Adapted from Vaidya et al..53 
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Figure 1.18 – Representation of structural changes from ubiquinone to ubiquinol (at Qi site) and 
from ubiquinol to ubiquinone (at Qo site). 
1.3.3. Inhibition of the cytochrome bc1 
Malaria parasites have retained the ability to generate a large electrochemical 
potential across their mitochondrial membrane. mtETC is critical for parasite survival 
and, as the inhibition of respiratory enzymes has severe consequences, drugs targeting 
these enzymes could be efficient tools for pathogen control. While complexes I and 
III are the main targets of mtETC in study for development of new antimalarial, the 
P. falciparum bc1 complex is the only component with an inhibitor clinically used as 
antimalarial drug (atovaquone).55,60,72 
Cytochrome bc1 inhibitors block the catalytic activity of the Complex III and, 
consequently, the respiratory chain is implicated. However, as the structure of 
cytochrome bc1, especially its catalytic core, is highly conserved between species, 
these inhibitors could evidence high toxicity to mammals and other non-pathogenic 
organisms. Despite this, some light unusual structural features in P. falciparum 
cytochrome b may be used to facilitate the design of inhibitors with some selectivity 
(decreased toxicity). In addition, the target (cytochrome b) is encoded by a 
mitochondrial gene that appears to accumulate mutations at a higher frequency than 
nuclear genes and resistance mutations are thus a possibility. From this viewpoint, the 
Qi site is a more desirable target than Qo because the first one reflects less point 
mutation issues.72–74 
Considering that the protonmotive Q-cycle (in cytochrome bc1 complex) 
requires two reaction sites (Qi or N; and Qo or P), the cytochrome bc1 complex 
inhibitors can be grouped in two categories, based on their binding site.67,69,75 
Class I inhibitors inhibit electron bifurcation at the Qo site and, historically, 
can be further subdivided into three or two subclasses, based on their chemical 
characteristics or on their structural effects on the protein target, respectively. 
Myxothiazol (Ia), stigmatellin (Ib) and 2-hydroxy quinone (Ic) analogues (such as 5-
n-undecyl-6-hydroxy-4,7-dioxobenzothiazole - UHDBT) are some examples of 
compounds that bind at the Qo site (Figure 1.19).
67,76 
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Figure 1.19 – Structural representation of myxothiazol, stigmatellin and UHDBT. 
Class Ia inhibitors (e.g. myxothiazol) bind at the Qo site, leaving the ISP mobile, 
while Ib and Ic inhibitors, when bound at the Qo site, fix the ISP region in a set position 
(temporary locking).76 
In addition to these three subclasses of organic compounds, zinc ions bind at the 
Qo site and prevent the release of protons formed during the ubiquinol oxidation, 
inhibiting reversibly the bc1 complex. However, Zn
2+ is not competitive to the binding of 
other Qo site inhibitors.
75 
Class II inhibitors target the Qi site and are represented by antimycin A (Figure 
1.20), a natural fungicide produced by Streptomyces sp.. Although less susceptible to 
development of resistance, Qi is situated on the inner face of the inner mitochondrial 
membrane, making it relatively inaccessible.67,75 
 
Figure 1.20 – Structural representation of antimycin A. 
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1.3.4. Atovaquone 
Atovaquone is a 2-hydroxynaphthoquinone, an analogue of ubiquinone, and 
acts as a competitive inhibitor of the cytochrome bc1 protein complex (binding 
specifically to Qo site – class Ib inhibitor) in the parasite mitochondria, disrupting the 
membrane potential that provides energy for mitochondrial function and is essential 
for pyrimidine synthesis. Besides, some recent studies have suggested that the 
inhibition of purine biosynthesis may be a further cellular consequence of 
mitochondrial inhibition by atovaquone.59,77,78 
The beginning of the atovaquone development goes back more than 50 years, 
when World War II caused substantial shortages in the supply of quinine. Thousands of 
compounds were then investigated and some members of the hydroxynaphthoquinone 
chemotype showed greater antiplasmodial activity than quinine. However, these 
compounds revealed low or null activity in clinical trials, due to poor absorption and rapid 
metabolism. Only in 1991, the chemical synthesis of atovaquone, a compound with good 
antimalarial activity, metabolic stability and inertness to human liver microsomes, was 
disclosed.79–81 
Atovaquone is active against blood-stage parasites but its effect is relatively 
slower than that showed by other antimalarials, such as artemisinin and chloroquine, 
because atovaquone acts only on late trophozoites and not on the earlier stages (“ring 
forms”). It is also active against liver stages of P. falciparum (important utility in 
prophylaxis), but not against P. vivax hypnozoites. In addition to the activity against 
Plasmodium, atovaquone shows activity against some opportunistic pathogens, e.g. 
Pneumocystis jiroveci and Toxoplasma gondii.22,23,80,82 
Atovaquone is effective at concentrations far lower than those at which the 
mammalian system is affected. In vitro, atovaquone IC50 (half maximal inhibitory 
concentration) is very low, ranging from 1 to 3.5 nM. Although the high levels of plasma 
protein binding (99.5%), atovaquone plasma concentrations (around 1–10 mM) are 
sufficient to produce total suppression of malaria.83 
 This class Ib inhibitor is generally well tolerated and just causes few and mild side 
effects, such as rash, fever, vomiting, diarrhoea, abdominal pain and headache. Overdoses 
(as large as 31500 mg) have been reported to cause little or no symptomatology. The main 
problem about toxicity in the development of antimalarials targeting the mitochondria of 
the parasite is the possibility of host mitochondrial toxicity, since some animal models 
manifest cardiotoxicity.80,84,85 
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Atovaquone has been successful clinically, especially if administered in 
combination with proguanil (a dihydrofolate reductase inhibitor) – Malarone® (Figure 
1.21). Malarone® combination was released in 2000 by GlaxoSmithKline and has been 
used for treatment and prevention of chloroquine-resistant infections, especially in 
Southeast Asia, where highly drug-resistant strains of P. falciparum prevail. It has also 
been used to slow development of resistance, since P. falciparum readily develops clinical 
resistance to monotherapy with either proguanil or atovaquone.22,55,59  
 
Figure 1.21 – Structural representation of the active compounds of the Malarone® (atovaquone 
and proguanil). 
One reason for the preference of combinations with atovaquone, as Malarone®, in 
detriment of monotherapy, is the synergism that the proguanil exerts. Proguanil as 
monotherapy has no effect on mitochondrial membrane potential, but significantly 
enhances the ability of atovaquone to collapse mtETC. Even in the presence of 
documented proguanil resistance or in patients who are deficient in cytochrome P450 
enzymes, required for the conversion of proguanil to cycloguanil, this synergetic activity 
emerges.86 
Despite well tolerated, the cost of Malarone® limits or even precludes its 
widespread use in resource-poor settings and disease-endemic areas, where it is most 
needed. The need of addition of proguanil in therapeutic doses and the obligation to keep 
the central cyclohexane ring of atovaquone in trans configuration have increased the 
complexity and the cost of this preparation.22 
1.3.4.1. Atovaquone binding at Qo 
Some studies have been carried out to define the exact binding position of 
atovaquone at Qo of P. falciparum. The plasmodial cytochrome bc1 has not been 
successfully isolated and crystallized, so the studies have analysed the interactions 
between atovaquone and bc1 complex homologs in bacterial and yeast based systems. 
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Trumpower et al. used the crystal structure coordinates of stigmatellin-bound 
Saccharomyces cerevisiae yeast bc1 as reference to model the interactions of 
atovaquone with the Qo pocket (Figure 1.22). S. cerevisiae yeast bc1 has a high 
sequence identity with Plasmodium bc1 complex, can be easily purified and its crystal 
structure is available.87–90 
 
Figure 1.22 - Trumpower et al. study: in silico docking results for atovaquone binding in the 
ubiquinol oxidation pocket at center P of the yeast bc1 complex. (cyan) cytochrome b; (orange) 
portion of the Rieske ISP; (yellow and purple atoms) iron-sulfur cluster [2Fe-2S]; (green) 
atovaquone (oxygen atoms are red and chlorine atom is yellow); key amino acids His181, Glu272 
and Leu275 are shown and highlighted.87–90 
As observed for stigmatellin (Ib inhibitor) and UHDBT (Ic inhibitor), the 
results obtained by Trumpower et al indicate that atovaquone binds to the Qo pocket 
when the water-soluble mobile region of the ISP is proximal to cytochrome b, 
allowing the direct interaction of atovaquone with both protein chains. Through 
docking studies, Trumpower et al. found that the hydroxyl group on the 
naphthoquinone ring of atovaquone forms a hydrogen bond with the His181 of ISP. 
A second hydrogen bond, water mediated, is formed between the Glu272 of 
cytochrome b and the quinone carbonyl of the naphthoquinone ring.87,89,90 
The same research group proposed to explain the difference in efficacy of 
inhibition of the yeast and the bovine (mammalian) bc1 complexes by atovaquone 
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(atovaquone is about eight times more potent against yeast bc1 complex than against 
the bovine enzyme). To be clinically used, atovaquone must exhibit selective 
inhibition of the targeted pathogen compared with the mammalian host. The bovine 
bc1 protein is 80% identical to the human protein and, for example, the ef loop of 
cytochrome b is a conserved domain containing residues in close contact to the 
atovaquone-binding pocket. However, in the mammalian sequence (both in bovine 
and human proteins), the Leu275 found in yeast is replaced by phenylalanine. 
Computational modelling for this change results in steric constraint to atovaquone 
binding, with a predicted decrease in the affinity of the inhibitor to the binding 
pocket.90 
1.3.4.2. Atovaquone and selection for resistance 
From the last four decades, P. falciparum has developed resistance to almost 
every available antimalarial drug. Selection for resistance by the parasite is a major 
obstacle in the control of the malaria. Thus, besides the study of new and more cost-
effective inhibitors, other strategies are urgently needed to control the development 
of resistance and, ideally, to reverse existing resistance. 
The most common measures to circumvent or delay selection for resistance are 
the use of combinations of synergetic antimalarials (e. g. Malarone®) and the 
immediate interruption of a particular drug when a certain level of treatment failure is 
observed. The removal of the selection pressure exerted by the drug in question may 
enable a susceptible parasites population to reestablish itself and gradually replace the 
resistant counterpart. In many organisms, mutations that confer resistance to drugs 
clearly provide the organism with a survival advantage in the presence or absence of 
drug. However, in other organisms, mutations that confer resistance can be a 
disadvantage for the survival of the population in the absence of drug pressure. In the 
case of Plasmodium, the relative fitness of the resistant strains in the absence of drug 
pressure is unclear.91 
Plasmodium resistance to atovaquone may be attributable to single point 
mutations in plasmodial cytochrome b that arise from increased oxidative damage to 
mitochondrial DNA generated by the action of the drug, reducing the binding affinity for 
the atovaquone to the Qo site. Besides that reason, the mitochondrial genome has, by 
nature, a high frequency of mutations. Several authors claim that these mutations can 
confer up to a 760-fold drop in potency, rendering the drug ineffective at safe therapeutic 
Chapter 1 - Introduction 
 
43 
doses. Several of these mutations cause alterations in the amino acids forming the 
hydrophobic channel of Qo rather than alterations in the structure of Qo itself, because an 
alteration of the catalytic site could render the protein complex inactive.23,92–95 
Over one-third of the patients treated with atovaquone as monotherapy are 
expected to evidence post-treatment recrudescence – one of the many reasons to use 
atovaquone in combination with proguanil. While parasites resistant to proguanil are 
affected by Malarone®, parasites resistant to atovaquone are not inhibited by this one. The 
first cases of Malarone® resistance were observed in Africa and were linked to the single 
amino acid mutation at codon 268, resulting in a change from tyrosine to serine 
(Tyr268Ser) or asparagine (Tyr268Asn) in the cytochrome b structure. This residue is 
involved in a hydrophobic interaction with the ubiquinol, so the mutation is likely to result 
in a significant respiratory penalty for the parasite. Similar mutations in other codons 
associated with atovaquone resistance have been identified, in clinical isolates and in 
experimental rodent malaria models.72,87,96,97 
1.3.5. Other antimalarial compounds targeting cytochrome bc1 protein 
complex 
Considering the growing emergence of resistance, development of new and 
effective antiplasmodial drugs is a priority. From the validation of mtETC as an important 
target and the knowledge regarding atovaquone interactions with the cytochrome bc1 
complex, new inhibitors for use against P. falciparum have been studied. The mtETC is 
an attractive target owing to the multistage activity of its inhibitors. However there are 
barriers to development of novel inhibitors, such as poor solubility and the possibility of 
cardiotoxicity. 
Furthermore, since some mutations associated to atovaquone resistance tend to 
confer cross resistance to other Qo inhibitors, the new and more cost-effective inhibitors 
of the bc1 complex must overcome the resistance mechanisms. So far, the more 
established compounds for the study of antimalarial bc1 inhibition are, essentially, based 
on aromatic ring systems and are classified into five classes, according with their core 
chemical structure.55 Studies about these classes have been reviewed by various authors, 
highlighting the works of Trumpower et al.,87 P. O’Neill et al.,73 G. Biagini et al.,55 
Beteck et al.98 and P. Gomes et al.99. 
 
 
Chapter 1 - Introduction 
 
 
44 
1.3.5.1. Atovaquone analogues (1,4-naphthoquinones) 
As discussed before, a sudden shortage of quinine (in 1950’s) boosted the 
investigation of thousands compounds, a large number of which being 
hydroxynaphthoquinone-type structures. From this huge effort resulted atovaquone, a 
hydroxynaphthoquinone with excellent antimalarial activity but with poor 
pharmaceutical properties, such as low bioavailability and high plasma protein binding. 
As such, several atovaquone analogues (1,4-naphthoquinones) have been investigated to 
improve atovaquone’s profile (Figure 1.23).55,73 
 
Figure 1.23 – Representation of the core structure of 1,4-naphthoquinone class; structures of 
naphthoquinones studied as antimalarials. 
El Hage et al. designed a library of compounds replacing the 3-hydroxyl 
functional group of atovaquone by more lipophilic ester and ether groups. Most of them 
showed potent activities with IC50 values in the range of 1.25–5 nM, however these 
modifications did not lead to an improvement in the atovaquone’s profile.100 
In another strategy, Trumpower´s group developed a series of atovaquone 
analogues based on a potent hydroxynaphthoquinone Plasmodium bc1 inhibitor (S-
10576) that had proved to be inactive in humans due to rapid metabolic degradation. 
Incorporation of a trifluoromethyl group into branched and straight chain alkyl groups 
and/or a methyl group on the aromatic ring led to the synthesis of NQ1-NQ3. This methyl 
group has been associated to van der Waals interactions with the Rieske ISP. While 
overcoming the metabolic instability, these compounds demonstrated reduced species 
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selectivity and reduced potency. 1,4-naphthoquinone-based compounds have potential as 
bc1 inhibitors but their drug-like profile needs to be improved.
101 
1.3.5.2. 4(1H)-pyridones 
Pyridones have been known as potent antimalarials since 1960’s, when clopidol 
(Figure 1.24) was found to exhibit activity against chloroquine resistant strains of P. 
falciparum. Actually, clopidol is also known to potentiate the action of 
hydroxynaphthoquinones and sustains activity against atovaquone-resistance strains. The 
overcome of the atovaquone resistance may suggest that pyridone derivatives could bind 
at a different site (not just at the Qo pocket).
55,73,85 
Considering the chemical structure of clopidol, various pyridone-based 
compounds have been synthesized and studied as potential antimalarials (Figure 1.24).  
 
Figure 1.24 – Structural representation of clopidol and other pyridone-based compounds with 
antimalarial properties. 
In 2006, GlaxoSmithKline (GSK) in collaboration with Yeates et al., reported the 
preclinical evaluation of new 4(1H)-pyridones targeting the bc1 complex of P. 
falciparum, highlighting that halogenation at the C-3 position (Figure 1.24) leads to a 10-
fold increase in activity in vitro, while the introduction of a phenoxyaryl side chain at C-
5 also gave an increased activity.  
The most promising candidate, GW844520 (Figure 1.24), exhibited impressive 
antimalarial potency (IC50 of 2 nM) and activity against atovaquone resistant strains. 
Further development, to solve the solubility issues often encountered with these 
compounds, by introduction of a hydroxyl group originated the synthesis of GSK932121 
(Figure 1.24), also potent against resistant strains. Unfortunately, these pyridones have 
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been suspended at clinical trials due to toxicity issues (unexpected cardiotoxicity) that 
have yet to be resolved.85,102,103 
1.3.5.3. Acridinediones and acridones 
Acridinediones (Figure 1.25) and acridones (Figure 1.26) are tricyclic compounds 
incorporating the 4-oxo-1,4-dihydroquinoline skeleton, being structurally related to 
quinolones. 
The antimalarial activity of selected acridinediones is known since 1947 and the 
interest in this class grew when floxacrine (Figure 1.25) revealed prophylactic properties 
(in 1970’s), although this drug had limited solubility, unacceptable side-effects (it was 
temporarily abandoned) and eventually became useless due to rapid development of 
resistance.98,104 
 
Figure 1.25 – Structural representation of the acridinedione ring system, of floxacrine and of 
WR249685. 
Floxacrine (Figure 1.25) was initially shown to bind to haem, preventing the 
crystallization of haemozoin, but a second mode of action has been considered recently. 
WR249685 (Figure 1.25) showed a higher in vitro antimalarial activity than floxacrine 
(IC50 around 15 nM for WR249685 vs 140 nM for floxacrine) and was found to inhibit 
the Plasmodium bc1 complex. This compound revealed a significant selectivity, with a 
ratio of inhibition towards P. falciparum bc1 protein of 4600, compared to the mammalian 
protein, while floxacrine failed to selectively inhibit the P. falciparum bc1 protein 
complex.105 
Acridones were initially isolated as intermediates in the synthesis of haem-
complexing compounds and have also been found to possess a dual mechanism of action, 
like some acridinediones: some acridone analogues expressed moderate to significant 
cross resistance with the atovaquone-resistant TM90 strain (mechanism of action may be 
similar to atovaquone). It is possible that the acridones exhibiting no cross resistance have 
overcome the resistance mechanism or they are predominantly haem binders.55,73 
Acridones are fully aromatic, so the issue of chiral isomers that can arise from the 
substitution of the alkyl C-ring of acridinediones is avoided. A variety of highly potent 
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acridone compounds was synthesized, from which some acridone 3-ethers steamed as 
very promising scaffolds.106,107 
 
Figure 1.26 – Structural representation of the acridone ring system and of antimalarially active 
3-ether derivatives. 
 After synthesis and optimization, a compound with an in vitro activity of around 
1 pM against P. falciparum (D6 and Dd2 strains) was selected for development. 
Considering its IC50, this compound, 3-chloro-6-((5,6,6,6-tetrafluoro-5-
(trifluoromethyl)hexyl)oxy)acridin-9(10H)-one (Figure 1.26), appears to be the most 
effective antimalarial ever synthesized and tested in laboratory, although its mode of 
action is still unknown. It bears a flexible alkoxy side chain at C-3, which resembles the 
isoprenyl side chain of ubiquinones, terminating with two trifluoromethyl units. This 
flexibility, currently used at the side-chains, may lead to problems of selectivity. 
However, in this case, no toxicity problems were reported following in vivo tests.98,106,107 
 More recent studies with this class resulted in the synthesis of T3.5 (Figure 1.26), 
an acridone derivative that incorporates a N-10 moiety that confers, additionally, a 
chemosensitization function (capacity to reverse Plasmodium resistance to classical 
antimalarial drugs, such as chloroquine).108 
1.3.5.4. Quinolones 
The scientific community dedicated to malaria chemotherapy has placed a number 
of antimalarially active quinolones at various stages of pre-clinical development. These 
compounds contain the 4-oxo-1,4-dihydroquinoline (4(1H)-quinolone or 4-oxo-
quinoline) scaffold (Figure 1.27) and were shown to bind to the Qo site of the cytochrome 
bc1 complex in 2008.
55 
 
Figure 1.27 – Structural representation of the quinolone scaffold. 
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This thesis is based on a PhD project that aims to explore the quinolone chemotype 
in view of the design and synthesis of quinolone-based antimalarial drugs. The rationale 
behind the use of these class is based on recent studies showing that selected quinolones 
are relatively potent against the blood, liver and transmission stages of malaria parasite, 
thus validating the selection on this chemotype in strategies for the development of drugs 
to eradicate malaria. However, additional studies are required in order to circumvent 
difficulties associated with quinolone compounds, including poor aqueous solubility and 
metabolic instability. Along this thesis, several aspects related to quinolones will be 
addressed.  
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1.4. Quinolones in medicinal chemistry 
The versatility of the quinolone chemotype has attracted intense research for 
several decades among medicinal chemists, and the interest in this class of compounds 
does not appear to fade. Many quinoline derivatives are known for their 
pharmacological properties targeting a variety of diseases, e.g. bacterial 
infections,109,110 cancer,111 hepatitis,112,113 HIV,114 herpes,115 fungal infections, 
immunodepression,116 tuberculosis117 or malaria.82,118–120 
Chemically, the quinolones are a group of chemical analogues derived from a 
bicyclic aromatic fused six-membered heterocyclic nucleus containing one to four 
nitrogen atoms. Some classic examples are represented in Figure 1.28.121 
 
Figure 1.28 – Structural representation of classic examples of the quinolone group. 
1.4.1. From antibacterial to antimalarial agents 
The use of quinolones as antibacterial agents (a well-established class of 
antibiotics) began in 1963, with the discovery of nalidixic acid (Figure 1.29), a 1,8-
naphthyridone 3-acid, during the synthesis of the antimalarial agent, chloroquine. 
Nalidixic acid is an example of a first-generation quinolone, which common structural 
features are the ethyl group at N-1 position and the good Gram-negative activity. 
However, nalidixic acid never became a useful agent to treat systemic infections due 
to its narrow spectrum of action, poor tissue penetrability, rapid emergence of 
bacterial resistance and frequent adverse effects in the central nervous 
system.110,121,122 However, this 1,8-naphthyridone provided the chemical foundations 
upon which modifications to improve the pharmacologic profile and limit adverse 
effects were built. More than 10 000 analogues of nalidixic acid were studied and/or 
synthesized and, after 20 years, only one analogue was approved for clinical use, the 
first fluoroquinolone antibiotic.121 
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Figure 1.29 – Structural representation of quinolones used as antibacterial agents.  
Fluoroquinolones (Figure 1.29) are 4-oxo-quinolines (usually just named as 
quinolones) bearing a fluorine atom at C-6 that increases the activity of the compound 
against both Gram-negative and Gram-positive organisms and expands the spectrum 
of action. This atom is also responsible for improving the penetration of quinolones 
into bacterial cells. Norfloxacin and ciprofloxacin (second-generation quinolones) 
and levofloxacin (third-generation quinolones) are examples of fluoroquinolone 
antibiotics with a piperazine ring at position 7, a structural feature that appears to be 
essential for enhancing potency, spectrum of action and pharmacokinetic profile. 
However, the comparatively lower potency against some Gram-positive bacteria, 
particularly S. aureus and Streptococcus pneumoniae, the rapid development of 
quinolone-resistance by Plasmodium parasites and the remaining adverse effects have 
prompted further research towards a more general utility of fluoroquinolones.109,110 
There are other aspects in the structure of fluoroquinolones that have direct 
impact on antibacterial activity: the 3-carboxylate and 4-carbonyl groups were found 
to mediate the binding to DNA gyrase and the transport across the bacterial 
membrane; and alterations at N-1, C-5 as well as at position 7 and 8 of the quinolone 
core were found to affect the potency, spectrum of activity, pharmacokinetics and 
safety profile.121 
Norfloxacin, the first fluoroquinolone (approved in 1986), has poor tissue 
distribution, which limited its applications to the treatment of urinary tract infections. 
Over the following decades, several compounds have derived from this quinolone lead 
and, for example, modification of the substituent at N-1 to a cyclopropyl group led to 
ciprofloxacin (approved in 1987), an antibiotic with a better clinical success. 
Ciprofloxacin presents an excellent systemic activity upon oral administration and is 
one of the most frequently prescribed antibiotics.109 
Levofloxacin, a third-generation quinolone, was approved in 1996. It is the 
levo isomer of the racemate ofloxacin (another quinolone antimicrobial agent). This 
generation exhibits more structural diversity (e.g. heteroaromatic ring between N-1 
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and C-8 for levofloxacin; and methylation of the piperazine ring at position 7 for other 
analogues not presented in this work) that results in novelties regarding biological 
properties. The third-generation quinolones preserve excellent potency against Gram-
negative bacteria while showing an increased activity towards Gram-positive bacteria, 
compared to ciprofloxacin.109,110 
The pharmacologic properties of fluoroquinolones justify their extensive use 
as second line therapeutics, not only in urinary tract infections but also for the 
treatment of certain sexually transmitted diseases, prostatitis, gastrointestinal 
infections, nosocomial acquired pulmonary infections, pseudomonas infections and 
osteomyelitis.109  
Other structural modifications may bring further improvements in the 
usefulness of fluoroquinolones for treatment of mycobacterial infections. The 
structural relationship of the quinolone core with some antimalarial drugs (for 
example atovaquone) can open new perspectives for the malaria treatment. Quite 
interesting is the fact, that during 1980s and 1990s, fluoroquinolones antibiotics, such 
as ciprofloxacin, were shown to have antimalarial properties, and the possibility of 
replacing the failing aminoquinolines by fluoroquinolones was considered, despite the 
lower potency of fluoroquinolones. However, the advent of more promising 
antimalarial drugs, like artemisinin, devalued the use of fluoroquinolones in 
malaria.123–125 
1.4.2. State of the art: endochin and endochin like quinolones (ELQ) 
The activity of quinolones against malaria was established in the 1940s with 
the synthesis of endochin (Figure 1.30).98 The  antimalarial activity of endochin has 
been known since 1948, after disclosure by Bayer of evidence for its synthesis and 
activity against avian malaria, both as a prophylactic as a therapeutic agent. Further 
research with this compound established that it was active against the liver and blood 
stages of parasites. However, it was demonstrated that endochin is ineffective in 
mammal models due to its rapid metabolism to inactive metabolites by cytochrome 
P450 enzymes.106,126,127 Besides that, the quinolone core continued to be considered 
as model for potential antimalarial compounds. 
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Figure 1.30 - Structural representation of endochin, by Bayer, and quinolone 3-esters, by Ryley. 
 
Ryley et al., during their research for anticoccidial drugs, noted that a number 
of the quinolone 3-esters developed (e.g. ICI 56780 and ICI 60128; Figure 1.30) were 
active against malaria (in rodent and monkey models), both as prophylaxis and 
treatment. These compounds appeared to be effective against all stages of the parasite 
(with a potency of up to 50 times that of chloroquine) and also against chloroquine 
resistant strains but there were problems related to fast resistance development in 
rodent models.128 
Recent advances suggest that previously abandoned lead molecules may be 
reexamined to generate more robust and potent analogues. A good example is the 
development of new endochin analogues (or endochin like quinolones – ELQ) with 
improved therapeutic properties compared to the parent compound. For example, in 
2008, Riscoe and Winter found that by extending the 3-heptyl chain of endochin to an 
undecyl (11C) chain, and terminating with a trifluoromethyl moiety (synthesis of 
ELQ-103, Figure 1.31), the activity against P. falciparum chloroquine resistant 
parasite strains was doubled in vitro (IC50 1.4nM vs 2.8nM). Additionally, the cross-
resistance for atovaquone resistant parasite strains was significantly diminished (IC50 
4.7nM vs 17.4nM for endochin). However, the solubility and in vivo activity of this 
compound was still very poor.106 
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Figure 1.31 – Structural representation of endochin and of ELQs, studied by Riscoe et al. and 
Manetsch et al.. 
In 2011, the same research group, in an effort to increase solubility and reduce 
metabolic instability, optimized the structure of ELQ-103 by changing the substitution 
pattern of the quinolone ring. From a library with several ELQs, ELQ-121 (Figure 
1.31) was established as a new lead, exhibiting a potency 10-fold higher than ELQ-
103 and enhanced metabolic stability. However, ELQ-121 exhibited increased cross-
resistance with atovaquone when compared to ELQ-103. The problem of solubility 
was not circumvented by this drug, but its prodrug (with a poly(ethylene) glycol group 
linked to the oxygen of the quinolone core) ELQ-125 (Figure 1.31) demonstrated a 
better solubility profile.129 
Manetsch et al. designed and synthesized several endochin-type quinolones to 
better understand the structure-activity relationship (SAR) profiles against P. 
falciparum. Some important aspects about SAR were established: the carbonyl at 
position 4 and the lack of substitution at N-1 are key factors; a halogen substituent 
(chlorine) at C-6 and/or a methoxy group at position 7 enhance activity and reduce 
cross-resistance; shortening the 3-alkyl chain length increases the solubility but 
results in a dramatic reduction in parasite selectivity (alkyl chain with at least 7 
carbons at C-3 is preferred); and 3-aryl substituted analogues exhibit a drop in 
potency, but less severe, while both solubility and metabolic stability are much 
improved. The most potent analogue from the library studied by Manetsch et al. is 
represented in Figure 1.31 – Compound55 Manetsch.130 
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More recently, Manetsch and Riscoe studied analogues containing a 
diarylether substituent at C-3 and, from them, the P. falciparum bc1 complex inhibitor 
ELQ-300 (Figure 1.32), was selected as a preclinical candidate (IC50 around 1.8nM 
against chloroquine resistant strains). Considering the side chain of the previously 
described pyridone (GW844520) and the endochin structure, ELQ-271 (Figure 1.32) 
was synthesized and, by introduction of a methoxy substituent at C-7 and a chlorine 
substituent at C-6, originated ELQ-300. In preclinical studies with mice, ELQ-300 
was found to be highly active against P. falciparum and P. vivax at all life cycle 
stages that play a role in the transmission of malaria, and to have good 
oral bioavailability. ELQ-300 was also shown to have no effect on intracellular ATP 
levels in two different mammalian cell lines (no toxicity) and no cross-resistance with 
atovaquone was observed.  
 
Figure 1.32 – Structural representation of ELQ-300 (a preclinical candidate), its precursor ELQ-
271 and the analogue P4Q-391. 
Compound P4Q-391 (Figure 1.32), containing a fluorine substituent in the 
diaryl ether side chain, has also demonstrated a promising profile (IC50 of around 
7.6nM against chloroquine resistant strains). However ELQ-300 was shown to be 
more potent and selective.131 
In parallel, Da Cruz et al. and Cowley et al. have investigated 3-ester 
substituted quinolones as P. falciparum bc1 complex inhibitors. From the libraries 
investigated, Da Cruz et al have selected decoquinate (Figure 1.33) as the most potent 
compound against the liver stages (IC50 around 2.6nM)
132, while Cowley et al., have 
demonstrated by SAR studies that RCQ (Figure 1.33) is a highly potent antimalarial, 
exhibiting an IC50 value of 0.46nM.
120 
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Figure 1.33 – Structural representation of decoquinate and RCQ, proposed by Da Cruz et al. 
and Cowley et al., respectively. 
Some quinolones derivatives are also known as potential inhibitors of PfNDH2 
in the respiratory chain of P. falciparum. Hydroxy-2-dodecyl-4-(1H)-quinolone 
(HDQ), represented in Figure 1.34, exhibits inhibitory activity both towards PfNDH2 
and the bc1 complex and, as such, was used as a starting point for drug discovery, 
leading to libraries with several new quinolone analogues with promising antimalarial 
activities. This multi-target inhibition confers a benefit over the single-target 
inhibition, due to delay in selection for drug resistance.82 
 
Figure 1.34 – Structural representation of HDQ and of some quinolones substituted at positions 
2 and/or 3 (studied by Pidathala et al. and Leung et al.). 
The metabolic liabilities evidenced by HDQ led to additional structural 
alterations. Pidathala et al. changed the HDQ-side chain at position 2, to a biaryl or 
phenoxyl biaryl (e.g. RKA073, Figure 1.34). After conversion of N-OH to N-H and 
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introduction of 7-Cl and 3-methyl substituents, CK-2-68 (Figure 1.34) was selected 
as a lead for further development, showing an activity in vivo of 31nM against P. 
falciparum, compared with 263nM for RKA073.118 Leung et al. introduced a 
heterocyclic substituent (pyridine group) into the quinolone side chain to improve 
solubility, leading to the analogs SL-2-64 and SL-2-25  (Figure 1.34) that evidenced 
IC50 values of 75nM and 54nM, respectively, against whole-cell P. falciparum.119 It 
was observed that, when moving from 2-aryl to 3-aryl substituted analogues, there is 
a loss in PfNDH2 activity.118,119 
1.4.3. Synthetic routes to the 4-oxo-quinoline core 
Given the interest of quinolones in major areas, including medicinal chemistry, 
the availability of mild, high yielding, selective and versatile synthetic routes to this class 
is a matter of upmost relevance. 
Skraup reported on the first formal synthesis of the quinoline core (part of the 
structure of quinine), over a century ago.133 Later, several variations to the original Skraup 
synthesis and new methods have been reported to afford quinoline derivatives, such as 
the Combes reaction,134 the Friedländer synthesis,135 the Doebner-von Miller synthesis,136 
the Pfitzinger-Borsche reaction137 and the Povarov reaction.138 
In parallel, many different synthetic approaches have been developed for 4-oxo-
quinoline synthesis, from a variety of starting points. These can be classified according 
to the bond or bonds that complete the ring-closure and the method used to increase the 
carbon chain length. A retrosynthetic diagram showing the possibilities for construction 
of the quinolone ring is represented in Scheme 1.1 and some of the available 
methodologies are described in following subtopics.  
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Scheme 1.1 – Approaches to the preparation of the 4-oxo-quinoline scaffold. 
1.4.3.1. Cyclisation of ortho-COR-substituted aromatic amines 
For ring closure to form quinolones through formation of A (Scheme 1.2 and 
Scheme 1.3) to afford 4-oxo-quinolines, two methods of cyclisation of ortho-COR-
substituted aromatic amines were proposed, by Koskinen139 and Igglessi-Markopoulou140 
groups. 
Following Koskinen procedure (Scheme 1.2) it is possible to synthesize 2,3-
unsubstituted 4-oxo-quinolines (III) from an enamine (II) under reducing conditions, in 
cyclohexene, using 10% Pd on charcoal as catalyst. Enamine II may be synthesized by 
condensation of o-nitroacetophenone (I) with N,N-dimethylformamide dimethylacetal 
((CH3)2NCH(OCH3)2) in N,N-dimethylformamide (DMF).
139 
 
Scheme 1.2 – Schematic representation of the synthetic approach to 2,3-unsubstituted 4-oxo-
quinolines, proposed by Koshinen. Conditions: (a) (CH3)2NCH(OCH3)2, DMF, 100 ºC, 90 
minutes; (b) 10% Pd, cyclohexene, ethanol, reflux, 60 minutes.139 
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Igglessi-Markopoulou et al. (Scheme 1.3) described a methodology for the 
synthesis of 3-ethoxycarbonyl 4-oxo-quinolines (VII). This methodology involves 
acylation of β-keto esters (V) with N-hydroxysuccinimide esters of anthranilic acids (IV). 
The conjugates formed (VI) progress spontaneously to the corresponding quinolone 3-
esters, through cyclisation.140 
 
Scheme 1.3 – Schematic representation of the synthetic approach to 3-ethoxycarbonyl 4-oxo-
quinolines, proposed by Igglessi-Markopoulou group. Conditions: (a) NaH, benzene, 3-5 days, 
room temperature (rt).140 
1.4.3.2. Camps cyclisation 
The Camps cyclisation is a base catalysed ring closure methodology to form 
quinolones, through formation of bond B (Scheme 1.4). This methodology provides an 
access to 2-substituted 4-oxo-quinolines (IX). However, depending of the conditions and 
starting material, the same methodology can also be used to prepare 2-hydroxy-quinolines 
(X).141 
 
Scheme 1.4 – Schematic representation of the Camps cyclisation methodology.141 
1.4.3.3. Niementowski quinoline synthesis 
The Niementowski methodology for quinoline synthesis consists in the 
condensation of anthranilic acids (XI) with ketones (XII) or aldehydes, at 200 ºC, to form 
2,3-substituted 4-oxo-quinolines (XIII) or 3-substituted 4-oxo-quinolines, 
respectively.142 It is a cyclisation reaction leading to a bicyclic core through the formation 
of bonds A and C (Scheme 1.5). 
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Scheme 1.5 – Schematic representation of the Niementowski methodology for quinoline 
synthesis.142 
1.4.3.4. Cyclisation from a Michael-type addition product 
The preparation of 3-aroyl 4-oxo-quinoline derivatives (XVII) through formation 
of bond C (Scheme 1.6) may be carried out, for example, by a Michael-type addition of 
methyl anthranylate (XIV) to β-ketonic enol ethers (XV). From this conjugate addition 
results a Michael adduct (XVI) that, through based promoted cyclisation originates the 4-
oxo-quinoline derivatives XVII. The ring closure is facilitated by heating at reflux in 
diphenyl ether, in the presence of sodium methoxide.143 
 
Scheme 1.6 – Schematic representation of the synthetic approach to 3-aroyl 4-oxo-quinolines, 
proposed by Hénichart group. Conditions: (a) THF (tetrahydrofuran), ZnCl2, rt, 24 hours. (b) 
MeONa, Ph2O, reflux (240 ºC), 4 hours.143   
1.4.3.5. Conrad-Limpach synthesis 
The Conrad-Limpach methodology can be used for the construction of 4-oxo-
quinoline derivatives (XXI) from the condensation of anilines (XVIII) with β-keto esters 
(XIX). The reaction affords an imine (XX) as intermediate, which must be heated at 250 
ºC for the ring closure to occur by the formation of the bond D (Scheme 1.7). This 
methodology can produce quinolones with various substitution patterns, defined by the 
nature and pattern of substitution present at starting compounds, the aniline and the β-
keto esters.144 
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Scheme 1.7 – Schematic representation of the Conrad-Limpach strategy for quinolone 
synthesis.144   
The group of reactions based on closure of bond D includes some of the most 
numerous methods used for the synthesis of 4-oxo-quinolines. The Gould-Jacobs reaction 
is one adaptation of the Conrad-Limpach synthesis and was chosen as synthetic 
methodology during the development of our research. As such, the Gould-Jacobs reaction 
will be discussed in deeper detail in the next section. 
1.4.3.6.  Cyclisation by formation of bond E (multistage reactions) 
Variously substituted 4-oxo-quinolines can be obtained by the formation of bond 
E (Scheme 1.8) and some examples have been reviewed. Scheme 1.8 presents an example 
of application of a methodology that includes multistage reactions with successive 
transformations, in which amino vinyl phenyl ketones (XXIII) are formed (for example 
by hydrolysis, decarboxylation and transamination reactions from XXII). The ring 
closure at the last stage involves the halogen atom (X) at the ortho position of the aryl 
substituent in XXIII. The cyclisation step to the formation of 4-oxo-quinolines (XXIV) 
can be achieved in the presence of various reagents.145 
 
Scheme 1.8 – Schematic representation of the synthetic approach to quinolones involving 
cyclisation by formation of bond E, including multistage reactions.145 
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1.5. PhD project’s presentation 
The discovery of the antimalarially active quinolones ICI 56780 and ICI 60128 
(Figure 1.30) followed by more recent research on compounds with antimalarial 
properties based on the quinolone 3-carboxyl core structure (decoquinate and RCQ; 
Figure 1.33), led us to further investigate the potential of quinolone 3-esters as 
antimalarials. Besides the inhibitory capacity showed, the compounds mentioned 
above also present pharmacological liabilities, such as the relatively fast development 
of resistance, cross-resistance, poor solubility and metabolic instability.  As such, a 
deeper investigation of the structure and properties of this class was considered 
relevant for the design and preparation of quinolone 3-esters, aiming at the 
development of new, safe and effective antiplasmodial drugs targeting the bc1 protein 
complex of P. falciparum. We proposed the design, synthesis and structural study of 
a library of new 4-oxo-quinoline 3-esters bearing different functional groups at 
positions 6 and/or 7 of the quinolone structure. The structure of the quinolone template  
proposed (Figure 1.35) includes the key groups required for a bc1 inhibitor (N-H and 
4-carbonyl of the quinolone core), in accordance with data from docking studies.120 
 
Figure 1.35 – General structure for 4-oxo-quinoline 3-esters investigated. 
The synthetic methodologies and reaction conditions used were optimized and 
some compounds prepared have been tested for activity in vitro against P. falciparum. A 
detailed structural investigation was undertaken on selected compounds. This information 
is relevant for a better understanding and prediction of chemical reactivity and activity. 
For the investigation of monomeric structure, contemporary DFT (density functional 
theory) methods (for theoretical analysis) and matrix isolation techniques coupled to 
FTIR (Fourier-transform infrared) spectroscopy (for experimental analysis) were used. 
For the investigation of solid-state structure, X-ray crystallography and spectroscopic 
techniques were used. Docking studies were also conducted to improve the knowledge 
regarding drug-target interaction for this class. Additionally, selected quinolones 
prepared in this project were tested for activity against Mycobacterium tuberculosis. 
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The PhD project in which this thesis is based can be divided in four parts:  
A - Synthesis of quinolone 3-esters with potential activity against P. falciparum; 
B – Structural investigation of selected quinolone 3-esters; 
C – Docking studies, CLogP calculations and evaluation of antimalarial activity;  
D - Synthesis of selected quinolone derivatives and evaluation of activity against M. 
tuberculosis. 
Along the thesis, a similar distribution of topics will be adopted. 
This project benefited from established collaborations between CCMar, 
Universidade do Algarve (Portugal), and other national and international institutions: 
CQC, Departamento de Química, Universidade de Coimbra (Portugal); CFisUC, 
Departamento de Física, Universidade de Coimbra (Portugal); Department of 
Chemistry, University of Liverpool (United Kingdom); Liverpool School of Tropical 
Medicine, University of Liverpool (United Kingdom); and CMDT and Instituto de 
Higiene e Medicina Tropical, Universidade Nova de Lisboa (Portugal).
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2.1. General synthetic approach 
In this chapter the synthesis of 4-oxo-quinoline 3-esters substituted at position 7 
and/or 6 is described and discussed. The general synthetic approach to these compounds 
is presented in Scheme 2.1. Three main steps are highlighted in the synthetic strategy 
proposed: (i) reduction of nitro aromatic compounds, meta and/or ortho substituted, to 
the corresponding anilines; (ii) coupling of the aniline with diethyl 
(ethoxymethylene)malonate (DEEMM) to afford the enamine derivative (α,β-unsaturated 
ester); (iii) thermally driven intramolecular cyclisation (Gould-Jacobs methodology) to 
prepare the final 4-oxo-quinoline 3-esters. The reactions involved in each step are 
described in detail in sections 2.1.1 and 2.1.2.  
 
Scheme 2.1 - Schematic representation of the general synthetic approach to prepare 4-oxo-
quinoline 3-esters derivatives. 
2.1.1. Reduction of nitro aromatic compounds to aniline derivatives  
The reduction of nitro compounds in the presence of zero-valent metals (e.g. Fe, 
Zn or Sn) is well documented and has been widely used in the synthesis of amines. Iron 
was one of the first metals employed for the reduction of organic compounds, around 150 
years ago, but the detailed molecular mechanism for the reduction is still not well 
understood.146–148 
In general, Fe-catalysed reductions are carried out in aqueous media. However, it 
is common to add methanol or ethanol to increase the solubility of the organic compounds 
in the medium. It is proposed that, initially, in aqueous system, the zero-valent iron metal 
(Fe0) is oxidized to ferrous iron (Fe2+), acting as electron donor, as described by equation 
(1). Ammonium chloride acts as proton donor, assisting in the conversion of the nitro to 
the amino group. 
3Fe0  3Fe2+ + 6e-        (1) 
The nitro group is then converted to aniline via intermediate species with various 
degrees of reduction, such as nitroso- and hydroxylamine compounds, in a process that 
consists of a series of two-electron additions (Scheme 2.2). Products resulting from 
coupling of reduction intermediates may also be formed, compromising the yield of the 
product required.147,148 
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Scheme 2.2 – Schematic representation of reduction pathway for conversion of nitro arenes to 
the corresponding anilines, via nitroso and hydroxylamine intermediates.147,148 
Formally, the overall nitro-to-amino reduction is a six-electron-transfer reduction, 
classically described by equation (2): 
Ar-NO2 + 6e
- + 6H+  Ar-NH2 + 2H2O           (2) 
In the general synthetic strategy to quinolone 3-esters (Scheme 2.1) this step can be 
skipped if the desired aniline is commercially available. 
2.1.2. Coupling of the aniline derivative with DEEMM and Gould-Jacobs 
cyclisation 
The enamine derivative required for cyclisation to the quinolone is prepared by 
coupling the aniline with an α,β-unsaturated ester (usually a malonate derivative). 
Malonic derivatives are very useful reagents in organic synthesis, especially in strategies 
to afford 5-, 6- or 7-membered rings, enabling the preparation of a variety of “malonyl 
heterocycles”. In this work we chose diethyl (ethoxymethylene)malonate (DEEMM) as 
the malonate derivative for the synthesis of 4-oxo-quinoline compounds bearing an ethyl 
ester group at position 3.149,150 From the solvent free reaction of an aniline derivative with 
DEEMM, at 100 ºC, an enamine ester is synthesized (Scheme 2.3). This intermediate step 
allows incorporation of functionalities, such as esters and nitriles, at position 3 of the 4-
oxo-quinoline compound. 
The enamine ester is then converted to quinolone using the Gould-Jacobs reaction. 
This methodology was published in 1939 and consists in an adaptation of the Conrad-
Limpach synthesis. The mechanism proposed for the Gould-Jacob reaction is represented 
in Scheme 2.3. In this cyclisation, conducted at 240-250 ºC, the aromatic ring acts as 
nucleophile, attacking the carbon of the ester carbonyl group and leading to a thermally 
driven intramolecular cyclisation.149 
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Scheme 2.3 – Schematic representation of the mechanism proposed for the Gould-Jacobs 
synthesis of 4-oxo-quinoline 3-esters.149 
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2.2. Exploring position 7 – modifying O-link   
Following the work of O’Neil’s group, and establishing the ethyl ester group as 
standard in the position 3, the preparation of a library of compounds with chemical 
diversity at position 7 was envisaged. The compounds prepared and synthetic methods 
followed are described below.   
2.2.1. Preparation of 4-oxo-quinolines with ester or ether linkage at 
position 7 
These compounds were prepared from 3-nitrophenol (1), by modification of the 
hydroxyl group. The synthetic approach is presented in Scheme 2.4. 3-nitrophenol (1) 
was used, instead of an aniline derivative, to avoid a side reaction resulting from the 
nucleophilic attack by nitrogen (Ar-NH2). Therefore, 1 was used as the starting material. 
After modification of the hydroxyl groups, the reduction step was conducted, followed 
by coupling with DEEMM and then by thermal cyclisation in Dowtherm A to afford the 
required 4-oxo-quinoline 3-ester derivatives (Scheme 2.4). 
 
Scheme 2.4 – General synthetic approach followed to prepare 7-ester and 7-ether substituted 4-
oxo-quinoline 3-esters. Conditions: (a) variable and adapted conditions according with the R; (b) 
NH4Cl, Fe, MeOH:H2O (1:1), 60 ºC, 4 hours; (c) 100 ºC, overnight; (d) Dowtherm A, 250 ºC, 3 
hours. 
The hydroxyl group was modified introducing directly the intended residue, 
through reaction with benzoyl chloride 2 or benzyl derivatives 3 (chlorine) / 4 (bromine), 
to afford a diphenyl ester 6 (Scheme 2.5) or a diphenyl ether 7 (Scheme 2.6), respectively. 
A similar procedure was used for the synthesis of 1-(tert-butoxy)-3-nitrobenzene (8) 
using tert-butyl bromide (5) as halide derivative (Scheme 2.7), however, the required 
product was not obtained. 
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Scheme 2.5 – Esterification of 3-nitrophenol to afford 3-nitrophenyl benzoate 6. 
 
Scheme 2.6 – Etherification of 3-nitrophenol to afford 3-nitrophenyl benzyl ether 7. 
 
Scheme 2.7 – Attempted etherification of 3-nitrophenol to afford compound 8. 
3-Nitrophenyl benzoate 6 was obtained as white needles, in good yield (91%), 
after work-up and crystallization. The procedure for this reaction includes the use of 
triethylamine as base. Considering the high reactivity of the acyl chlorides (2), for 
example with alcohols (1), this reaction is extremely rapid, complicating mechanistic 
studies. From the literature, two mechanisms, represented in Scheme 2.8 and Scheme 2.9, 
may be considered. 
The mechanism presented in Scheme 2.8 involves attack to the carbonyl bond of 
2 by the amine, forming a quaternary acyl ammonium salt after displacement of the 
chlorine atom. This salt is susceptible to attack by the hydroxyl group of 1, leading to 6 
as the final product. Another mechanistic proposal considers deprotonation of the 
hydroxyl group of 1 and subsequent attack of the phenoxide to the carbonyl carbon of 2 
(Scheme 2.9).151 
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Scheme 2.8 – Schematic representation of a mechanistic proposal for the triethylamine-catalysed 
esterification to afford 3-nitrophenyl benzoate 6.151 
 
Scheme 2.9 – Representation of an alternative mechanistic proposal for the TEA-catalysed 
esterification to afford compound 3-nitrophenyl benzoate 6.151 
As shown in Scheme 2.8 and Scheme 2.9, triethylamine hydrochloride 
(triethylammonium chloride) is a secondary product from the amine-catalysed 
esterification described. Clearance of the triethylamine (TEA) in excess, after reaction, 
can be improved with the acidification with HCl that leads to formation of more 
triethylammonium chloride salt, which is easily removed because of the higher affinity 
for the aqueous layer (during extraction). 
A similar procedure was carried out to afford 1-benzyloxy-3-nitrophenyl 7 from 
benzyl chloride 3, but as the yield was poor, an alternative procedure was implemented: 
NaH for prior deprotonation of the phenol. Benzyl chloride 3 bears a carbon-halogen bond 
conferring electrophilicity to this carbon (-CH2-), but not as great as for the carbonyl 
carbon of benzoyl chloride (2) and, therefore, a stronger base is required for the formation 
of 7 from 3. 
However, the product 7 was recovered with a low yield (34%) after purification 
by column chromatography, so the synthesis was repeated, but replacing benzyl chloride 
3 by benzyl bromide 4. Besides less electronegative, bromide is a better leaving group 
than chlorine because it is bigger, better stabilizes the charge and the C-Br bond is weaker 
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than the C-Cl bond. It was possible to improve the yield to 87%, using benzyl bromide. 
The product was recovered, after crystallization, as light yellow crystals. 
The reaction between 3-nitrophenol (1) and 4, to form ether 7, using NaH as base, 
is described as Williamson’s synthesis and is represented in Scheme 2.10.152 This 
synthesis consists in two steps, with initial deprotonation of the alcohol 1 by NaH 
followed by nucleophilic attack on benzyl bromide 4 to afford 1-benzyloxy-3-nitrophenyl 
(7). 
 
Scheme 2.10 – Schematic representation of the mechanism proposed for the synthesis of 
compound 7.152 
The procedure used for the synthesis of 7 was also applied for the synthesis of 1-
(tert-butoxy)-3-nitrobenzene (8) using tert-butyl bromide (5) as halide derivative 
(Scheme 2.7).  
However, the required product was not obtained, even when reaction conditions, 
such as, base, solvent, temperature, time of reaction and halide derivative (tert-butyl 
chloride was also considered) were changed. In some cases 3-nitrophenol (1) was 
recovered and, although the product required was not isolated, it is possible that the failure 
is due to the fact that any hydrogen positioned on any carbon adjacent to the carbon center 
bearing the leaving group on 5 can participate in an elimination reaction, whereby the 
carbon rehybridizes from sp3 to sp2 and an alkene (isobutylene) is obtained from tert-
butyl bromide (see Scheme 2.11). Alcohol 1 (or its alkoxide, if proton is removed by 
NaH) could be the Lewis base responsible for the displacement of the proton involved in 
the elimination step.153 
 
Scheme 2.11 – Schematic representation of the mechanism of elimination proposed as one 
possible reason for the failure of the synthesis of compound 8.153 
Once synthesized, nitro arenes 6 and 7 (nitro arenes) were reduced to the 
corresponding anilines (9 and 10), considering the reduction pathway represented in 
Scheme 2.2, with good yields (97% and 99%, respectively). Compounds 9 and 10 were 
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then reacted with DEEMM (Scheme 2.3) to afford the enamine derivatives (11 and 12), 
in yields of 35% and 99%, respectively. The lower yield for the coupling reaction, in the 
case of compound 11, can be explained by the fact that the reaction was not completed 
(monitoring by TLC – thin layer chromatography) and not all the product was isolated in 
a pure form from the column chromatography. 
Enamines 11 and 12 were heated at 250 ºC in order to perform the cyclisation to 
afford 4-oxo-quinoline 3-esters 13 and 14 (Scheme 2.4). The 4-oxo-quinoline 3-ester with 
a benzyloxy substituent at position 7 (14) was synthesized, although with low yield (17%) 
and with some problems of solubility.  
   
The quinolone derivative 13 (with a benzoyloxy at position 7) also presents 
problems of solubility and thus the characterization results were not easy to interpret. 
Analysis by mass spectrometry indicated that the desired product had been synthesized 
(peak of m/z 360 for the adduct [M + Na]+) but the powder obtained was not pure and 
other peaks, with higher mass, were observed in the spectrum (see Appendix 2 - Figure 
S1). The NMR (nuclear magnetic resonance) data reinforce the idea that the product 13 
has been synthesized: 1H NMR signals around 4.2 and 1.3 ppm, corresponding to 
resonances of the ester hydrogens, are present (see Appendix 2 - Figure S2); the 13C NMR 
signals at 14.8 and 60.1 ppm demonstrate the presence of an ester group and those at 129-
130 ppm indicate the presence of a benzoyl substituent (see Appendix 2 - Figure S3). 
There is no evidence for the presence of the starting material 11 from MS (mass 
spectrometry) or 13C NMR analysis (since an expected peak around 94 ppm for the 
C(CO2Et)2 is not present, for example; see Appendix 2 - Figure S2 and Figure S3). 
Elemental analysis indicates that the product isolated is not pure. However, it was not 
possible to purify the compound due to very low solubility and because the Rf (retention 
factor) of the impurities were essentially close to that of the product, rendering the 
purification of the product impractical. 
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2.2.2. Preparation of 4-oxo-quinolines with an heterocyclic group as 
substituent in position 7 
Continuing the work leading to the preparation of a library of quinolone 3-esters 
with chemical diversity in position 7 of the quinolone core structure, further modifications 
of the 7-hydroxyl group were envisaged, with the aim of introducing heterocyclic groups 
in the same position. Considering that some substituents could be susceptible to the 
conditions used in the reduction step, an adapted strategy was considered (Scheme 2.12). 
 
Scheme 2.12 – Schematic representation of the general synthetic approach followed to prepare 
4-oxo-quinoline 3-esters with 7-substituents susceptible to the reduction conditions. Conditions: 
(a) NH4Cl, Fe, MeOH:H2O (1:1), 60 ºC, 4 hours; (b) 100 ºC, overnight; (c) variable and adapted 
conditions according with the R; (d) Dowtherm A, 250 ºC, 3 hours. 
3-Nitrophenol (1) was used as starting material and reduced to 3-aminophenol 
(15). Then, to avoid a side reaction between the nitrogen (Ar-NH2) and the electrophilic 
carbon of the compound to be used in the modification of the hydroxyl group, the 
coupling reaction with DEEMM preceded the esterification/etherification reaction 
(linkage of the heterocycle at position 7, mediated by the hydroxyl group). Finally, 
thermal cyclisation in Dowtherm A was carried out to afford 4-oxo-quinoline 3-ester 
derivatives (Scheme 2.12). The fact that the reduction and coupling reactions are common 
steps in the strategies to the six target compounds is an advantage to this strategy. 
3-Nitrophenol (1) was reduced to 3-aminophenol (15) and then coupled with 
DEEMM to afford diethyl 2-(((3-hydroxyphenyl)amino)methylene)malonate (16). These 
reactions were optimized and generally gave yields greater than 90%, after purification. 
16 is a common intermediate for the synthesis of a library of target compounds bearing 
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various substituents at position 7, introduced by modification of the hydroxyl group 
(Scheme 2.13 to Scheme 2.17). 
 
Scheme 2.13 – Derivatization of the hydroxyl group in 16 to afford compound 23. 
 
 
Scheme 2.14 – Derivatization of the hydroxyl group in 16 to afford compound 24. 
 
Scheme 2.15 – Derivatization of the hydroxyl group in 16 to afford compound 25. 
 
Scheme 2.16 – Derivatization of the hydroxyl group in 16 to afford compound 26. 
 
Scheme 2.17 – Derivatization of the hydroxyl group in 16 to afford compound 27. 
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The reactions conducted to prepare compounds 23, 24, 25 and 27 were carried out 
using potassium tert-butoxide in dry THF (tetrahydrofuran), adapting the methodology 
of etherification or esterification known as Williamson synthesis.  Firstly there is 
formation of alkoxide from 16, which is able to attack the electrophilic carbon linked to 
the halide atom present in 17 (exemplified in Scheme 2.18), 18, 19 and 22. Tert-butoxide 
anion (t-ButO-) is a strong base that can remove the hydrogen from the hydroxyl group 
and is also very hindered, avoiding its attack to the halide-carbon (side-reaction). ButO- 
is also a strong base and may lead to elimination products, especially when primary alkyl 
halides are used, which is not the case of our substrates.152,153 
 
Scheme 2.18 – Schematic representation of the mechanism proposed for the t-ButOK-catalysed 
esterification to afford compound 23.151 
Among the four reactions carried out using this methodology, only one lead to a 
low yield of product (16% for the synthesis of 25) while the synthesis of 23, 24 and 27 
were conducted with moderate to good yields. 
To afford compound 26 a different methodology was carried out, adopting a 
similar procedure to that followed for the synthesis of 6, i.e. TEA-catalysed etherification 
but, in this case, using toluene as solvent. Before the coupling to get 26, it was required 
to synthesize 3-chloro-1,2-benzisothiazole 1,1-dioxide (pseudo-saccharyl chloride, 21) 
from saccharin (20), by halogenation using PCl5 (at 180 ºC) (Scheme 2.19). The reaction 
affords HCl and POCl3 as side products. 
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Scheme 2.19 – Schematic representation of the mechanism proposed for the synthesis of pseudo-
saccharyl chloride (21).154 
The intermediate compound formed by this halogenation reaction is sulfonyl 
chloride (i, Scheme 2.19) and, once synthesized, the cyclisation to give 21 requires the 
attack of a chlorine anion on the carbon atom of the cyano group, which has a low 
nucleophilic susceptibility. Therefore, it is necessary to use higher temperatures (180 ºC) 
and/or longer reaction times (3 hours) to improve the yield for the saccharine chlorination. 
Furthermore, phosphorus oxychloride and HCl must be distilled before the crystallization 
step. Some reports described that when recrystallized from toluene, 21 was found to be 
quite stable over a period of months.154 
Saccharyl chloride 21 was synthesized, evidencing a melting range compatible to 
that reported in the literature,154 however with a poor yield (25%), due to the possibility 
of the process to stop at intermediate compound i or to a possible conversion to the 
starting material 20 (by hydrolysis of 21 in the presence of water), suggesting some 
instability for this product. 
The instability of 21 is the reason why we used a different methodology for the 
synthesis of 26 (hydroxyl group modification), to avoid side reactions: TEA is a weaker 
base than tButOK; toluene is not miscible with water (THF is miscible with water, 
extremely hygroscopic and upon exposure to air decomposes to form unstable 
compounds) and the desired product 26 is not soluble in toluene, leading to an easy 
purification or isolation (occurs precipitation). 
Enamines 23, 24, 25 and 26 (malonate derivatives substituted with heterocyclic 
groups) were heated at 250 ºC in order to perform the cyclisation step to afford 4-oxo-
quinoline 3-ester derivatives 28, 29, 30 and 31 (Scheme 2.12).  
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4-Oxo-quinoline 3-ester 31 was recovered with a yield of around 48%. However 
analysis indicated contamination of the solid with a trace amount of solvent (Dowtherm 
A). The characteristic 1H NMR peaks for Dowtherm A appear typically at 7.65 (d), 7.47 
(t), 7.39 (t), 7.14 (t) and 7.02 (d) ppm and are visible in the spectrum of 31 (see Appendix 
2 - Figure S4). The solubility problems did not allow to get a 13C NMR with quality and 
the presence of Dowtherm A masked the elemental analysis of this quinolone. 
From the cyclisation steps to afford quinolones derivatives 28, 29 and 30 it was 
not possible to isolate the product: no precipitate appeared after cooling and adding 
appropriated solvents; the high boiling point for Dowtherm A complicates its extraction 
or separation from the desired organic products; the insolubility problems also render the 
purification, for example by column chromatography, difficult or impossible. 
In an attempt to synthesize 32a by the Gould-Jacobs methodology, from enamine 
27, an unwanted diazirine (32b) was obtained as product. The synthesis of 32b is easily 
explained, considering the high temperatures required for intramolecular cyclisation of 
27 that lead to problems adjacent to this methodology such as the susceptibility to 
degradation of the tetrazole residue, releasing N2. 
 
By NMR it is not easy to find spectral differences that can prove the presence of 
32b and/or the absence of 32a, thus, the characterization method used to distinguish 32a 
(377.35 g/mol) from 32b (349.34 g/mol) was mass spectrometry. Initially, by EI, a peak 
around 349 was observed (see Appendix 2 - Figure S5). To exclude the hypothesis that 
this peak could be due to a mass spectrometric fragment from the ionisation of 32a, other 
MS analysis, with different ionisation methods, were carried out, all of them 
demonstrating the presence of 32b and the absence of 32a. 
At the same time, the presence of a diazirone residue at position 7 (compound 32c) 
instead of a diazirine, was considered. However, the chemical shifts observed by 1H NMR 
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and, especially, by 13C NMR (see Appendix 2 - Figure S6), are compatible with 32b and 
not with 32c. 
 
To overcome the possibility of thermolysis of fragile residues, for example the 
tetrazole ring (in 27 and 32a), during the cyclisation step using Gould-Jacobs 
methodology (250 ºC, 3 hours), a new synthetic approach was considered, based in direct 
cyclisation of 16 followed by synthesis of 4-chloroquinoline intermediate, modification 
of the hydroxyl residue and conversion to the corresponding 4-oxo-quinoline (Scheme 
2.20). Thus, only the hydroxyl group of compound 16 would be subject to high 
temperatures, protecting the more susceptible residue from extreme conditions. 
 
Scheme 2.20 – Representation of the general synthetic approach followed to afford 7-substituted 
4-oxo-quinoline 3-esters, using ethyl 4-chloroquinoline as intermediate compound. Conditions: 
(a) Dowtherm A, 250 ºC, 3 hours; (b) POCl3, 97 ºC, overnight; (c) variable and adapted conditions 
according to the nature of R; (d) DMF (N,N-dimethylformamide), HCO2H/EtOH (80/20), 145 ºC, 
18 hours.  
The problems encountered with this approach were ascribed to the presence of a 
mixture of structural isomers. Considering that cyclisation involves an aromatic 
substitution at the adjacent carbon to the NH group of the enamine, when both carbons 
are unsubstituted (as in compound 16) two substitution patterns are possible, leading to 
final quinolones with substituents in different positions (hydroxyl group at position 7 for 
33a; or at position 5 for 33b).  
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It was not possible to separate the isomers, so the synthetic strategy (Scheme 2.20) 
for the synthesis of ethyl 4-oxo-quinoline 3-ester derivatives with an ether or ester at 
position 7, using the 4-chloroquinoline as intermediate compound, was not successful. 
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2.3. Exploring position 7 – from nucleophilic aromatic substitution  
Nucleophilic aromatic substitution normally consists of substitution of halogen, 
linked to an aromatic ring carbon, by a nucleophile group. Aiming to incorporate 
tetrazolyl and morpholinyl groups at position 7 of 4-oxo-quinoline 3-esters, a general 
synthetic approach was considered, involving aniline derivatives with halide atoms as 
substituents (iodine155 and fluorine) in meta and/or para position at the starting material. 
The synthesis of 3-fluoroaniline 35 was attempted, from the 3-fluoronitrobenzene 34 by 
reduction using iron and ammonium chloride (Scheme 2.21), but proved unsuccessful 
(reaction did not progress). As such, considering the commercial availability of 35 and its 
cost, we used this aniline as starting material and did not invest in the reduction 
optimization. 
 
Scheme 2.21 – Attempted reduction of 34 to 35. 
From selected anilines with m-fluorine (35), m- and p-fluorine (36), m-iodine and 
p-methyl (37) and m-iodine (38)155, we proceeded to the coupling step with DEEMM to 
prepare enamine derivatives and, subsequently, to the Gould-Jacobs intramolecular 
cyclisation to afford corresponding 4-oxo-quinoline 3-esters (Scheme 2.22) bearing 
halide substituents at positions 6 and/or 7 (43, 44a, 45a and 46). 
 
Scheme 2.22 – General synthetic approach followed to prepare 4-oxo-quinoline 3-esters with 
halide substituents at positions 6 and/or 7. Conditions: (a) 100 ºC, overnight; (b) Dowtherm A, 
250 ºC, 3 hours. 
Enamines 39-42, were synthesized with excellent yields: 90% for 39; 99% for 40; 
91% for 41; and 99% for 42. However, in the cyclisation step to the synthesis of the 
corresponding quinolones 43, 44a, 45a and 46, the results are not so good due to the 
different yields obtained (around 3% for 44a; 44% for 43 and 46; 62% for 45a).  
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Considering the poor yield of 44a obtained from the cyclisation reaction of 40 we 
envisaged to optimize the reaction conditions to improve this yield. Two alterations were 
implemented separately: a) decrease the temperature to 200 ºC (during 24 hours); b) 
change the concentration of enamine 40 in Dowtherm A. However, these alterations did 
not lead to successful results, as we could not isolate quinolone 44a. Instead, two different 
side products were recovered (44b and 44c). 
  
The side products in question were characterized by mass spectrometry, 1H NMR 
spectroscopy, elemental analysis and their structure were proved by X-ray 
crystallography (see Appendix 2 - Figure S7 for 44b and Figure S8 for 44c). A possible 
route to the synthesis of these compounds involves reaction between molecules of 
enamine 40, however, studies to mechanism elucidation are required and should be 
performed. 
To introduce chemical diversity at position 7, a strategy approaching nucleophilic 
aromatic substitution was considered to replace the halogen atoms by tetrazole residues. 
However, due to the residual amount of 44a, this strategy was not implemented for this 
quinolone derivative. Modification of quinolone 43 (Scheme 2.23) was attempted, 
through reaction with aminotetrazole 47 and mercapto-1-methyl tetrazole 48, in an 
attempt to synthesize 49 and 50, but the poor character of fluorine as leaving group and 
the poor solubility of 43 compromised the reactions (43 was recovered from the reaction). 
 
Scheme 2.23 – General synthetic approach followed to the attempted preparation of 4-oxo-
quinoline 3-esters linked to tetrazole residues at position 7 (49 and 50) from 43. 
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Scheme 2.24 – General synthetic approach followed for the attempted preparation of 4-oxo-
quinoline 3-esters linked to a 2-methyl tetrazole residue at position 7 (54). 
Considering that iodine is a better leaving group than fluorine, quinolone 3-ester 
46 was submitted to the above devised strategy (Scheme 2.24), so as to introduce a 2-
methyl-aminotetrazole residue (53) in position 7. 53 was previously synthesized from 51, 
albeit in low yield (1-methyl-aminotetrazole 52 is another product; Scheme 2.25). The 
two products obtained from methylation of aminotetrazole 51 can be distinguished by 
mass spectrometry, considering their fragmentation patterns (see Appendix 2 - Figure 
S9). 
 
Scheme 2.25 – Representation of the synthetic approach followed for methylation of 
aminotetrazole 51 to afford 52 and 53. 
The procedure for the mono-methylation of 5-aminotetrazole in aqueous medium 
has been optimized156,157 to give around 51% of 52 and 25% of 53. In this context we 
used dimethyl sulfate (DMS) as methylating agent. The mechanism proposed is depicted 
in Scheme 2.26. DMS (liquid and its vapors) is especially dangerous, as it may cause 
delayed burns to lungs and tissues, may be fatal if inhaled, is carcinogenic and mutagenic 
and is environmentally hazardous. So, its use should be prudent and, if possible, it should 
be replaced by dimethyl carbonate, a safer and environmentally friendly methylating 
agent. DMS is generally employed for methylation of hydroxyl compounds and for 
primary and secondary amines. Despite the presence of a primary amine in 51, some 
studies have shown that the alkylation of the 5-amino group (to afford mono and 
dimethylated derivatives) apparently occurs only in a very limited extension. The 
methylation occurs preferably at position 1, to afford 52, because the H-N of the tetrazole 
ring is the most acidic proton. However, 2-methylated isomer 53 can be recovered. 53 is 
more soluble in organic solvents than 52 so we chose it to incorporate at position 7 of 
quinolone 46.  
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Scheme 2.26 – Schematic representation of the mechanism proposed for the mono-methylation 
of 51 to afford 1- and 2-methyl-5-aminotetrazoles 52 and 53. 
Notwithstanding the good solubility in THF demonstrated by 53 and the better 
profile of iodine as leaving group (comparing to fluorine), the attempt to incorporate the 
tetrazole residue in position 7 of 46 (Scheme 2.24) to synthesize 54, following the 
Buchwald-Hartwig methodology, was not successful. 
The Buchwald-Hartwig amination is a methodology used to construct carbon-
nitrogen bonds based on the cross-coupling reaction of an aryl halide with an amine, using 
palladium, as a catalyst, and a strong base. However, using as substrate a 4-oxo-quinoline 
3-ester, since the ester group was found important for antiplasmodial activity, and should 
therefore be conserved, it is convenient to use a weaker base (e.g. K2CO3) because the 3-
ethyl ester moiety can be affected by a stronger base. The mechanism proposed for this 
methodology (Scheme 2.27) is firstly based in oxidative addition of the aryl halide to 
palladium (0), followed by coordination of the amine to palladium. Then, a base removes 
a proton from the amine, which attacks the palladium, and the halide is removed as a 
leaving group. Finally, a reductive elimination step leads to the final desired aryl amine, 
regenerating the catalyst [Pd(0)].158,159 
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Scheme 2.27 – Schematic representation of the mechanism proposed for the Buchwald-Hartwig 
coupling.158,159 
Considering the poor solubility of quinolones (e.g. derivative 46), an alternative 
methodology, involving the synthesis of a 4-chloroquinoline as intermediate, was 
proposed (quinolone halogenation by using phosphorus oxychloride). 4-Chloroquinolines 
are more easily solubilized and isolated and may be subsequently converted into the 
corresponding quinolones. Then, these intermediates (55 and 56, obtained from 
halogenation of 45 and 46, respectively; Scheme 2.28) represent versatile building blocks 
from which several compounds can be synthesized, introducing chemical diversity at 
position 7 (and position 4), for example by Buchwald-Hartwig amination or by Suzuki 
coupling reactions. 
Inexplicably, it was not possible to synthesize 4-chloroquinoline 55 by 
chlorination, while the analogue without a methyl group at position 6 (56) was 
synthesized and recovered with very good yield (95%). The detailed structure of 56 was 
studied experimentally, using X-ray crystallography and matrix isolation techniques 
coupled to infrared spectroscopy, and also theoretically, using contemporary molecular 
orbital calculations. Results are described in the next chapter.155  
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Scheme 2.28 – Schematic representation of the mechanism proposed for the chlorination of 4-
oxo-quinolines at position 4.  
Although 56 exhibits a better solubility profile than its 4-oxo precursor, the 
attempted Buchwald-Hartwig amination reaction between that 4-chloroquinoline and 
tetrazole derivative 53, to afford derivative 57, was not successful, probably because the 
base used is not strong enough for this methodology. 
 
An alternative procedure was applied to introduce variability at position 7 of ethyl 
4-chloro-7-iodo-quinoline-3-carboxylate (57), based on the Suzuki coupling 
methodology. This approach involves coupling between an organoborane and 
an organohalide, catalysed by a palladium [Pd(0)] complex and a base, leading to carbon-
carbon single bond formation. The mechanism proposed for the Suzuki coupling (Scheme 
2.29) bears similarities with the mechanism proposed for the Buchwald-Hartwig 
methodology, starting with oxidative addition of the aryl halide to the Pd(0). Thereafter, 
a molecule of base (KNu) replaces the halide on the palladium complex, and another one 
forms a borate with a more nucleophilic R’’ group. This activation of the boron atom 
enhances and facilitates transmetalation, where R’’ replaces the Nu group on the 
palladium complex. Reductive elimination ensues, leading to the final coupled product 
and regenerating the palladium catalyst.160 
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Scheme 2.29 – Schematic representation of the mechanism proposed for the Suzuki-Miyaura 
coupling reaction.160 
In this project we choose to introduce a 4-(4-morpholinomethyl)-phenyl group at 
position 7, following the Suzuki-Miyaura methodology described above and considering 
56 as starting material (Scheme 2.30). The reaction was carried out successfully, affording 
the 4-chloroquine derivative with the desired substituent at position 7 (59) in a reasonable 
yield (52%). The presence of a chlorine substituent at position 4 may interfere in this step, 
since coupling could occur at the carbon 4 (with displacement of a chlorine atom). After 
the coupling reaction, compound 59 was converted to the corresponding quinolone 60, 
the active form that has been shown to act as strong inhibitor of the parasitic bc1 protein 
complex. The solubility problems related to compound 60 have complicated its 
purification and isolation, and this led to the poor yield obtained (13%) for the isolated 
product. 
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Scheme 2.30 – Representation of the synthetic approach to 7-(4-(4-morpholinomethyl)-phenyl)-
4-oxo-quinoline 3-ester (60) from 7-iodo-4-chloroquinoline 3-ester (56). 
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2.4. Exploring positions 6 and 7 – the issue of isomeric mixture 
Throughout this project, some criticisms were raised regarding the Gould-Jacobs 
methodology. Considering the mechanism proposed for this cyclisation, one of the 
criticisms is related with the possibility of formation of structural isomers. In the 
thermally driven intramolecular cyclisation, the phenyl ring of the malonate derivative 
(70 to 78, for example) acts as nucleophile, attacking the carbon of the ester carbonyl 
group. Then, this step may result in a cyclisation to both ortho carbons adjacent to the 
NH group of the malonate derivative, and an isomeric mixture can thus be obtained (7- 
or 5-substituted 4-oxo-quinolines). This problem was evident throughout the research 
described in this thesis, affecting compounds with various substituent groups (Scheme 
2.31, 79a-84a vs 79b-84b) although with different impact. 
 
Scheme 2.31 – Summary of the synthetic approach followed and results obtained for the 
preparation of a library of 4-oxo-quinoline 3-esters bearing substituents at positions 6 and/or 7; 
in some examples, a 5-substituted structural isomer was obtained upon Gould-Jacobs cyclisation. 
Conditions: (a) 100 ºC, overnight; (b) Dowtherm A, 250 ºC, 3 hours. 
As represented in Scheme 2.31, the coupling step gave high yield of the required 
products, but the results for the following cyclisation steps were generally poor, 
considering the yields and the ratio of structural isomers (5- vs 7-substituted) obtained. 
These isomers are not easy to isolate and separate from each other, furthermore they have 
the same molecular weight and, consequently, the MS and CHN (elemental analysis) data 
are similar, but by NMR (especially by 1H NMR) it is possible to differentiate these 
compounds and estimate the ratio of structural isomers since the chemical shifts and the 
splitting patterns are distinct. However, in some cases, the poor solubility of quinolones 
hinders this characterization (NMR spectra with poor resolution).  
As reported in a previous section, during the synthesis of 7-hydroxy-4-oxo-
quinoline 3-methylester (33a) an isomeric mixture was obtained and detected by 1H 
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NMR. In the spectrum we observed the presence of two quartets at 4.27-4.17 ppm 
referring to the CH2 and two triplets at 1.31-1.25 ppm corresponding to the CH3 of the 3-
ethyl ester (instead of one quartet and one triplet, respectively). In the spectrum, 8 
aromatic peaks (between 8.6 to 6.6 ppm) are noticed (Figure 2.1), while the quinolone 
33a only has four aromatic hydrogens (one of them at the heterocyclic ring, with a 
characteristic chemical shift around 8.6 ppm). So, considering the integration value 
(singlet peak at 8.59 ppm as reference) and the splitting shift, we can associate signals 
8.59 (s), 7.56 (t), 7.03 (d) and 6.70 (d) to isomer 33b and 8.42 (d), 7.97 (d), 6.87 (s) and 
6.86 (d) ppm to isomer 33a. So, there is an isomeric mixture, in a proportion of around 
60% for quinolone 33b (5-substituted) and around 40% for 33a (7-substituted). Analysis 
of the 13C NMR spectrum is in keeping to those results. 
The same rationale was applied to the synthesis of 4-oxo-quinolines 3-esters 
substituted with acetyl, nitro or nitrile, and the 1H NMR signals obtained for each case 
(Figure 2.1) were used to estimate the approximate ratio of structural isomers: 48% of 
79a vs 52% for 79b; 44% of 80a vs 56% for 80b; and 45% of 81a vs 55% for 81b. 
Noteworthy is the fact that the antiplasmodial activity may differ substantially 
between 5-substituted and 7-substituted isomers, since the two isomers may bind 
differently to the enzyme active site. 
 
Figure 2.1 - 1H NMR spectra showing the chemical shifts of aromatic protons (8.6-6.7 ppm), for 
the isomeric mixtures of 33a/33b, 79a/79b, 80a/80b and 81a/81b in D6-DMSO (dimethyl 
sulfoxide); integration values are indicated below the corresponding peaks. 
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Three other 7-substituted-4-oxo-quinoline-3-esters have been synthesized (with 
methyl, trifluoromethyl and methoxy as substituents) and the results are distinct. 
Cyclisation by Gould-Jacobs methodology to afford compound 82a (7-methyl substituted 
derivative) was achieved with a yield of around 12% (this compound and its derivatives 
will be studied in detail in the next chapter). Apparently, 83 (ethyl 7-trifluoromethyl-4-
oxo-quinoline-3-carboxylate) was synthesized relatively pure, although its poor solubility 
does not allow us to ensure it with security. Applying the same methodology to obtain a 
methoxy substituted quinolone (84a and 84b), it was afforded a powder that also 
demonstrated solubility problems: the 1H NMR spectrum did not have good resolution 
but, by integration, only one ester group appeared to be present; however, in the 13C NMR 
spectrum two signals for the CH3O are observed at 56.0 ppm and 55.9 ppm (see Appendix 
2 - Figure S10). 
Simultaneously, the cyclisation of enamine malonate derivatives with para-
substituents (76-78) was considered. For these compounds, the issue about structural 
isomerism does not arise since the intramolecular cyclisation to either of the carbons 
adjacent to the NH group always gives rise the same substitution pattern (6-substituted 
quinolone derivative: 85-87). 
   
In an attempted to synthesize 85, only the starting material 76 was recovered. 
However, 4-oxo-quinoline derivatives 86 and 87 were successfully synthesized with a 
yield of around 17% and 13%, respectively. 
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2.5. Cyclisation by using phosphorus oxychloride 
The thermally driven intramolecular cyclisation previously discussed, known as 
Gould-Jacobs methodology, presents limitations, mostly related to the high temperature 
(above 225 °C) required for reaction. Cyclisation was found to be concentration 
dependent and the product may undergo thermal degradation.115 At the same time, as has 
been demonstrated in this project, most quinolones exhibit low solubility, leading to 
difficulties in extraction and purification and, consequently, poor yields of isolated 
product. Furthermore, it was demonstrated that this procedure may lead to side products, 
some of them resulting from structural isomerism.  
The liabilities of the Gould-Jacobs cyclisation called for the development of an 
alternative methodology for cyclisation. An alternative approach was proposed,  
involving the cyclisation of an enamine and chlorination at position 4, in one pot, 
mediated by phosphoryl chloride (Scheme 2.32).161 
 
Scheme 2.32 – Schematic representation of the mechanism proposed for the phosphorus 
oxychloride mediated cyclisation to afford 4-chloroquinoline-3-esters.161  
This alternative synthetic approach was applied to several of the enamines 
mentioned in the previous section, in an attempt to improve results, regarding yields and 
purity of the products. However, in all of them, the 4-chloroquinoline intermediate was 
not isolated: either the reaction did not progress or it was not possible to isolate a pure 
product (as observed for the attempted cyclisation of enamines 13, 16, 26, 70, 71, 72 and 
74); or, instead, unexpected products were obtained (as were the case for the attempted 
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cyclisation of enamines 12, 39, 41 and 73). Interestingly, the cyclisation of enamines 12 
and 39 mediated by phosphorus oxychloride was successful, affording products that 
coincided with the quinolones obtained by using the Gould-Jacobs methodology (14 and 
43), although in improved yields (40% vs 17% and 49% vs 44%, respectively). Applying 
the methodology based on phosphorus oxychloride mediated cyclisation to enamine 73 
afforded a salt, 4-hydroxy-quinoline 82b.HCl, while 41 originated a quinolone-4-
phenoxyether derivative (45b), this implying, once again, that prior synthesis of the 
corresponding hydroxy-quinoline had occurred. 
These results prompted us to undertake a more detailed investigation regarding 
the structure of the quinolone core, the possibility of tautomerism in quinolone 3-esters 
and its possible impact on activity. 
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2.6. Synthesis of 4-oxo-quinoline 
Considering the data gathered regarding substituted quinolone 3-esters it was 
decided to investigate further the effect of substituents at positions 6 or 7, regarding 
consequences on the tautomeric and conformational preferences of the quinolone core 
and corresponding impact in pharmacodynamic and pharmacokinetic profiles. As such, 
and in view of a deeper analysis, we deemed important to synthesize the parent 
unsubstituted 4-oxo-quinoline (92a), the 3-ethyl ester derivative (90) and the 3-carboxylic 
acid derivative (91). As shown in Scheme 2.33, compounds 90 and 91 are intermediate 
compounds in the preparation of 92a. 
 
Scheme 2.33 – Representation of the synthetic approach followed to the unsubstituted 4-oxo-
quinoline (92a); Conditions: (a) 100 ºC, overnight; (b) Dowtherm A, 250 ºC, 3 hours; (c) 
Methanol, NaOH (10%), 100 ºC, overnight; (d) heating at 300 ºC, 20 minutes. 
The synthetic approach followed was based on the general method adopted along 
the work (Scheme 2.33), starting with the coupling of the aniline 88 with DEEMM to 
give enamine 89 in good yield (99%) and following to the cyclisation step by using 
Dowtherm A to afford ethyl 4-oxo-quinoline-3-carboxylate 90 (31%). The ethyl ester 
group was then successfully hydrolyzed with a yield of 75%, forming 4-oxo-quinoline 3-
carboxylic acid (91) that, upon decarboxylation, led to 92a. The reaction conditions for 
the last step still need optimization since the melting point of 91 is higher than 250 ºC.  
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2.7. Summary, conclusions and future work 
This chapter was dedicated to the synthesis of quinolone 3-esters, with general 
structure represented in Scheme 2.1 (the target template proposed), with potential activity 
as inhibitors of the bc1 protein complex of P. falciparum. A general synthetic approach 
to the designed scaffolds was devised (Scheme 2.1), generally starting from nitro arenes. 
Reaction conditions for the reduction of meta and/or ortho substituted nitro arenes to the 
corresponding anilines (step 1) and for the coupling of anilines with DEEMM (step 2) to 
afford enamine derivative (α,β-unsaturated ester) were optimized to give high yield of the 
desired products. Additional reactions to increase the diversity of the compounds were 
performed, for example by modification of hydroxyl or halogen groups. Regarding the 
cyclisation of the enamine derivatives to afford the quinolone scaffolds, most reactions 
were performed following the thermally driven Gould-Jacobs intramolecular cyclisation 
methodology. However, this step posed some problems that should not be neglected: 
 the cyclisation reaction did not occur for all the enamine derivatives 
prepared and, when occurring, the yields varied from 3% to 62%; 
 the cyclisation reaction proved to be concentration dependent; 
 the solubility in quinolone derivatives is poor (it is difficult to isolate and 
purify the compounds and also to characterize by 13C NMR and sometimes even difficult 
to obtain 1H NMR data with good quality); 
 the high boiling point of Dowtherm A renders its total extraction or 
separation from the desired organic products a difficult task; 
 the problems associated to the purification of the products (insolubility 
problems also render difficult the purification, for example, by column chromatography);  
 the high temperatures required for Gould-Jacobs intramolecular 
cyclisation can lead to degradation of susceptible groups (thermolysis); 
 the strategy may lead to mixtures of structural isomers, with different 
substitution patterns on the carbocyclic ring (cyclisation consists in an aromatic 
substitution at the adjacent carbon to the NH group of the enamine);  
 additionally, there is a possibility of oxo-quinoline/hydroxy-quinoline 
tautomerism, which may impact in activity and/or mode of action, due to functional group 
interconversions and resulting alterations in drug-target interactions; 
 side products may be obtained from the reaction (e.g. amide and urea 
derivatives). 
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To overcome some of these problems, for example those related to the poor 
solubility and the high reaction temperatures, a new synthetic approach was considered, 
based in the synthesis (in one pot from the corresponding enamine) of 4-chloroquinoline 
derivatives as intermediate compounds, which are more easily solubilized and isolated 
and may be, subsequently, converted into the corresponding quinolones. However, for 
this alternative cyclisation methodology, mediated by POCl3, some limitations were also 
found. In some cases the reaction did not progress or it was not possible to isolate a pure 
product and, in other situations, unexpected products were obtained.  
Thus, and considering all the aspects involved in the synthesis of quinolone 
derivatives, additional studies to elucidate the structure, the possibility of tautomerism 
and its impact on biological activity, and deep efforts to develop reliable synthetic routes, 
are a major priority. 
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2.8. Experimental 
Solvents, reagents and other consumables used in the preparation and isolation 
of compounds 
Commercially available reagents and solvents were purchased from commercial 
sources (Sigma-Aldrich, Alfa Aesar, Acros Organics, Merck, Apollo Scientific Ltd, 
Fluorochem, Fisher Chemical, Panreac, VWR, Fluka, LabChem, Laborspirit) and used as 
received. When required, solvents were freshly distilled in the laboratory, from 
appropriate drying agents, before use: THF was distilled from metallic sodium, using 
benzophenone as indicator, under a constant flow of dry nitrogen. Whenever required, 
inorganic solids were removed by filtration through a layer of Celite® 512 medium 
sourced from Fluka Analytical. 
Synthesis: monitoring and purification 
The reactions were monitored by thin layer chromatography (TLC), using pre-
coated plates with silica gel 60 with fluorescent indicator UV254. After elution, the plates 
were visualised using an ultra-violet lamp (254 nm) and developed in anisaldehyde dip: 
previously prepared from ethanol (280 ml), concentrated sulphuric acid (21 ml), glacial 
acetic acid (6.25 ml) and p-anisaldehyde (1.5ml). Purification by column chromatography 
was carried out using silica gel 60 (particle size 40-63 μm) sourced from Merck and using 
hand bellows or air flow to apply pressure to the column. 
Spectroscopy 
NMR spectra for compounds were recorded at 400 and 100 MHz, for 1H and 13C, 
respectively, using spectrometers available at the University of Liverpool (Department of 
Chemistry) as those that are part of The National NMR Facility, supported by Fundação 
para a Ciência e Tecnologia (RECI/BBB-BQB/0230/2012), in REQUIMTE, 
Departamento de Química e Bioquímica, Universidade Nova de Lisboa, Monte da 
Caparica. Chemical shifts (δ) are described in parts per million (ppm) relative to an 
internal tetramethylsilane standard (TMS; δ=0.0 ppm). Appropriate deuterated solvents 
(D6-DMSO; D1-chloroform; D4-methanol) were supplied by Sigma-Aldrich and were 
used without additional purification. Splitting patterns are designated as singlet (s), broad 
singlet (bs), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets 
(dt), doublet of quartets (dq) or multiplet (m). 
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Mass Spectrometry data was acquired at Laboratório de Análises / REQUIMTE, 
Departamento de Química, Universidade Nova de Lisboa or at the University of 
Liverpool (Department of Chemistry). For electrospray ionisation (ES) and electron 
impact ionisation (EI), Micromass LCT (liquid chromatography time of flight) and 
Micromass GCT (gas chromatography time of flight) mass spectrometers were used 
respectively. Chemical ionisation (CI) was recorded using an Agilent QTOF (quadrupole 
time of flight) 7200 spectrometer. MALDI (matrix-assisted laser desorption/ionisation) 
analyses were performed in a Voyager-DETM PRO Workstation. In the description of 
mass spectra, [M]+ refers to the molecular ion, [M + H]+ to the protonated molecular ion 
peaks, while [M + K]+, [M + Na]+ and [M + NH4]
+ represent the peaks for the compound’s 
molecular ion adducts. 
Other analysis 
Melting ranges were recorded on a Stuart Scientific SMP3 melting point apparatus 
and are uncorrected. 
Elemental analysis (CHN) were performed in the micro analytical laboratory 
available at the University of Liverpool, Department of Chemistry. 
Synthesis; general methods 
General method A: reduction of nitro arenes to aniline derivatives 
The nitro arene derivative (1 eq.) was dissolved in a mixture of methanol and 
water (1:1; 40 ml).  Ammonium chloride (6.7 eq.) was added, followed by iron powder 
(4.2 eq.) and the resulting mixture was stirred at 85 ºC for 4 hours. The reaction mixture 
was then cooled and diluted with methanol (around 50 mL) and the inorganic solids were 
removed by filtering through a layer of Celite®. The filtrate was concentrated by 
evaporation under reduced pressure and the aqueous residue extracted with ethyl acetate 
(2x30 ml). The combined organic extracts were dried over anhydrous MgSO4, filtered, 
and the filtrate was evaporated to dryness under reduced pressure.  
General method B: coupling of aniline derivatives with DEEMM to afford 
enamines 
The appropriate aniline derivative (1 eq.) was dissolved in diethyl 
(ethoxymethylene)malonate (DEEMM; 1 eq.) and the mixture was stirred overnight, 
under reflux (100 ºC).  
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General method C: Gould-Jacobs cyclisation of enamines to 4-oxo-quinoline 3-
esters 
The diethyl malonate enamine intermediate was suspended in Dowtherm A®, 
under a nitrogen atmosphere, and the mixture was refluxed at 250 ºC for some hours 
(generally 3 hours) according with the reaction progress monitored by TLC. The reaction 
mixture was cooled to room temperature and the resulting precipitate (that generally 
appeared) was filtered, washed with hexane and diethyl ether and dried. 
General method D: modification of hydroxyl group from 16, introducing 
heterocyclic substituents 
Diethyl 2-(((3-hydroxyphenyl)amino)methylene)malonate 16 (1 eq.) and 
potassium tert-butoxide (3 eq.) were dissolved in dried THF (30mL) and stirred at 64 ºC 
for 1 hour. The heterocyclic halide derivative (1.2 eq.) was then added, and the mixture 
was kept stirring at 64 ºC (reflux), under a N2 atmosphere, for 24 hours. 
 The mixture was cooled to r.t. and the THF was removed under reduced pressure. 
The solid residue was washed, dissolved and extracted using ethyl acetate (3 x 20 ml). 
The organic layers were combined, dried over anhydrous MgSO4, filtered and the filtrate 
was concentrated under reduced pressure. 
General method E: cyclisation of enamine mediated by phosphorus oxychloride 
The diethyl malonate enamine derivative was suspended in phosphorous 
oxychloride, under a nitrogen atmosphere, and the mixture was refluxed overnight at 95 
ºC. Evaporation of the phosphoryl byproducts under reduced pressure and heating, 
followed by co-evaporation with toluene ensued. The final residue was dissolved in 
isopropanol at 90 ºC (around 30 minutes), the solution was cooled to room temperature 
and the resulting precipitate was filtered and washed with cold isopropanol and light 
petroleum ether.  
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Detailed synthetic procedures  
Synthesis of 7-substituted 4-oxo-quinoline 3-esters involving modification of the 
hydroxyl group of 3-nitrophenol, to afford diphenyl ester and ether derivatives 
3-Nitrophenyl benzoate (6) 
  
3-Nitrophenol 1 (4.00 g; 28.75 mmol; 1 eq.) was dissolved in dried TEA (2.5 eq.), 
under a nitrogen atmosphere. Benzoyl chloride 2 (1 eq.) was mixed with dried THF (30 
mL) and the mixture was added to the solution of 1 in TEA. The reaction was stirred at 
room temperature, under nitrogen atmosphere, for 4 hours. 
Cold water was added and the mixture was acidified to around pH 3 using 
hydrochloric acid (37%). The THF was removed under reduced pressure and the aqueous 
residue was extracted with ethyl acetate (3x20 ml). The organic extracts were combined, 
dried under anhydrous MgSO4 filtered and the solvent was removed under reduced 
pressure. Recrystallization of the solid residue from ethanol (DCM assisted in the 
dissolution) gave the desired product as white needles (6.33 g; 26.04 mmol; yield 91%). 
 Melting range: 94-96 ºC; 1H NMR (400 MHz, (CD3)2SO)  8.24-8.14 (m, 4H), 
7.83-7.74 (m, 3H), 7.61 (t, 2H); 13C NMR (101 MHz, (CD3)2SO) δ 164.64 (C=O), 151.28, 
148.73, 134.72, 131.25, 130.37 (2C), 129.50, 129.39 (2C), 128.80, 121.43, 117.94; MS 
m/z (CI) [M + H]+ C13H9NO4 requires 244.1304, found 244.0604. 
3-Aminophenyl benzoate (9) 
  
Synthesised, according to general method A, from 3-nitrophenyl benzoate 6 (4.40 
g; 18.1 mmol) to afford a brown oil (3.73g; 17.47 mmol; yield 97%). 
1H NMR (400 MHz, (CD3)2SO) δ 8.08 (d, 2H), 7.71 (t, 1H), 7.60-7.56 (t, 2H), 
7.07-7.03 (t, 1H), 6.49 (d, 1H), 6.41 (s, 1H), 6.35 (d, 1H); 13C NMR (101 MHz, CDCl3) 
δ 165.24 (C=O), 151.96, 147.69, 133.51, 130.15 (2C), 129.68, 128.66, 128.54 (2C), 
112.74, 111.56, 108.44; MS m/z (MALDI-TOF) [M + H]+ C13H11NO2 requires 214.0868, 
found 214.0831. 
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Diethyl 2-(((3-benzoyloxyphenyl)amino)methylene)malonate (11) 
  
Synthesised according to the general method B, from 3-aminophenyl benzoate 9 
(3.73 g; 17.47 mmol). Isolated as yellow crystals (2.33 g; 6.07 mmol; yield 35%), after 
purification by column chromatography (eluting with 10% ethyl acetate in 90% hexane). 
Melting range: 55-57 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.69 (d, NH), 8.39 
(d, CHNH), 8.18 – 8.10 (d, 2H), 7.74 (t, 1H), 7.61 (t, 2H), 7.46 (m, 2H), 7.31 (d, 1H), 
7.07 (d, 1H), 4.20-4.11 (m, 2 x OCH2CH3), 1.23 – 1.14 (m, 2 x OCH2CH3); 13C NMR 
(101 MHz, (CD3)2SO) δ 167.68 (C=O), 165.36 (CO2Et), 164.89 (CO2Et), 152.09, 151.17 
(CHNH), 141.11, 134.51, 130.97, 130.27 (2C), 129.38 (2C), 129.29, 118.33, 115.67, 
111.64, 94.49 [C(CO2Et)2], 60.19 (OCH2CH3), 59.99 (OCH2CH3), 14.68 (OCH2CH3), 
14.60 (OCH2CH3); MS m/z (EI) [M]
+ C21H21NO6 requires 383.1369, found 383.1521; 
CHN for C21H21NO6 requires C 65.79%, H 5.52%, N 3.65%, found C 65.83%, H 5.67%, 
N 3.44%. 
Ethyl 7-benzoyloxy-4-oxo-quinoline-3-carboxylate (13) 
  
Synthesised according to the general method C, from enamine 11 (1.05 g; 2.71 
mmol) in Dowtherm A (10 ml; 3 hours), to afford a brown powder (0.67 g; crude yield 
73%). It was not possible to purify the compound due to insolubility problems and 
because the Rf (retention factor) of impurities were essentially close to that of 13, making 
efficient purification of the product impractical. 
Some characteristic data that prove the presence of 13 in the mixture: 1H NMR 
(400 MHz, DMSO) δ 4.24 (OCH2CH3), 1.29 (OCH2CH3); 13C NMR (101 MHz, 
(CD3)2SO) δ 130.49-129.51 (ArCOO), 60.12 (2C, OCH2CH3), 14.79 (2C, OCH2CH3); 
MS m/z (ES) [M + Na]+ C19H15NO5Na requires 360.0845, found 360.0975. 
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1-Benzyloxy-3-nitrobenzene (7) 
  
3-Nitrophenol 1 (3.00 g; 21.57 mmol; 1 eq.) and NaH (2 eq.) were mixed in dry 
THF (30 mL), under a nitrogen atmosphere. The mixture was stirred for 30 minutes at 
room temperature. Benzyl bromide 4 (1 eq.) was then added and the resulting mixture 
was kept stirring at 60 ºC for 4 days, keeping the anhydrous conditions. 
Cold water was added, the mixture was concentrated under reduced pressure (THF 
was removed) and the aqueous residue was extracted with ethyl acetate (3x20 ml). The 
organic extracts were dried under anhydrous MgSO4, filtered, and the solvent was 
removed under reduced pressure. Recrystallization of the solid residue from ethanol gave 
the desired product as yellow crystals (4.29 g; 18.70 mmol; yield 87%). 
A similar procedure was applied, to afford the same product, but using benzyl 
chloride 3 (1 eq.). 
Melting range: 59-60 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 7.80 (d, 2H), 7.57 (t, 
1H), 7.48 (m, 3H), 7.40 (t, J = 7.3 Hz, 2H), 7.36 – 7.32 (m, 1H), 5.23 (s, OCH2Ar); 13C 
NMR (101 MHz, (CD3)2SO) δ 159.20, 149.09, 136.56, 131.09, 128.90 (2C), 128.48, 
128.22 (2C), 122.66, 116.07, 109.39, 70.30 (OCH2Ar); MS m/z (CI) [M + H]
+ C13H11NO3 
requires 230.1504, found 230.0820.  
3-Benzyloxy-aniline (10) 
  
Synthesised according to the general method A, from 1-benzyloxy-3-nitrobenzene 
7 (3.00 g; 13.10 mmol). The product was recovered as a dark oil (2.60 g; 13.05 mmol; 
yield 99%). 
1H NMR (400 MHz, (CD3)2SO) δ 7.41-7.38 (m, 5H), 6.91-6.87 (t, 1H), 6.22 (s, 
1H), 6.21-6.15 (d, 2H), 5.05 (s, OCH2Ar), 4.98 (s, NH2); 
13C NMR (101 MHz, (CD3)2SO) 
δ 159.73, 150.36, 137.89, 129.90, 128.73 (2C), 128.00, 127.86 (2C), 107.43, 102.56, 
100.67, 69.05 (OCH2Ar); MS m/z (CI) [M + H]
+ C13H14NO requires 200.1075, found 
200.1074. 
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Diethyl 2-(((3-benzyloxyphenyl)amino)methylene)malonate (12) 
  
Synthesised according to the general method B, from 3-benzyloxy aniline 10 (1.04 
g; 5.24 mmol), to afford a brown solid (1.91 g; 5.16 mmol; yield 99%). 
Melting range: 67-68 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.66 (d, NH), 8.40 
(d, CHNH), 7.48-7.28 (m, 6H), 7.08 (t, 1H), 6.94 (d, 1H), 6.81 (d, 1H), 5.14 (s, OCH2Ar), 
4.21 (q, OCH2CH3), 4.12 (q, OCH2CH3), 1.28 – 1.23 (m, 2 x OCH2CH3); 13C NMR (101 
MHz, (CD3)2SO) δ 167.69 (CO2Et), 165.29 (CO2Et), 159.79, 151.36 (CHNH), 140.99, 
137.21, 130.98, 128.82 (2C), 128.27, 128.12 (2C), 111.60, 110.06, 104.67, 93.68 
[C(CO2Et)2], 69.72 (OCH2Ar, 60.06 (OCH2CH3), 59.87 (OCH2CH3), 14.61 (OCH2CH3), 
14.54 (OCH2CH3); MS m/z (ES) [M + Na]
+ C21H23NO5Na requires 392.1474, found 
392.1467. 
Ethyl 7-benzyloxy-4-oxo-quinoline-3-carboxylate (14) 
  
Synthesised according to the general method C, from enamine 12 (1.00 g; 2.71 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a brown powder (0.15 g; 0.45 mmol; 
yield 17%). 
Melting range: 269-270 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.08 (s, NH), 8.47 
(s, CHNH), 8.05 (d, 1H), 7.49-7.35 (m, 6H), 7.07 (m, 1H), 5.22 (s, OCH2Ar), 4.19 (q, 
OCH2CH3), 1.26 (t, OCH2CH3); 
13C NMR data not obtained due to poor solubility in all 
available deuterated solvents; MS m/z (EI) [M]+ C19H17NO4 requires 323.1158, found 
323.1204; CHN for C19H17NO4 requires C 70.58%, H 5.30%, N 4.33%, found C 70.34%, 
H 5.24%, N 4.09%. 
The compound was also synthesized using the general method E. From enamine 
12 (0.65 g; 1.76 mmol), in 5 ml of POCl3, to afford a beige powder (0.23 g; 0.70 mmol; 
40%). 
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1H NMR (400 MHz, (CD3)2SO) δ 12.02 (s, NH), 8.39 (d, CHNH), 7.97 (d, 1H), 
7.40 (m, 2H), 7.37 (m, 2H), 7.30 (m, 1H), 7.00 (m, 2H), 5.14 (s, OCH2Ar), 4.11 (q, 
OCH2CH3), 1.19 (t, OCH2CH3). 
Synthesis of 4-oxo-quinolines bearing heterocyclic substituents at position 7, from 
the common intermediate diethyl 2-(((3-hydroxyphenyl)amino)methylene)malonate (16) 
3-Aminophenol (15) 
  
Synthesised according to the general method A, from 3-nitrophenol 1 (1.00 g; 7.19 
mmol) to afford a brown solid (0.78 g; 7.15 mmol; yield 99%). 
Melting range: 110-112 ºC; 1H NMR (400 MHz, CD3OD)  6.90-6.86 (t, 1H), 
6.22-6.19 (m, 2H), 6.14 (d, 1H); 13C NMR (101 MHz, (CD3)2SO) δ 158.41 (COH), 150.13 
(CNH2), 129.78, 105.78, 103.66, 101.32; MS m/z (CI) [M + H]
+ C6H8NO requires 
110.0606, found 110.0600. 
Diethyl 2-(((3-hydroxyphenyl)amino)methylene)malonate (16) 
  
Synthesised according to general method B, from 3-aminophenol 15 (2.00 g; 
18.33 mmol). Crystallization from ethanol and DCM afforded yellow crystals (4.65 g; 
16.66 mmol; yield 91%). 
Melting range: 141-142 ºC; 1H NMR (400 MHz, CD3OD)  8.53 (s, CHNH), 7.21 
(t, 1H), 6.66 (m, 3H), 4.2-4.22 (m, 2 x OCH2CH3), 1.35 (m, 2 x OCH2CH3); 
13C NMR 
(101 MHz, (CD3)2SO) δ 167.69 (CO2Et), 165.23 (CO2Et), 158.90 (COH), 151.27 
(CHNH), 140.81, 130.97, 112.29, 108.59, 104.57, 93.25 [C(CO2Et)2], 60.02 (OCH2CH3), 
59.81 (OCH2CH3), 14.63 (OCH2CH3), 14.56 (OCH2CH3); MS m/z (ES) [M + Na]
+ 
C14H17NO5Na requires 302.1004, found 302.0994. 
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Isomeric mixture: ethyl 7-hydroxy-4-oxo-quinoline-3-carboxylate (33a) and ethyl 5-
hydroxy-4-oxo-quinoline-3-carboxylate (33b) 
 
Obtained following the general method C, from enamine 16 (0.63 g; 2.26 mmol) 
in 10 ml of Dowtherm A (3 hours). Precipitated as white powder (0.09 g; 0.39 mmol; 
yield 17%, identified as a mixture of isomers). 
1H NMR (400 MHz, (CD3)2SO) δ 12.75 (s, NH), 12.00 (s, NH), 8.59 (s, 
CHNH)33b, 8.42 (d, CHNH)33a, 7.97 (d, 1H)33a, 7.56 (t, 1H)33b, 7.03 (d, 1H)33b, 6.87 (m, 
2H)33a, 6.70 (d, 1H)33b, 4.24 (q, OCH2CH3), 4.19 (q, OCH2CH3), 1.30 (t, OCH2CH3), 1.27 
(t, OCH2CH3); ); 
13C NMR (101 MHz, (CD3)2SO) δ 180.29, 165.40, 164.29, 162.11, 
161.41, 146.36, 144.97, 141.29, 140.35, 135.08, 128.14, 120.86, 119.22, 114.04, 110.49, 
109.82, 108.77, 107.99, 102.40, 60.34 (OCH2CH3), 59.87 (OCH2CH3), 14.81 
(OCH2CH3), 14.76 (OCH2CH3); MS m/z (ES) [M + Na]
+ C12H11NO4Na requires 
256.0586, found 256.0581; CHN for C12H11NO4 requires C 61.80%, H 4.75%, N 6.01%, 
found C 61.47%, H 4.63%, N 5.82%. 
Diethyl 2-(((3-((4-morpholinecarbonyl)oxy)phenyl)amino)methylene)malonate (23) 
  
Synthesised following the general method D, from 16 (1.00 g; 3.58 mmol) and 4-
morpholine carbonyl chloride 17 (0.49 ml; 4.30 mmol), to afford brown crystals (0.90 g; 
2.30 mmol; yield 64%), after crystallization from ethanol and DCM. 
1H NMR (400 MHz, (CD3)2SO) δ 10.64 (d, NH), 8.36 (d, CHNH), 7.37 (t, 1H), 
7.26 (s, 1H),  7.22 (d, 1H), 6.92 (d, 1H), 4.19 (q, OCH2CH3), 4.11 (q, OCH2CH3), 3.64-
3.41 (m, 8H), 1.24 (m, 2 x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 167.60 
(CO2Et), 165.44 (CO2Et), 153.22, 152.57, 151.23, 140.88, 130.72, 118.37, 115.01, 
111.70, 94.32 [C(CO2Et)2], 66.23 (2 x OCH2CH2N), 60.20 (OCH2CH3), 60.02 
(OCH2CH3), 45.06 (OCH2CH2N), 44.30 (OCH2CH2N), 14.73 (OCH2CH3), 14.64 
(OCH2CH3); MS m/z (ES) [M + Na]
+ C19H24N2O7Na requires 415.1481, found 415.1; 
CHN for C19H24N2O7 requires C 58.16%, H 6.16%, N 7.14%, found C 58.20%, H 6.90%, 
N 7.18%. 
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Diethyl 2-(((3-((4-methylpiperazine-1-carbonyl)oxy)phenyl)amino)methylene)malonate 
(24) 
 
Synthesised following the general method D, from 16 (1.00 g; 3.58 mmol) and 4-
methyl-1-piperazine carbonyl chloride 18 (0.70 g; 4.30 mmol). Isolated as an orange oil 
(0.98 g; 2.41 mmol; yield 67%) after purification by column chromatography (eluting 
with 5% methanol in 95% DCM). 
1H NMR (400 MHz, (CD3)2SO) δ 10.64 (d, NH), 8.35 (d, CHNH), 7.36 (t, 1H), 
7.24 (s, 1H), 7.21 (d, 1H) 6.95 (d, 1H), 4.20 (q, OCH2CH3), 4.12 (q, OCH2CH3), 3.49 (m, 
2 x MeNCH2CH2), 2.35 (m, 2 x MeNCH2), 2.21 (s, H3CN), 1.24 (m, 2 x OCH2CH3); 
13C 
NMR (101 MHz, (CD3)2SO) δ 167.58 (CO2Et), 165.43 (CO2Et), 153.11, 152.63, 151.23, 
140.88, 130.70, 118.37, 114.89, 111.75, 94.34 [C(CO2Et)2], 60.18 (OCH2CH3), 60.01 
(OCH2CH3), 54.70 (NCH2CH2N), 54.55 (NCH2CH2N), 46.17 (H3CN), 44.63 
(NCH2CH2N), 44.61 (NCH2CH2N), 14.73 (OCH2CH3), 14.65 (OCH2CH3); MS m/z (EI) 
[M]+ C20H27N3O6 requires 405.1900, found 405.2060; CHN for C20H27N3O6 requires C 
59.25%, H 6.71%, N 10.36%, found C 59.69%, H 7.18%, N 9.82%. 
Diethyl 2-(((3-((4,6-dimethoxy-1,3,5-triazin-2-yl)oxy)phenyl)amino)methylene)malonate 
(25) 
  
Synthesised according to the general method D, from 16 (1.00 g; 3.58 mmol) and 
2-chloro-4,6-dimethoxy-1,3,5-triazine 19 (0.75 g; 4.30 mmol), to afford a yellow solid 
(0.24 g; 0.58 mmol; yield 16%) by purification in column chromatography (eluting with 
DCM). 
1H NMR and 13C NMR data not obtained due to insolubility in all available 
deuterated solvents; MS m/z (EI) [M]+ C19H22N4O7 requires 418.1489, found 418.1675. 
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3-Chloro-1,2-benzisothiazole 1,1-dioxide (pseudo-saccharyl chloride) (21) 
  
Saccharin 20 (21.00 g; 114.00 mmol)) was mixed with phosphorus pentachloride 
(1.1 eq.) and heated at 180°C for 3 hours. Phosphorus oxychloride and HCl (side 
products) and phosphorus pentachloride (in excess) were distilled under vacuum and 
heating. The residue was cooled to 135 ºC, dissolved in toluene (60 ml) and crystallized 
on cooling to room temperature. The crystals were filtered, washed with cold toluene, 
dried and recrystallized until the desired pure product was afforded as white crystals (5.93 
g; 29.40 mmol; 26% yield). 
Melting range: 141-142 ºC; 1H NMR (400 MHz, CDCl3)  7.95-7.93 (d, 2H), 
7.88-7.82 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 166.08 (C-Cl), 140.63 (C-SO2), 
134.93, 134.41, 129.94, 125.07, 122.49. 
Diethyl 2-(((3-(((benzysothiazol-3-yl)oxy)phenyl)amino)methylene)malonate (26) 
  
Diethyl 2-(((3-hydroxyphenyl)amino)methylene)malonate 16 (1.00 g; 3.58 mmol) 
was dissolved in TEA (2 eq.), under a nitrogen atmosphere. Pseudo saccharin chloride 
(21; 1.3 eq.) was added and the mixture was dissolved in toluene (15 ml), under anhydrous 
conditions, at 50 ºC, for 3 hours. The product appeared as a precipitate, was filtered and 
washed with cold toluene and recrystallized from ethanol (and DCM) to give white 
crystals (0.80 g; 1.81 mmol; 51%). 
Melting range: 143-144 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.71 (d, NH), 8.37 
(d, CHNH), 8.21 (d, 1H), 8.13 (d, 1H), 8.03 – 7.93 (m, 2H), 7.67 (s, 1H), 7.53 (t, 1H), 
7.41 (d, 1H), 7.26 (d, 1H), 4.21 (q, OCH2CH3), 4.11 (q, OCH2CH3), 1.24 (dt, OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available deuterated solvents; MS 
m/z (EI) [M]+ C21H20N2O7S requires 444.0991, found 444.1267. 
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Ethyl 7-benzysothiazoloxy-4-oxo-quinoline-3-carboxylate (31) 
  
Synthesised according to the general method C, from enamine 26 (0.50 g; 1.13 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a brown powder (0.21 g; 0.54 mmol; 
yield 48% with Dowtherm A). 
Melting range: 265-267 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.51 (s, NH), 8.60 
(d, CHNH), 8.29 (d, 1H), 8.23 (d, 1H), 8.16 (d, 1H), 8.00 (m, 2H), 7.80 (s, 1H), 7.55 (d, 
1H) and Dowtherm A characteristics peaks; 13C NMR data not obtained due to poor 
solubility in all available deuterated solvents; MS m/z (ES) [M + Na]+ C19H14N2O6SNa 
requires 421.0470, found 421.0466; CHN for C19H14N2O6S requires C 57.28%, H 3.54%, 
N 7.03%, S 8.05% found C 61.50%, H 4.02%, N 5.98%, S 6.34% (presence of Dowtherm 
A increase the percentage of C and H, decreasing the percentage of N and S). 
Diethyl 2-(((3-((1-phenyl-1H-tetrazol-5-yl)oxy)phenyl)amino)methylene)malonate (27) 
  
Synthesised according to the general method D, from 16 (1.00 g; 3.58 mmol) and 
5-chloro-1-phenyl-1H-tetrazole 22 (0.78 g; 4.30 mmol), to afford yellow crystals (1.20 g; 
2.84 mmol; yield 79%) from crystallization in ethanol. 
Melting range: 117-118 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.72 (d, NH), 8.39 
(d, CHNH), 7.87 (d, 2H), 7.74 – 7.65 (m, 3H), 7.62 (d, 1H), 7.51 (t, 1H), 7.37 (d, 1H), 
7.29 (d, 1H), 4.22 (q, OCH2CH3), 4.14 (q, OCH2CH3), 1.26 (dt, 2 x OCH2CH3); 
13C NMR 
(101 MHz, (CD3)2SO) δ 167.56 (CO2Et), 165.41 (CO2Et), 159.88, 154.73, 150.98, 
141.51, 132.98, 131.49, 130.35, 130.31 (2C), 123.69 (2C), 116.12, 116.03, 109.60, 94.89 
[C(CO2Et)2], 60.27 (OCH2CH3), 60.09 (OCH2CH3), 14.69 (OCH2CH3), 14.61 
(OCH2CH3); MS m/z (EI) [M]
+ C21H21N5O5 requires 423.1543, found 423.1868; CHN 
for C21H21N5O5 requires C 59.57%, H 5.00%, N 16.54%, found C 59.32%, H 4.97%, N 
16.48%. 
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Ethyl 7-(1-phenyl-1H-diazirin-3-yl)oxy-4-oxo-quinoline-3-carboxylate (32b) 
 
Synthesised according to the general method C, from enamine 27 (0.60 g; 1.42 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a yellow powder (0.11 g; 0.31 mmol; 
yield 22%). 
1H NMR (400 MHz, (CD3)2SO) δ 10.03 (s, NH), 8.59 (s, 1H), 8.43 (d, 1H), 7.65 
(d, 1H), 7.48 – 7.35 (m, 3H), 7.17–7.11 (m, 2H), 6.98 (m, 1H), 4.26 (q, OCH2CH3), 1.29 
(t, OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 163.16, 158.52, 156.17, 149.76, 
146.59, 141.65, 140.21, 130.80, 130.14, 125.87, 123.09, 118.74, 117.46, 117.07, 115.44, 
114.32, 102.36, 60.92 (OCH2CH3), 14.67 (OCH2CH3); MS m/z (EI) [M]
+ C19H15N3O4 
requires 349.1063, found 349.1133; MS m/z (MALDI-TOF) [M + H]+ C19H16N3O4 
requires 350.1141, found 350.0479; MS m/z (ES) [M + Na]+ C19H15N3O4Na requires 
372.0960, found 372.0962. 
Synthesis of 7-substituted 4-oxo-quinoline 3-esters from the nucleophilic aromatic 
substitution of halogen by tetrazolyl and morpholinyl derivatives 
Diethyl 2-(((3-fluorophenyl)amino)methylene)malonate (39) 
  
Synthesised according to the general method B, from 3-fluoroaniline 35 (3.0 ml; 
31.21 mmol). The product was recovered as brown crystals (7.90 g; 28.10 mmol; yield 
90%), from crystallization in ethanol. 
Melting range: 43-45 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.62 (d, NH), 8.35 
(d, CHNH), 7.35 (dd, 2H), 7.18 (d, 1H), 6.95 (s, 1H), 4.15 (m, 2 x OCH2CH3), 1.23 (m, 
2 x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 165.30 (CO2Et), 164.49 (CO2Et), 
162.07 (CF), 151.17 (CHNH),141.87, 131.78, 113.99, 111.35, 105.31, 94.71 
[C(CO2Et)2], 60.25 (OCH2CH3), 60.06 (OCH2CH3), 14.70 (OCH2CH3), 14.67 
(OCH2CH3); MS m/z (EI) [M]
+ C14H16FNO4 requires 281.1063, found 281.1096. 
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Ethyl 7-fluoro-4-oxo-quinoline-3-carboxylate (43) 
 
Synthesised according to the general method C, from enamine 39 (1.00 g; 3.56 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a white powder (0.37 g; 1.57 mmol; 
yield 44%). 
Melting range: 297-298 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.32 (s, NH), 8.56 
(s, CHNH), 8.17 (t, 1H), 7.36 (d, 1H), 7.26 (t, 1H), 4.20 (q, OCH2CH3), 1.26 (t, 
OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available deuterated 
solvents; MS m/z (EI) [M]+ C12H10FNO3 requires 235.0645, found 235.0652; CHN for 
C12H10FNO3 requires C 61.28%, H 4.28%, N 5.95%, found C 61.12%, H 4.20%, N 
5.88%. 
The synthesis of this compound was repeated following the general method E, 
from enamine 39 (4.00 g; 14.22 mmol) in 40 ml of POCl3, to afford a beige powder (1.64 
g; 6.98 mmol; 49%). 
Melting range: 280-282 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.30 (s, NH), 8.57 
(s, CHNH), 8.18 (t, 1H), 7.37 (d, 1H), 7.26 (t, 1H), 4.20 (q, OCH2CH3), 1.26 (t, 
OCH2CH3). 
Diethyl 2-(((3,4-difluorophenyl)amino)methylene)malonate (40) 
  
Synthesised according to the general method B, from 3,4-difluoroaniline 36 (3.0 
ml; 30.25 mmol).  The product was recovered as brown crystals (8.99 g; 30.04 mmol; 
yield 99%), from crystallization in ethanol. 
Melting range: 60-62 ºC; 1H NMR (400 MHz, CD3OD) δ 8.41 (s, CHNH), 7.27 
(m, 2H), 7.07 (s, 1H), 4.23 (dq, 2 x OCH2CH3), 1.31 (dt, 2 x OCH2CH3); 
13C NMR (101 
MHz, (CD3)2SO) δ 167.52 (CO2Et), 165.33 (CO2Et), 151.71, 151.28, 137.40, 137.34, 
118.63, 114.80, 108.04, 94.58 [C(CO2Et)2], 60.21 (OCH2CH3), 60.04 (OCH2CH3), 14.71 
(OCH2CH3), 14.65 (OCH2CH3); MS m/z (MALDI-TOF) [M + H]
+ C14H16F2NO4 requires 
300.1042, found 300.1100. 
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Ethyl 6,7-difluoro-4-oxo-quinoline-3-carboxylate (44a) 
 
Synthesised according to the general method C, from enamine 40 (0.50 g; 1.67 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a beige powder (12 mg; 0.05 mmol; 
yield 3%). 
Melting point, 1H NMR and 13C NMR data not obtained due to the low quantity 
obtained and to the insolubility in all available deuterated solvents; MS m/z (CI) [M + 
H]+ C12H10F2NO3 requires 254.0629, found 254.0622. 
Diethyl 2-(((3-iodo-4-methylphenyl)amino)methylene)malonate (41) 
  
Synthesised according to the general method B, from 3-iodo-4-methylaniline 37 
(3.00 g; 12.87 mmol). The product was recovered as white crystals (4.74 g; 11.75 mmol; 
yield 91%), from crystallization in ethanol (and ethyl acetate, to help dissolution). 
Melting range: 119-121 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.57 (d, NH), 8.30 
(s, CHNH), 7.86 (s, 1H), 7.31 (s, 2H), 4.15 (m, 2 x OCH2CH3), 2.32 (s, CH3), 1.23 (m, 2 
x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 167.58 (CO2Et), 165.61 (CO2Et), 151.41 
(CHNH), 138.80, 137.49, 130.88, 127.88, 117.91, 102.01 (CI), 93.99 [C(CO2Et)2],  60.26 
(OCH2CH3), 60.12 (OCH2CH3), 27.12 (CH3), 14.69 (OCH2CH3), 14.62 (OCH2CH3); MS 
m/z (EI) [M]+ C15H18INO4 requires 403.0281, found 403.0353. 
Ethyl 6-methyl-7-iodo-4-oxo-quinoline-3-carboxylate (45a) 
 
Synthesised according to the general method C, from enamine 41 (1.00 g; 2.48 
mmol) in 10 ml of Dowtherm A (3 hours). The product was recovered as a white powder 
(0.55 g; 1.53 mmol; yield 62%). 
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Melting range: 316-318 ºC; 1H NMR and 13C NMR data not obtained due to 
insolubility in all available deuterated solvents; MS m/z (ES) [M + Na]+ C13H12INO3Na 
requires 379.9760, found 379.9755; CHN for C13H12INO3 requires C 43.72%, H 3.39%, 
N 3.92%, found C 43.67%, H 3.30%, N 3.73%. 
Ethyl 7-iodo-4-(3-iodo-4-methylphenoxy)-6-methylquinoline-3-carboxylate (45b) 
 
Synthesised according to the general method E, from enamine 41 (2.00 g; 4.96 
mmol) in 15 ml of POCl3. The product was recovered as a mixture of yellow 
powder/crystals (0.35 g; 0.61 mmol; 12%). 
Melting range 216-218 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 8.87 (s, CHN), 8.60 
(s, 1H), 8.57 (s, 1H), 7.73 (s, 1H), 7.36 (d, 1H), 7.21 (d, 1H), 3.76 (q, OCH2CH3), 2.53 
(s, CH3), 2.37 (s, CH3), 1.10 (t, OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 166.95 
(CO2Et), 164.36 (COAr), 151.31, 146.70, 139.85, 139.20, 138.34, 131.32, 130.04, 
128.63, 123.54, 119.30, 109.20, 107.66, 101.07, 61.52 (OCH2CH3), 27.64 (CH3), 26.84 
(CH3), 13.68 (OCH2CH3); MS m/z (MALDI-TOF) [M]
+ C20H17I2NO3 requires 572.9298, 
found 572.9696. 
Diethyl 2-(((3-iodophenyl)amino)methylene)malonate (42) 
  
Synthesised according to the general method B, from 3-iodoaniline 38 (2.0 ml; 
16.63 mmol). The product was recovered as a white solid (6.42 g; 16.50 mmol; yield 
99%) from precipitation in hexane, at room temperature. 
Melting range: 86-88 ºC; 1H NMR (400 MHz, CDCl3) δ 10.97 (d, NH), 8.45 (d, 
CHNH), 7.51 – 7.46 (m, 2H), 7.11 – 7.08 (m, 2H), 4.28 (dq, 2 x OCH2CH3), 1.36 (dt, 2 x 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 168.92 (2 x CO2Et), 151.26 (CHNH), 140.44 
(CNH), 133.76, 131.22, 125.96, 116.41, 94.97, 94.63, 60.60 (OCH2CH3), 60.31 
(OCH2CH3), 14.43 (OCH2CH3), 14.28 (OCH2CH3); MS m/z (ES) [M + Na]
+ 
C14H16INO4Na requires 412.0022, found 412.0020. 
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Ethyl 7-iodo-4-oxo-quinoline-3-carboxylate (46) 
 
Synthesised according to the general method C, from enamine 42 (10.14 g; 26.06 
mmol) in 80 ml of Dowtherm A (3 hours). The product was recovered as a white powder 
(3.97 g; 11.57 mmol; yield 44%). 
Melting range: 306-308 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 8.56 (s, CHNH), 
8.02 (s, 1H), 7.88 (d, 1H), 7.71 (d, 1H), 4.21 (q, OCH2CH3), 1.27 (t, OCH2CH3); 
13C 
NMR (100 MHz, (CD3)2SO) δ 176.4 (C=O), 165 (CO2Et), 150.4, 147.7, 132.3, 128.8, 
128.1, 125.6, 112.3 (CCO2Et), 100.9 (CI), 61.4 (OCH2CH3), 14.2 (OCH2CH3); MS m/z 
(ES) [M + Na]+ C12H10INO3Na requires 365.9603, found 365.9591; CHN for C12H10INO3 
requires C 42.01%, H 2.94%, N 4.08%, found C 42.17%, H 2.84%, N 3.95%. 
1-Methyl-5-aminotetrazole (52) and 2-methyl-5-aminotetrazole (53) 
         
5-Amine-1H-tetrazole 51 (10.30 g; 121.00 mmol) was mixed in water (30mL) and 
aqueous sodium hydroxide 5M (≈30mL) was added, dropwise, until dissolution of 51. 
The solution was kept at 50 ºC and dimethyl sulphate (20.0 mL; 211.00 mmol) was added 
dropwise, keeping the pH around 14. The reaction mixture was stirred under reflux, at 
100 ºC, for 1 hour.  
The mixture was cooled and kept inside the fridge. Compound 52 precipitated as 
crystals, which were collected by filtration and dried (3.07 g; 31.00 mmol; 26%). The 
aqueous residue was extracted with diethyl ether (2 x 30 ml), then with DCM (2 x 30 ml). 
The organic layers were combined, the solvent was removed under reduced pressure and 
the solid residue was recrystallized from ethanol (mixture kept inside the fridge) to afford 
53 as white crystals (1.27 g; 12.82 mmol; 11%). 
52: Melting range: 219-220 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 6.62 (s, NH2), 
3.69 (s, CH3);
 13C NMR (101 MHz, (CD3)2SO) δ 156.29 (CNH2), 31.93 (CH3); MS 
m/z (EI) [M]+ C2H5N5 requires 99.0545, found 99.0545 (and 57.0442: fragment N3CH3). 
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53: Melting range: 99-100 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 5.94 (s, NH2), 
4.06 (s, CH3); 
13C NMR (101 MHz, DMSO) δ 167.63 (CNH2), 39.26 (CH3); MS m/z (EI) 
[M]+ C2H5N5 requires 99.0545, found 99.0545 (and 71.0475: fragment NH2CN2CH3). 
Ethyl 4-chloro-7-iodo-quinoline-3-carboxylate (56) 
 
Ethyl 7-iodo-4-oxo-quinoline-3-carboxylate 46 (0.70 g; 2.04 mmol) was 
suspended in phosphoryl chloride (5 mL), under a nitrogen atmosphere, and the resulting 
mixture was refluxed at 97 ºC overnight. The mixture was cooled to room temperature, 
poured into a beaker with ice, stirred for 1 hour and then extracted with chloroform. The 
organic layers were collected, dried over anhydrous MgSO4, filtered, and the solvent was 
removed by evaporation under reduced pressure to afford 56 as yellow solid (0.70 g, 1.94 
mmol; 95%).  
Melting range: 269-271 ºC; 1H NMR (400 MHz, CDCl3) δ 9.19 (s, CHN), 8.60 (s, 
1H), 8.12 (d, 1H), 7.99 (d, 1H), 4.50 (q, OCH2CH3), 1.47 (t, OCH2CH3). 
13C NMR (100 
MHz, CDCl3) δ 164.18, 150.95, 149.75, 138.69, 137.29, 126.59 (2C), 125.52, 123.33, 
99.18 (CI), 62.28 (OCH2CH3), 14.25 (OCH2CH3); MS m/z (ES) [M + Na]
+ 
C12H9ClINO2Na requires 383.9264, found 383.9291; CHN for C12H9ClINO2 requires C 
39.86%, H 2.51%, N 3.87%, found C 39.28%, H 2.73%, N 3.56%. 
Ethyl 4-chloro-7-(4-(morpholinomethyl)phenyl)-quinoline-3-carboxylate (59) 
 
A mixture of toluene:H2O (10 ml; 9:1) was added to a mixture of ethyl 4-chloro-
7-iodo-quinoline-3-carboxylate 56 (0.42 g; 1.16 mmol), potassium carbonate (2.5 eq.), 
Pd(PPh3)4 (5%) and 4-(4-morpholinomethyl)phenyl boronic acid pinacol ester 58 (1.1 
eq.). The final mixture was refluxed at 100 ºC for 24 hours, under a nitrogen atmosphere. 
The reaction mixture was cooled to room temperature and the inorganic solids were 
filtered through sand, silica and MgSO4 and washed with ethyl acetate (around 250 ml). 
After filtration, the solution was concentrated to dryness by solvent evaporation under 
reduced pressure to provide the product 59 as a yellow solid (0.25 g; 0.60 mmol; 52%). 
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 1H NMR (400 MHz, , (CD3)2SO) δ 9.20 (s, CHN), 8.47 (d, 1H), 8.42 (s, 1H), 8.23 
(d, 1H), 7.91 (d, 2H), 7.51 (d, 2H), 4.45 (q, OCH2CH3), 3.60 (m, 6H), 2.41 (m, 
O(CH2CH2)2N), 1.41 (t, OCH2CH3); 
13C NMR (101 MHz, , (CD3)2SO) δ 164.31, 150.76, 
149.87, 144.08, 137.31, 137.23, 132.00, 130.26, 129.30, 129.18, 128.58, 127.74 (2C), 
126.59, 126.26, 110.69 (CCO2Et), 66.69 (2C), 62.45 (2C), 53.69 (2C), 14.51 (OCH2CH3); 
MS m/z (ES) [M + H]+ C23H24ClN2O3 requires 411.1475, found 411.1469. 
Ethyl 7-(4-(morpholinomethyl)phenyl)-4-oxo-quinoline-3-carboxylate (60) 
 
Ethyl 4-chloro-7-(4-(morpholinomethyl)phenyl)-quinoline-3-carboxylate 59 
(0.25 g; 0.60 mmol) was added to DMF (10 ml) and the mixture was stirred for 15 min. 
A solution of HCO2H (80%) in ethanol (5 ml) was added, and the resulting mixture was 
refluxed at 145˚ C for 18 hours. The reaction mixture was cooled to room temperature, 
DMF was removed by evaporation under reduced pressure and the residue was basified 
(with sodium bicarbonate) and extracted with a mixture of methanol (10%) in DCM (2 x 
30 ml). The combined organic extracts were washed with brine and dried over MgSO4. 
The organic solution was collected by filtration and concentrated by solvent evaporation 
under reduced pressure. The residue was purified by silica gel chromatography (eluting 
from 5% of methanol in DCM to 15% of methanol in DCM) to give a palid powder 60 
(0.03 g; 0.08 mmol; 13%). 
1H NMR (400 MHz, (CD3)2SO) δ 8.59 (s, CHN), 8.22 (d, 1H), 7.83 (s, 1H), 7.73 
(m, 3H), 7.47 (m, 2H), 4.23 (q, OCH2CH3), 3.62 (m, 6H), 2.40 (m, O(CH2CH2)2N), 1.30 
(t, OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available 
deuterated solvents; MS m/z (ES) [M + Na]+ C23H24N2O4Na requires 415.1634, found 
415.1620. 
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Synthesis of 6- or 7-substituted 4-oxo-quinoline 3-esters; the issue of isomeric 
mixtures 
Diethyl 2-(((3-acetylphenyl)amino)methylene)malonate (70) 
  
Synthesised according to the general method B, from 3-aminoacetophenone 61 
(2.40 g; 17.76 mmol). The product precipitated in hexane, as a brown solid (5.41 g; 17.70 
mmol; yield 99%). 
Melting range: 79-80 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.72 (d, NH), 8.42 
(d, CHNH), 7.88 (s, 1H), 7.71 (d, 1H), 7.62 (d, 1H), 7.53 (t, 1H), 4.20 (d, OCH2CH3), 
4.12 (d, OCH2CH3), 2.59 (s, CH3), 1.24 (m, 2 x OCH2CH3); 
13C NMR (100 MHz, 
(CD3)2SO) δ 198.04 (COCH3), 167.58 (CO2Et), 165.47 (CO2Et), 151.40 (CHNH), 
140.45, 138.46, 130.51, 124.57, 122.40, 117.84, 94.44 [C(CO2Et)2], 60.20 (OCH2CH3), 
60.05 (OCH2CH3), 27.38 (CH3), 14.73 (OCH2CH3), 14.66 (OCH2CH3); MS m/z (EI) 
[M]+ C16H19NO5 requires 305.1263, found 305.1266. 
Isomeric mixture: ethyl 7-acetyl-4-oxo-quinoline-3-carboxylate (79a) and ethyl 5-
acetyl-4-oxo-quinoline-3-carboxylate (79b) 
 
Synthesised according to the general method C, from enamine 70 (0.61 g; 2.00 
mmol) in 10 ml of Dowtherm A (3 hours). The products precipitated as a beige powder 
(0.09 g; 0.35 mmol; yield 18%) and were characterised as an isomeric mixture of 79a and 
79b. 
1H NMR (400 MHz, (CD3)2SO) δ 12.53 (s, 2 x NH)79a and 79b, 8.66 (s, CHNH)79b, 
8.61 (s, CHNH)79a, 8.24 (d, 1H)79a, 8.19 (s, 1H)79a, 7.93 (d, 1H)79b, 7.75 (t, 1H)79b, 7.68 
(d, 1H)79b, 7.15 (d, 1H)79a, 4.23 (dq, 2 x OCH2CH3), 2.51 (s, 2 x CH3CO), 1.29 (dt, 2 x 
OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available deuterated 
solvents; MS m/z (ES) [M + Na]+ C14H13NO4Na requires 282.0742, found 282.0745; 
CHN for C14H13NO4 requires C 64.86%, H 5.05%, N 5.4%, found C 64.81%, H 4.95%, 
N 5.21%. 
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Diethyl 2-(((3-nitrophenyl)amino)methylene)malonate (71) 
  
Synthesised according to the general method B, from 3-nitroaniline 62 (3.00 g; 
21.72 mmol). The product was recovered as yellow solid (6.69 g; 21.68 mmol; yield 99%) 
from precipitation in ethyl acetate, after slow evaporation at room temperature. 
Melting range: 80-82 ºC; 1H NMR (400 MHz, CDCl3) δ 11.18 (d, NH), 8.52 (d, 
CHNH), 8.00 (M, 2H), 7.56 (t, 1H), 7.44 (d, 1H), 4.31 (dq, 2 x OCH2CH3), 1.37 (dt, 2 x 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 169.21 (CO2Et), 165.61 (CO2Et), 151.04 
(CHNH), 149.72 (CNO2), 140.94, 131.21, 123.07, 119.46, 111.87, 96.42 [C(CO2Et)2],  
61.26 (OCH2CH3), 60.93 (OCH2CH3), 14.81 (OCH2CH3), 14.64 (OCH2CH3); MS m/z 
(ES) [M + Na]+ C14H16N2O6Na requires 331.0906, found 331.0915. 
Isomeric mixture: ethyl 7-nitro-4-oxo-quinoline-3-carboxylate (80a) and ethyl 5-nitro-
4-oxo-quinoline-3-carboxylate (80b) 
 
Synthesised according to the general method C, from enamine 71 (1.00 g; 3.24 
mmol) in 10 ml of Dowtherm A (3 hours). The product was recovered as a yellow solid 
(0.18 g; 0.70 mmol; yield 22%) as was characterised as a mixture of isomers 80a and 80b. 
1H NMR (400 MHz, (CD3)2SO) δ 12.71 (s, 2 x NH)80a and 80b, 8.71 (s, CHNH)80a, 
8.63 (s, CHNH)80b, 8.50 (s, 1H)80a, 8.35 (d, 1H)80a, 8.13 (d, 1H)80b, 7.82 (d, 2H)80a and 80b, 
7.62 (t, 1H)80b, 4.20 (m, 2 x OCH2CH3), 1.27 (m, 2 x OCH2CH3); 
13C NMR data not 
obtained due to poor solubility in all available deuterated solvents; MS m/z (MALDI-
TOF) [M + H]+ C12H11N2O5 requires 263.0668, found 263.0119; CHN for C12H10N2O5 
requires C 54.97%, H 3.84%, N 10.68%, found C 54.70%, H 3.73%, N 10.59%. 
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Diethyl 2-(((3-cyanophenyl)amino)methylene)malonate (72) 
  
Synthesised according to the general method B, from 3-aminobenzonitrile 63 
(3.00 g; 25.39 mmol). The product was recovered as a beige powder/crystal mixture (4.21 
g; 14.60 mmol; yield 58%) from recrystallization in ethanol. 
Melting range: 114-115 ºC; 1H NMR (400 MHz, CDCl3) δ 11.07 (d, NH), 8.46 (d, 
CHNH), 7.50 (t, 1H), 7.42 (m, 2H), 7.36 (d, 1H), 4.30 (dq, 2 x OCH2CH3), 1.36 (dt, 2 x 
OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 165.60 (CO2Et), 165.36 (CO2Et), 151.07 
(CHNH), 140.57 (CNH), 131.24, 128.35, 121.69, 120.27, 118.29 (CN), 114.44 (CCN) 
95.96 [C(CO2Et)2], 61.21 (OCH2CH3), 60.88 (OCH2CH3), 14.81 (OCH2CH3), 14.64 
(OCH2CH3); MS m/z (ES) [M + Na]
+ C15H16N2O4Na requires 311.1008, found 311.1020. 
Isomeric mixture: ethyl 7-cyano-4-oxo-quinoline-3-carboxylate (81a) and ethyl 5-
cyano-4-oxo-quinoline-3-carboxylate (81b) 
 
Synthesised according to the general method C, from enamine 72 (1.03 g; 3.58 
mmol), in 10 ml of Dowtherm A (3 hours). The product was recovered as a beige powder 
(0.17 g; 0.69 mmol; yield 19%) and was characterised as a mixture of isomers 81a and 
81b. 
1H NMR (400 MHz, (CD3)2SO) δ 12.60 (s, 2 x NH)81a and 81b, 8.66 (s, CHNH)81a, 
8.61 (s, CHNH)81b, 8.27 (d, 1H)81a, 8.08 (s, 1H)81a, 7.88 (t, 2H)81b, 7.82 (d, 1H)81b, 7.76 
(d, 1H)81a, 4.23 (m, 2 x OCH2CH3), 1.27 (m, 2 x OCH2CH3); 
13C NMR (101 MHz, 
(CD3)2SO) δ 172.19, 164.79, 145.59, 140.20, 133.55, 132.60, 127.32, 124.25, 119.02 
(CN), 111.15, 109.92, 60.31 (OCH2CH3), 14.50 (OCH2CH3); MS m/z (MALDI-TOF) [M 
+ H]+ C13H11N2O3 requires 243.0770, found 243.0695; CHN for C13H10N2O3 requires C 
64.46%, H 4.16%, N 11.56%, found C 64.11%, H 4.07%, N 11.51%. 
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Diethyl 2-(((3-methylphenyl)amino)methylene)malonate (73) 
  
Synthesised according to the general method B, from 3-methylaniline 64 (3.03 ml; 
28.00 mmol). The product was recovered as brown oil (7.19 g; 25.90 mmol; yield 93%) 
after purification by silica gel column chromatography (eluting with DCM). 
Melting range 38-39 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.63 (d, NH), 8.40 (d, 
CHNH), 7.25 (t, 1H), 7.18 – 7.06 (m, 2H), 6.96 (s, 1H), 4.14 (m, 2 x OCH2CH3), 2.29 (s, 
CH3), 1.23 (m, 2 x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 167.95 (CO2Et), 165.40 
(CO2Et), 151.50 (CHNH), 139.73, 139.64, 129.91, 125.82, 118.28, 114.99, 93.44 
[C(CO2Et)2], 60.06 (OCH2CH3), 59.87 (OCH2CH3), 23.36 (CH3), 14.68 (OCH2CH3), 
14.59 (OCH2CH3); MS m/z (EI) [M]
+ C15H19NO4 requires 277.1314, found 277.1312; 
CHN for C15H19NO4 requires C 64.97, H 6.91, N 5.05, found: C 65.07, H 6.95, N 4.77. 
Ethyl 7-methyl-4-oxo-quinoline-3-carboxylate (82a) 
 
Synthesised according to the general method C, from enamine 73 (1.07 g; 3.86 
mmol) in 10 ml of Dowtherm A (3 hours). The product was recovered as white powder 
(0.11 g; 0.48 mmol; yield 12%). 
Melting range: 282-284 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.17 (s, NH), 8.49 
(s, CHNH), 8.04 (d, 1H), 7.38 (s, 1H), 7.24 (d, 1H), 4.20 (m, OCH2CH3), 2.44 (s, CH3), 
1.28 (t, OCH2CH3); 
1H NMR (400 MHz, CDCl3) δ 12.20 (s, NH), 8.52 (s, CHNH), 8.26 
(d, 1H), 7.38 (s, 1H), 7.25 (d, 1H), 4.35 (m, OCH2CH3), 2.48 (s, CH3), 1.39 (m, 
OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 176.02, 165.02, 143.52, 140.64, 140.02, 
131.56, 127.42, 125.25, 116.96, 111.02, 59.58 (OCH2CH3), 23.42 (CH3), 14.35 
(OCH2CH3); MS m/z (CI) [M + H]
+ C13H14NO3 requires 232.0974, found 232.0977; CHN 
for C13H13NO3 requires C 67.53, H 5.67, N 6.06; found: C 67.29, H 5.63, N 5.96. 
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Ethyl 4-hydroxy-5-methyl quinolinium chloride 3-carboxylate (82b.HCl) 
 
Synthesised according to the general method E, from enamine 73 (1.37 g; 4.94 
mmol), in 15 ml of POCl3.  The product was recovered as an orange powder/crystal 
mixture (0.25 g; 1.10 mmol; 22%). 
Melting range 146-147 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 8.38 (s, CHN), 7.49 
(t, 1H), 7.44 (d, 1H), 7.10 (d, 1H), 4.18 (q, OCH2CH3), 2.78 (s, CH3), 1.26 (t, OCH2CH3); 
1H NMR (400 MHz, CDCl3) δ 9.26 (s, CHN), 8.51 (d, 1H), 7.91 (t, 1H), 7.59 (d, 1H), 
4.58 (q, OCH2CH3), 3.01 (s, CH3), 1.50 (t, OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) 
δ 171.1, 171.1, 161.3, 144.6, 144.1, 140.1, 140.6, 132.0, 127.9, 117.3, 114.3, 60.1 
(OCH2CH3), 23.9 (CH3), 14.8 (OCH2CH3); MS m/z (EI) [M]
+ C13H13NO3 requires 
231.0895, found 231.0899; CHN for C13H13NO3 requires C 67.53, H 5.67, N 6.06; found: 
C 67.43, H 5.63, N 6.03. 
Diethyl 2-(((3-(trifluoromethyl)phenyl)amino)methylene)malonate (74) 
  
Synthesised according to the general method B, from 3-aminobenzotrifluoride 65 
(3.0 ml; 24.02 mmol).  The product was recovered as white crystals (5.94 g; 17.90 mmol; 
yield 75%) after purification by silica gel column chromatography (eluting with 10% of 
ethyl acetate in hexane) and recrystallization from ethanol. 
Melting range: 41-43 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.71 (s, NH), 8.40 
(s, CHNH), 7.79 (s, 1H), 7.67 (d, J 1H), 7.58 (t, 1H), 7.45 (d, 1H), 4.16 (m, 2 x OCH2CH3), 
1.24 (t, 2 x OCH2CH3); 
13C NMR (100 MHz, (CD3)2SO) δ 167.35 (CO2Et), 165.42 
(CO2Et), 151.12 (CHNH), 140.96 (CNH), 131.20, 130.85, 130.54, 121.66, 121.14, 
115.28, 95.17 [C(CO2Et)2], 60.20 (2 x OCH2CH3), 14.68 (2 x OCH2CH3); MS m/z (ES) 
[M + Na]+ C15H16F3NO4Na requires 354.0929, found 354.0928. 
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Ethyl 7-trifluoromethyl-4-oxo-quinoline-3-carboxylate (83) 
 
Synthesised according to the general method C, from enamine 74 (1.03 g; 3.11 
mmol), in 10 ml of Dowtherm A (3 hours). The product was recovered as a white powder 
(0.31 g; 1.10 mmol; yield 35%). 
Melting range: 323-324 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.60 (s, NH), 
8.69 (s, CHNH), 8.33 (d, 1H), 7.97 (s, 1H), 7.68 (d, 1H), 4.22 (q, OCH2CH3), 1.28 (t, 
OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available deuterated 
solvents; MS m/z (MALDI-TOF) [M + H]+ C13H11F3NO3 requires 286.0691, found 
286.0738; CHN for C13H10F3NO3 requires C 54.74%, H 3.53%, N 4.91%, found C 
54.77%, H 3.47%, N 4.81%. 
Diethyl 2-(((3-methoxyphenyl)amino)methylene)malonate (75) 
  
Synthesised according to the general method B, from m-anisidine 66 (2.0 ml; 
17.80 mmol). The product was obtained as a white solid (3.84 g; 13.11 mmol; yield 74%) 
after purification by silica gel column chromatography (eluting with 20% of ethyl acetate 
in hexane). 
Melting range: 44-45 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.66 (d, NH), 8.38 
(d, CHNH), 7.26 (t, 1H), 6.94 (s, 1H), 6.91 – 6.85 (d, 1H), 6.70 (d, 1H), 4.15 (dq, 2 x 
OCH2CH3), 3.76 (s, CH3), 1.24 (dt, 2 x OCH2CH3)); 
13C NMR (101 MHz, (CD3)2SO) δ 
167.80 (CO2Et), 165.40 (CO2Et), 160.82 (COCH3), 151.53 (CHNH), 141.12 (CNH), 
131.03, 110.90, 109.78, 104.06, 93.72 [C(CO2Et)2], 60.13 (OCH2CH3), 59.95 
(OCH2CH3), 55.76 (H3CO), 14.71 (OCH2CH3), 14.65 (OCH2CH3); MS m/z (MALDI-
TOF) [M]+ C15H19NO5 requires 293.1263, found 293.1171; CHN for C15H19NO5 requires 
C 61.42%, H 6.53%, N 4.78%, found C 61.26%, H 6.54%, N 4.59%. 
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Isomeric mixture: ethyl 7-methoxy-4-oxo-quinoline-3-carboxylate (84a) and ethyl 5-
methoxy-4-oxo-quinoline-3-carboxylate (84b) 
 
Synthesised according to the general method C, from enamine 75 (1.50 g; 5.11 
mmol), in 15 ml of Dowtherm A (3 hours). The product was recovered as a white powder 
(0.34 g; 1.41 mmol; yield 28%) and identified as a mixture of isomers 84a and 84b. 
1H NMR (400 MHz, (CD3)2SO) δ 12.07 (s, NH), 11.51 (?), 8.47 (s, CHNH), 8.04 
(d, 1H), 7.95 (?), 7.78 (?), 7.00 (d, 2H), 6.90 (?), 4.19 (q, OCH2CH3), 3.85 (s, CH3), 1.26 
(t, OCH2CH3);
 13C NMR (101 MHz, (CD3)2SO) δ 176.90, 165.29, 162.73, 145.27, 142.23, 
141.21, 139.49, 127.95, 127.25, 114.65, 113.60, 110.23, 109.04, 100.53, 99.49, 59.96 
(OCH2CH3), 56.05 (H3CO), 55.87 (H3CO), 14.80 (OCH2CH3); CHN for C13H13NO4 
requires C 63.15%, H 5.30%, N 5.67%, found C 62.89%, H 5.23%, N 5.55%. 
Diethyl 2-(((4-hydroxyphenyl)amino)methylene)malonate (76) 
  
Synthesised according to the general method B, from 4-aminophenol 67 (2.00 g; 
18.33 mmol). The product was obtained as yellow crystals (3.52 g; 12.59 mmol; yield 
69%) after purification by silica gel column chromatography (eluting with DCM). 
Melting range: 125-127 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.69 (d, NH), 9.48 
(s, CHNH), 7.19 (d, 2H), 6.78 (d, 2H), 4.15 (dq, 2 x OCH2CH3), 1.24 (dt, 2 x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 168.11 (CO2Et), 165.47 (CO2Et), 155.45, 152.52, 
131.84 (CNH), 119.90 (2C), 116.50 (2C), 91.81 [C(CO2Et)2], 59.86 (OCH2CH3), 59.67 
(OCH2CH3), 14.75 (OCH2CH3), 14.69 (OCH2CH3); MS m/z (ES) [M + Na]
+ 
C14H17NO5Na requires 302.1004, found 302.0928; CHN for C14H17NO5 requires C 
60.21%, H 6.14%, N 5.02%, found C 60.91%, H 6.95%, N 4.68%. 
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Diethyl 2-(((4-cyanophenyl)amino)methylene)malonate (77) 
  
Synthesised according to the general method B, from 4-aminobenzonitrile 68 
(4.00 g; 33.86 mmol). The product was obtained as white crystals (9.76 g; 33.80 mmol; 
yield 99%) from crystallization in DCM. 
Melting range: 103-105 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.67 (s, NH), 8.40 
(s, CHNH), 7.81 (d, 2H), 7.53 (d, 2H), 4.17 (dq, 2 x OCH2CH3), 1.24 (m, 2 x OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 167.18 (CO2Et), 165.17 (CO2Et), 149.80 (CHNH), 
143.90 (CNH), 134.34 (2C), 119.32 (CN), 118.31 (2C), 106.38 (CCN), 96.60 
[C(CO2Et)2], 60.47 (OCH2CH3), 60.28 (OCH2CH3), 14.68 (OCH2CH3), 14.60 
(OCH2CH3); MS m/z (ES) [M + Na]
+ C15H16N2O4Na requires 311.1008, found 311.1015. 
Ethyl 6-cyano-4-oxo-quinoline-3-carboxylate (86) 
 
Synthesised according to the general method C, from enamine 77 (1.00 g; 3.47 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a yellow powder (0.15 g; 0.62 mmol; 
yield 18%). 
Melting range: 325-326 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.66 (s, NH), 8.65 
(s, 1H), 8.49 (s, 1H), 8.05 (d, 1H), 7.78 (d, 1H), 4.21 (q, OCH2CH3), 1.29 (t, OCH2CH3); 
13C NMR data not obtained due to poor solubility in all available deuterated solvents. 
Diethyl 2-(((4-ethylphenyl)amino)methylene)malonate (78) 
  
Synthesised according to the general method B, from 4-ethylaniline 69 (4.0 ml; 
32.18 mmol). The product was recovered as a brown solid (9.28 g; 31.86 mmol; yield 
99%) after purification by silica gel column chromatography (eluting with 20% of ethyl 
acetate in hexane). 
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Melting range: 30-31 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.70 (d, NH), 8.37 
(d, CHNH), 7.22 (dd, 4H), 4.14 (dq, 2 x OCH2CH3), 2.56 (q, CH2Ar), 1.23 (dt, 2 x 
OCH2CH3), 1.14 (t, CH3CH2Ar); 
13C NMR (101 MHz, (CD3)2SO) δ 168.03 (CO2Et), 
165.37 (CO2Et), 151.77 (CHNH), 140.74, 137.61, 129.27 (2C), 117.92 (2C), 93.02 
[C(CO2Et)2], 59.97 (OCH2CH3), 59.77 (OCH2CH3), 27.95 (CH3CH2Ar), 15.92 
(CH3CH2Ar), 14.64 (OCH2CH3), 14.57 (OCH2CH3); MS m/z (ES) [M + Na]
+ 
C16H21NO4Na requires 314.1368, found 314.1208; CHN for C16H21NO4 requires C 
65.96%, H 7.27%, N 4.81%, found C 66.25%, H 7.41%, N 4.59%. 
Ethyl 6-ethyl-4-oxo-quinoline-3-carboxylate (87) 
 
Synthesised according to the general method C, from enamine 78 (1.00 g; 3.43 
mmol) in 10 ml of Dowtherm A (3 hours), to afford a yellow powder (0.11 g; 0.43 mmol; 
yield 13%). 
Melting range: 262-264 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.57 (s, NH), 8.51 
(s, 1H), 7.97 (s, 1H), 7.56 (m, 2H), 4.22 (q, OCH2CH3), 2.73 (q, ArCH2), 1.29 (m, 2 x 
CH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 173.83 (C=O), 165.34 (CO2Et), 144.88 
(CHNH), 140.88, 137.65, 133.09, 127.71, 124.14, 119.28, 109.95, 59.96 (OCH2CH3, 
28.31 (ArCH2CH3), 16.01 (ArCH2CH3), 14.81 (OCH2CH3). 
Synthesis of 4-oxo-quinoline core 
Diethyl 2-((phenylamino)methylene)malonate (89) 
  
Synthesised according to the general method B, from aniline 88 (2.0 ml; 21.9 
mmol). The product was recovered as an orange solid/crystal mixture (5.74 g; 21.80 
mmol; yield 99%) after purification by silica gel column chromatography (eluting with 
15% of ethyl acetate in hexane). 
Melting range: 45-46 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 10.72 (d, NH), 8.42 
(d, CHNH), 7.44 – 7.35 (m, 4H), 7.17 (t, 1H), 4.17 (dq, 2 x OCH2CH3), 1.26 (m, 2 x 
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OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 167.86 (CO2Et), 165.37 (CO2Et), 151.59 
(CHNH), 139.84, 130.11 (2C), 125.09, 117.98 (2C), 93.90 [C(CO2Et)2], 60.09 
(OCH2CH3), 59.90 (OCH2CH3), 14.69 (OCH2CH3), 14.63 (OCH2CH3); MS m/z (ES) [M 
+ Na]+ C14H17NO4Na requires 286.1055, found 286.1; CHN for C14H17NO4 requires C 
63.87%, H 6.51%, N 5.32%, found C 63.68%, H 6.58%, N 5.12%. 
Ethyl 4-oxo-quinoline-3-carboxylate (90) 
 
Synthesised according to the general method C, from enamine 89 (1.06 g; 4.01 
mmol) in 10 ml of Dowtherm A (3 hours). The product was recovered as a white powder 
(0.27 g; 1.25 mmol; yield 31%). 
Melting range > 350 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 12.30 (s, NH), 8.53 (s, 
CHNH), 8.14 (d, 1H), 7.69 (t, 1H), 7.60 (d, 1H), 7.40 (t, 1H), 4.20 (q, OCH2CH3), 1.27 
(t, OCH2CH3); 
13C NMR (101 MHz, (CD3)2SO) δ 173.89, 165.28, 145.35, 139.42, 
132.86, 127.73, 126.09, 125.15, 119.24, 110.26, 60.02 (OCH2CH3), 14.80 (OCH2CH3); 
MS m/z (MALDI-TOF) [M + H]+ C12H12NO3 requires 218.0817, found 218.0973; CHN 
for C12H11NO3 requires C 66.35%, H 5.10%, N 6.45%, found C 66.40%, H 5.03%, N 
6.41%. 
4-Oxo-quinoline-3-carboxylic acid (91) 
 
Ethyl 4-oxo-quinoline-3-carboxylate 90 (0.20 g; 0.92 mmol) was suspended in 
methanol (5mL). Sodium hydroxide (10% aq, 7.5mL) was added and the mixture was 
heated at 100 ºC, overnight. The resulting solution was cooled to room temperature and 
acidified by addition of HCl(aq) (10%; pH≈1).  A precipitate was formed, filtered and 
washed with chloroform, methanol and hexane to give the product as a white powder 
(0.13 g; 0.69 mmol; 75%). 
Melting range: 278-280 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 15.34 (s, CO2H), 
13.41 (s, NH), 8.89 (s, CHNH), 8.29 (d, 1H), 7.89 (t, 1H), 7.82 (d, 1H), 7.61 (t, 1H); 13C 
NMR (101 MHz, (CD3)2SO) δ 178.82, 166.85 (CO2H), 145.68, 139.93, 134.42, 126.69, 
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125.53, 124.88, 120.14, 108.06; MS m/z (MALDI-TOF) [M - H]- C10H6NO3 requires 
188.0348, found 188.0562; CHN for C10H7NO3 requires C 63.49%, H 3.73%, N 7.40%, 
found C 63.02%, H 3.68%, N 7.23%.
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3.1. Structural, conformational and vibrational analysis of ethyl 4-
chloro-7-iodoquinoline-3-carboxylate (56) 
The work described in this section was included in the following publication:  
P.C. Horta, M. S. C. Henriques, N. Kuş, J. A. Paixão, P. M. O’Neill, M. L. S. 
Cristiano and R. Fausto, “Synthesis, structural and conformational analysis, and IR 
spectra of ethyl 4-chloro-7-iodoquinoline-3-carboxylate”, Tetrahedron (2015), volume 
71, pages 7583-7592 (doi:10.1016/j.tet.2015.07.076).155 
The solubility problems often exhibited by quinolones are reported in the literature 
and were also encountered along the work described in this thesis. To circumvent these 
problems, we were led to the synthesis of 4-chloroquinoline derivatives, expected to be 
more soluble than the corresponding 4-oxo precursors. One such example is compound 
56. This compound may act as a versatile building block, enabling the preparation of 
quinolone derivatives with chemical diversity at position 7. Additionally, the presence of 
chlorine at position 4 may allow to introduction of chemical diversity at the carbon 4, 
through nucleophilic displacement of halide.  
 
The structure of 4-chloro-7-iodo-quinoline (CIQC) 56 was studied in the solid 
phase (crystalline and low-temperature amorphous phases), by X-ray crystallography and 
vibrational spectroscopy.  The monomeric structure of 56 was studied experimentally, as 
isolated species in a cryogenic argon matrix (at around 15 K), using infrared spectroscopy 
as analytical method, and theoretically, using contemporary molecular orbital 
calculations (B3LYP/LANL2DZ+cc-pVDZ level of approximation). 
3.1.1. Theoretical calculations 
The potential energy profile of CIQC was investigated. From analysis of the 
potential energy landscape obtained from rotation about the two C-O bonds (carboxylic 
and ester) and the C-C bond connecting the carboxylic ester to the C5N ring, different 
conformers may result. The results obtained from this study revealed that a trans 
conformation of the carboxylic ester moiety (O=C–O–C dihedral in the 180º region) is 
generally energetically unfavoured (higher energy forms) and, in this case, the higher 
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energy is also expected due to the steric hindrance resulting from the proximity between 
the ethyl-ester fragment and the substituents in ortho position (H, Cl).  
Considering the generally more stable cis conformation (O=C–O–C dihedral in 
the 180º region), four main different minimum energy structures (Figure 3.1) have 
resulted from the scanning.  
 
Figure 3.1 - Optimized geometries (B3LYP/LANL2DZ+cc-pVDZ level of approximation) for 
the lower energy conformers of 56. The atom numbering and the optimized values of the C–C–
C=O, O=C–O–C and C–O–C–C dihedrals (º) are indicated. 
Conformers sa and sg (with the carbonyl oxygen atom in the same side of the 
chlorine atom - syn) are slightly more stable than those with the chlorine atom facing the 
ester oxygen atom (aa and ag conformers - anti), indicating that the steric relevance of 
the ester oxygen atom is more important than that of to the carbonyl oxygen atom, in this 
context. For each pair of conformers, the structures with the ester group in anti 
conformation are more stable than the corresponding gauche forms, so the conformer sa 
is the most stable form of 56. Nevertheless, the less stable conformer (ag) is just 0.92 kJ 
mol-1 higher in energy than the most stable sa conformer (calculated electronic energies 
for the four conformers are rather similar, as shown in Table 3.1). 
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Table 3.1 – B3LYP/LANL2DZ++cc-p VDZ calculated relative electronic energies (∆E: kJ        
mol -1) for minima of 56 and expected room temperature (298.15 K) gas phase populations 
(p298.15: %). 
 
All the conformers described can be expected to have significant populations in 
the room temperature gas phase equilibrium (298.15 K). These populations for sa, aa, sg 
and ag are, respectively 41.8, 15.7, 25.2 and 17.3% (Table 3.1). 
The calculations yield minimum energy geometries for each conformer that are 
slightly non-planar and thus two equivalent-by-symmetry minima exist for each one. 
However, the energy difference between the found minima and the nearby structure 
exhibiting a planar skeleton is extremely small. 
The barriers for interconversion between the conformers of 56 have also been 
calculated. With exception of the direct conversion between the equivalent-by-symmetry 
gauche forms, the energy barriers for conformational rotation between the various 
conformers are sufficiently low to be overpassed by warming of a cryogenic argon matrix 
of the compound to an experimentally accessible temperature (see Appendix 3 - Figure 
S11 and Figure S12). 
Structure-activity relationship studies on the 4-oxo-quinoline 3-ester chemotype 
and docking studies performed in silico at the yeast Qo site of the bc1 protein complex of 
P. falciparum indicated that both the 4-oxo-quinoline and the ethyl ester moieties are 
relevant for activity. The low barriers predicted for conformational isomerization around 
the ethyl ester moiety may be important to facilitate structural adjustments of the ethyl 
ester moiety in the enzyme pocket, to as to maximize drug-target interactions and, thus, 
to improve the pharmacodynamic profile. 
3.1.2. Matrix isolation - Infrared spectroscopy studies 
An interesting experimental strategy was used in this project, aiming to investigate 
spectroscopically solid samples of CIQC at cryogenic temperatures, under some 
conformation control. 
Table 1. B3LYP/LANL2DZ+cc-pVDZ calculated relative electronic energies (E/ kJ mol–1), 
zero-point corrected energies (E0/ kJ mol
–1
) and Gibbs energies (Gº/ kJ mol–1) for minima 
of CIQC, and expected room temperature (298.15 K) gas phase populations (p
298.15
/ %). 
 
Conformer 
a
 E 
 
E0 Gº p
298.15 b
 
sa 0.00 0.00 0.00 41.8 
aa 0.61 0.77 2.43 15.7 
sg 0.43 1.23 2.97 25.2 
ag 0.92 1.64 3.90 17.3 
a
 See Figure 1 for structures of the conformers. 
b
 Conformers sa and aa considered to be 
represented by a single structure (see text); conformers sg and ag have two equivalent-by-
symmetry forms (sg±; ag±), and their degenerescence was set equal to 2.   
Table 1. B3LYP/LANL2DZ+cc-pVDZ calculated relative electronic energies (E/ kJ mol–1), 
zero-point corrected energies (E0/ kJ mol
–1
) and Gibbs energi s (Gº/ kJ mol–1) for minima 
of CIQC, and expected room temperature (298.15 K) gas phase p pulations (p
298.15
/ %)  
 
Conformer 
a
 E 
 
E0 Gº p
298.15 b
 
sa 0.00 0.00 41.8 
aa 0.61 0.77 2 43 15.7 
sg 0.43 1.23 2 97 25.2 
ag 0.92 1.64 3 0 17.3 
a
 See Figure 1 for structures of the conformers. 
b
 Con mers sa and aa considered to be 
represented by a single structure (see text); co formers sg and ag hav two equivale t-by-
symmetry forms (sg±; ag±), and their degenerescence was set equal to 2.   
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Initially, an argon matrix of the compound to be studied, CIQC, was prepared. 
Then, the host inert gas matrix-atoms were allowed to evaporate, while the guest 
molecules could diffuse and form a thin film of the substance. This permits to know the 
conformational composition existing in the matrix immediately before the evaporation of 
the host atoms, which can be probed spectroscopically. 
The experimental infrared spectrum of 56 isolated in an argon matrix (15 K) 
agrees with the simulated spectrum, assuming the room temperature equilibrium of the 
conformational mixture existing in the gas phase (Figure 3.2). This is particularly evident, 
for example, in the C=O stretching region, between 1700 and 1800 cm–1, where the 
experimental spectrum shows essentially a double-band structure (in opposition to the 
single band in the sole spectrum of the most stable conformer sa). 
 
Figure 3.2 - From top to bottom: simulated IR spectra (calculated at the B3LYP/LANL2DZ+cc-
pVDZ level) for the most stable conformer (sa) and for the expected conformational equilibrium; 
observed IR spectrum of 56, isolated in solid argon (15 K), from the vapor at room temperature 
(rt). 
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The same argon matrix of the compound 56, used to demonstrate the results 
explained, was subjected to further warming. At 43 K (upon annealing) the matrix sample 
showed partial conversion (less than 10%) of the higher energy conformers into the most 
stable sa form, in consonance with the low predicted barriers for conformational 
isomerization. The assignment of the spectral bands to the different conformers is 
provided in Table S1 (Appendix 3). 
In Figure 3.3 it is possible to see the evolution of the infrared spectrum of a sample 
of 56 along the performed thermal treatment. The selected spectral region corresponds to 
a characteristic feature of conformers exhibiting the anti orientation of the ethyl 
carboxylic ester substituent in relation to the ring system.  
 
Figure 3.3 - IR spectra of 56 obtained along the warming/cooling cycle. From bottom to top: 
spectrum of the argon matrix of the compound at 40 K, at 43 K (after evaporation of the argon) 
at 233 K, at 243 K and at 17 K (re-cooled crystal). The shadow calls the attention to the band at 
around 1320 cm-1 (characteristic of aa and ag conformers). 
When reaching the temperature of 233 K, spectral changes started being observed, 
which were completed when the temperature attained 243 K (generalized band narrowing 
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and disappearance of the bands which originate only in conformers other than the sa 
form). The sample was then heated to 270 K and re-cooled back to 17 K, to allow for a 
crystal relaxation. As expected, the spectrum predicted for the sa conformer reproduces 
well that of the re-cooled sample as single molecule (the amorphous state rearranged to 
the crystalline state).  
3.1.3. Single crystal X-ray 
The X-ray data performed at room temperature shows that, in the crystal, 
monomeric 56 has a geometry close to that of the conformer predicted theoretically as the 
most stable for the isolated molecule (sa) – see Figure S13 (Appendix 3) with an ORTEP 
plot of the molecule. The crystal structure consists of layers of molecules and, in each 
layer, the main packing motif consists of a group of 3 molecules joined together by a 
weak C-H…O (carbonyl) hydrogen-bond, with the chlorine atoms facing to the center of 
the group (see Figure S14 - Appendix 3).  In the same plane, the interaction between 
groups occurs via a short contact between the iodine atom and an aromatic H atom of a 
neighbor molecule (Figure 3.4).  
 
Figure 3.4 - Intermolecular hydrogen-bond interactions between molecules of 56 in the same 
plane. 
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The oxygen carbonyl atom is placed in a position as to act as possible acceptor of 
the π-electron clouds of the aromatic rings of the molecules of the layers located above 
and below its own layer (weak intermolecular interactions between layers).  
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3.2. Investigation of the 4-oxo/4-hydroxy-quinoline tautomerism in 
quinolone 3-esters: 
Structural, conformational and vibrational study of ethyl 7-methyl-4-
oxo-quinoline-3-carboxylate (82a) and 4-hydroxy-5-methyl-quinoline-3-
carboxylate (82b) 
Part of the work described in this section was included in the following 
publication:  
P.C. Horta, N. Kuş, M. S. C. Henriques, J. A. Paixão, L. Coelho, F. Nogueira, P. 
M. O’Neill, R. Fausto and M. L. S. Cristiano, “The quinolone-hydroxyquinoline 
tautomerism in quinolone 3-esters; preserving the 4-oxo-quinoline structure to retain 
antimalarial activity”, The Journal of Organic Chemistry (2015), volume 80, pages 
12244-12257 (doi: 10.1021/acs.joc.5b02169).162 
As mentioned in the introduction, docking studies performed with yeast bc1
120 
suggested an important role for the amino and 4-oxo functionalities in inhibition of the 
enzyme by quinolone 3-esters. In this section, we describe the results of our investigation 
on the 4-oxo/4-hydroxy-quinoline tautomerism in this chemotype, using ethyl 7-methyl-
4-oxo-quinoline-3-carboxylate 82a and ethyl 4-hydroxy-5-methyl-quinoline-3-
carboxylate 82b as model compounds. 
As described in chapter 2, compound 82a was obtained by thermal cyclisation 
from enamine 73, in Dowtherm A, at 250 ºC, and isolated as sole product. Because this 
quinolone presents poor solubility, an alternative synthetic approach was considered, 
involving the synthesis of the 4-chloroquinoline intermediate from enamine 73. 
Surprisingly, cyclisation of 73 mediated by POCl3 at 95 ºC led to the isolation of a mixture 
of an amorphous powder and crystals, corresponding to the hydrochloride salt of one 
hydroxy-quinoline 3-ester isomer (82b.HCl). 
    
Beyond the issue regarding the pattern of aromatic substitution (the synthesis may 
lead to 7- or 5-substituted quinolones, as previously discussed), the hydroxy-
quinoline/oxo-quinoline tautomerism is, in this case, a real possibility, due to the isolation 
of the hydrochloride salt of 82b. The tautomerism involving this ring system may be 
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compared to the equilibrium between 4-pyridones (oxo form) and 4-hydroxy-pyridines. 
For this system, it was found that the keto form is more stable in the crystal and in the 
liquid phase or in solution, while the enol form predominates in the vapor phase.163 
N-substitution (present in quinolones used as antibacterial agents – e.g. nalidixic 
acid, ciprofloxacin and norfloxacin) hinders the possibility of tautomerism. However, it 
was suggested that the antimalarial activity of quinolone 3-esters requires the presence of 
N-H and 4-oxo groups in their structure, since the information from docking studies in 
silico at the yeast Qo site of the bc1 protein complex establishes a relevant role for the 4-
oxo and N–H groups in drug-target interactions.120 As such, tautomerization will translate 
in alteration of chemical and physical properties, with consequences for pharmacokinetic 
and pharmacodynamic profiles, and should therefore be investigated. 
The detailed structures (with emphasis on tautomer and conformer preferences) 
of 4-oxo and 4-hydroxy-quinoline 3-esters, 82a and 82b, were investigated 
experimentally: in solution, using NMR spectroscopy; in the solid state, using X-ray 
crystallography and FTIR spectroscopy; and in the monomeric state, using matrix 
isolation coupled with infrared spectroscopy. The structures of compounds 82a and 82b 
were also studied theoretically, through molecular orbital calculations, using DFT 
methods, at the B3LYP/6-311++G(d,p) level of approximation.  
3.2.1. Single crystal X-ray of 82b.HCl 
The crystal structure of 82b.HCl is presented in Figure 3.5 (and an ORTEP plot 
of the molecule is available in Appendix 3 - Figure S15). Two strong hydrogen bonds are 
evidenced, one between the amine group and the halide ion (NH…Cl) and the other 
between the hydroxyl substituent and the oxygen of the ester carbonyl group (OH…O). 
The major intermolecular interactions stabilizing the crystal structure are probably weak 
dispersion forces (𝜋-𝜋 type interactions) between the 𝜋 electron clouds of the aromatic 
rings. The stacking of the molecules is such that the electron clouds of each N-substituted 
ring in one layer interact with the methyl-substituted phenyl rings in the adjacent layer. 
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Figure 3.5 - Crystal structure of ethyl 4-hydroxy-5-methyl quinolinium chloride 3-carboxylate 
(82b.HCl), showing (a) the intramolecular hydrogen-bonding pattern and (b) the molecular 
stacking and interactions between 𝜋 electron clouds of aromatic rings. 
3.2.2. NMR and FTIR spectroscopy 
Compounds 82a and 82b are easily distinguished by 1H NMR and 13C NMR 
spectroscopy. In D6-DMSO, 82a is identified, in the 
1H NMR spectrum (see Appendix 3 
- Figure S16; 1H NMR spectrum of 82a in D-Chloroform is also available - Appendix 3, 
Figure S18), by the presence of specific signals due to resonances of the N–H proton (bs, 
δ= 12.17 ppm) and of the proton at position 8 (s, δ= 7.38 ppm), and, in the 3C NMR 
spectrum (see Appendix 3 - Figure S17), by the resonance of the carbonyl carbon of the 
oxo-quinoline system, at position 4 (δ= 176.02 ppm). The expected NMR signals for the 
4-hydroxy-quinoline tautomer of 82a were not observed, indicating that the 4-oxo-
quinoline tautomer was the sole compound present. 
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The 1H-NMR spectra of crystalline hydroxy-quinoline 82b.HCl, in D6-DMSO  
and in D-Chloroform (see Appendix 3 - Figure S19 and Figure S20, respectively), show 
the absence of a signal corresponding to the 1H resonance of N–H. In both solvents, the 
splitting patterns are compatible with the hydroxy-quinoline form with a methyl group at 
position 5. However, the 1H-chemical shifts were found to be different in D6-DMSO and 
in D-Chloroform. This difference is more pronounced for signals due to resonances of the 
hydrogens linked to positions 2 and 8 of the quinolone core, with the proton resonances 
in D-Chloroform appearing downfield (H2, d, δ= 9.26 ppm; H8, s, δ= 8.51 ppm), 
compared to the corresponding resonances in D6-DMSO (H2, d, δ= 8.38 ppm; H8, s, δ= 
7.44 ppm). It appears reasonable to deduce that the differences in chemical shifts observed 
for 82b.HCl in both solvents were due to loss of HCl from the salt, with formation of the 
free base 82b, induced by the more polar media. The 13C-NMR spectrum, in D6-DMSO 
(see Appendix 3 - Figure S20), shows characteristic signals for the hydroxy-quinoline 
form, namely a signal corresponding to the resonance of the carbon at position 4 at δ= 
171.1 ppm (predicted at δ= 184.2 ppm for the quinolone tautomer), demonstrating the 
sole presence of the 4-hydroxy-quinoline tautomer in solution.  
Structures of 82a and 82b may also be distinguished by FTIR spectroscopy 
(Figure 3.6). As it could have been anticipated, the two ATR spectra do not differ much, 
except in the characteristic regions of the OH group, present in 82b and absent in 82a, 
and for the carbonyl stretching mode of the quinolone carbonyl group of this latter 
compound, absent in the first. On the other hand, since the spectrum of 82b corresponds 
to that of the HCl salt of the compound (82b.HCl), the quinolinic N is protonated and the 
vibration of this moiety is observed at a similar frequency than for 82a.  
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Figure 3.6 - ATR-IR spectrum of crystalline 82b.HCl – top frame – and 82a – bottom frame – at 
room temperature. 
The crystalline 82b.HCl was washed with an aqueous solution of sodium 
bicarbonate. Analysis of the resulting compound revealed the presence of the 
corresponding keto form, 82c (Figure 3.7), resulting from tautomerization of 82b in basic 
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media. The ATR-IR spectrum of 82c is similar to that of the 82a (quinolone form with a 
methyl at position 7).  
 
Figure 3.7 – Structural representation of the tautomers of ethyl 4-hydroxy-5-methylquinoline-3-
carboxylate (82b) considered in this work. 
3.2.3. Theoretical calculations – Molecular structure, potential energy and 
aromaticity 
In view of evaluating the tautomeric and conformations preferences of 82b in the 
gas phase we considered the possibility of equilibrium between 3 tautomeric forms: 4-
hydroxy-quinoline 82b, 4-oxo-quinoline (or 4-quinolone) 82c and 3-ethoxy(hydroxy)-4-
oxo-quinoline 82d (Figure 3.7). To assess the relative importance of the different 
tautomers of the compound as isolated species (or in the gas phase) we investigated the 
structure of monomeric compounds and the possibility of oxo-quinoline/hydroxy- 
quinoline equilibria, by theoretical methods (DFT/B3LYP/6-311++G(d,p)). The isomer 
82a (7-methyl-4-oxo-quinoline 3-ester) analogue was also investigated theoretically, at 
the same level of theory, for comparison.  
The study of the potential energy surface of the tautomer 82b yielded 8 non-
equivalent-by-symmetry conformers, graphically depicted in Figure 3.8 and whose 
relative energies are given in Table 3.2.  
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(82bI; anti) 
 
(82bV) 
 
(82bII; gauche) 
 
(82bVI) 
 
(82bIII) 
 
(82bVII) 
 
(82bIV) 
 
(82bVIII) 
Figure 3.8 – Representation of the conformers obtained for the 4-hydroxy-quinoline form of 82b 
(DFT/B3LYP/6-311++G(d,p)). 
Conformers 82bI and 82bII (82bII is higher in energy than 82bI by only 1.9 kJ 
mol-1) have much lower energy than the other forms and shall represent around, 
respectively, 78% and 22% of the total population in the gas phase equilibrium at room 
temperature. The considerably lower energy of forms 82bI and 82bII can be correlated 
with the presence, in these forms, of the stabilizing O–H...O(carbonyl) intramolecular H-bond 
interaction (Figure 3.8). The intermediate relative energies of forms 82bIII and 82bIV 
(∆E around 18 kJ mol-1) can be ascribed to the presence of the stabilizing O–H…O(ester) 
(expected to be weaker than the O–H...O(carbonyl)) intramolecular H-bond interaction. 
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Conformers 82bV to 82bVIII do not evidence intramolecular H-bonds and the repulsive 
interactions between the OH and ester substituents dominate, justifying their much higher 
energies (∆E > 60 kJ mol-1).   
Table 3.2 - Relative energies (∆E: kJ mol-1) of the relevant conformers for tautomeric forms 82b, 
82c and 82d. 
Conformers of 82b, 82c and 82d 
 
∆E 
82b I (anti) 0.0 
82b II (gauche) 1.9 
82b III 17.3 
82b IV 18.3 
82b V 61.3 
82b VI 63.0 
82b VII 60.6 
82b VIII 62.3 
  
82c I 26.6 
82c II 28.7 
82c III 34.4 
82c IV 35.4 
  
82d I 157.8 
82d II 160.2 
 
The calculated potential energy proﬁle for internal rotation about the C-O-C-C 
dihedral, interconverting conformers 82bI (around 180º) and 82bII at 90º (Figure 3.9), 
shows that this two conformers are separated by a small energy barrier (3.5 kJ mol-1 in 
the 82bI82bII direction; 1.6 kJ mol-1 in the reverse direction). However, the direct 
interconversion between the two symmetry-equivalent gauche (82bII) implies crossing a 
large energy barrier (~30 kJ mol-1) corresponding to the highly sterically hindered 
transition state with C-O-C-C dihedral equal to 0º. 
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Figure 3.9 – B3LYP/6-311++G(d,p) calculated relaxed potential energy proﬁle for 
interconversion between conformers I and II of 82b. 
The conformers of 82c and 82d, calculated at the same level of theory, are 
represented in Figure 3.10 and Figure 3.11, respectively. The most stable conformer of 
82c (I) is higher in energy than the most stable conformer of the hydroxy-quinoline 
tautomer (82bI) by 27 kJ mol-1, while the two lowest energy conformers for 82d have 
larger energies (more than 155 kJ mol-1) (Table 3.2).  
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Figure 3.10 – Representation of selected (lowest energy) conformers calculated for tautomer 82c 
(DFT/B3LYP/6-311++G(d,p)). 
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(82dI) 
 
(82dII) 
Figure 3.11 – Representation of selected (lowest energy) conformers obtained for tautomer 82d 
(DFT/B3LYP/6-311++G(d,p)). 
The conformational and tautomeric preferences for monomeric 4-oxo-quinoline 
82a (7-methyl substituted quinolone) and its corresponding hydroxy-quinoline tautomer 
were also theoretically investigated, at the same level of theory, leading to the same 
conclusions as for compound 82b. The hydroxy-quinoline form of 82a is more stable in 
the gas phase than the oxo forms (∆E ~38.0 kJ mol-1). Also the hydroxy-quinoline 
tautomer of 82a has two low energy conformers exhibiting an OH...O=C intramolecular 
H-bond (similar to the two most stable forms of 82b).  
Thus, the tautomeric and conformational patterns in the studied molecules, in the 
gas phase, are not significantly affected by the position of the methyl substituent on the 
benzenic ring of the quinoline moiety.   
The aromaticity of the two rings in the 5-methyl substituted molecules (82b, 82c 
and 82d) has been estimated using two well-known aromaticity indexes: the harmonic 
oscillator measure of aromaticity (HOMA index), defined by Kruszewski and 
Krygowsky,164,165 and the Bird index.166 
Despite its simplicity, the HOMA index has been found to be one of the most 
effective structural indicators of aromaticity and a good measure of π-electron 
delocalization. If HOMA equals to 1 the ring is fully aromatic, if equals to 0 the ring is 
completely nonaromatic and if assumes a significantly negative value then the ring shows 
anti-aromaticity character.  
The Bird index is another geometry-based quantity aimed at measuring 
aromaticity and the closer the Bird index is to 100 the stronger the aromaticity is. 
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Table 3.3 – Calculated aromaticity indexes (HOMA and Bird) for tautomers 82b, 82c and 82d. 
  Tautomer 
  82b 82c 82d 
HOMA 
C5N-ring 0.73 0.04 –0.07 
C6-ring 0.76 0.90 0.89 
BI 
C5N-ring 78.7 57.3 60.2 
C6-ring 80.0 88.3 88.1 
The HOMA and BI indexes for 82b, 82c and 82d tautomers (Table 3.3), 
determined using the B3LYP/6-311++G(d,p) calculated bond lengths, agree with each 
other.  For 82b, both rings are aromatic, with the heteroaromatic ring being only slightly 
less aromatic than the benzenic ring. However for 82c and 82d the nitrogen-containing 
ring is essentially non-aromatic, while the benzenic ring is more aromatic than in 82b. 
The reduced aromaticity of the heterocyclic ring for 82c and 82d can also be considered 
a relevant factor in rendering these species more energetic than 82b.    
3.2.4. Matrix-isolation - IR spectroscopy and photostability studies 
The structure of monomeric 82b was studied using matrix isolation coupled to 
FTIR spectroscopy (upon sublimation of 82b.HCl, HCl is evolved and sole the free base, 
82b, is isolated in the argon matrix). 
Considering the theoretical results, prevalence of 82bI and 82bII in the gas phase 
should be expected. Also, there is the possibility of partial conversion of 82bII into the 
most stable 82bI, during preparation of the low temperature matrices, taking into account 
the low energy barrier for this conversion (conformational cooling). The matrices are 
prepared from deposition of a very diluted gaseous solution of the vapour of the 
compound in the noble gas onto the cold (15 K) IR transparent CsI optical substrate of 
the cryostat.167 Since the gas phase population of 82bII is already small (22%, according 
to the performed calculations) and its predicted IR spectrum is quite similar to those of 
82bI, the presence of 82bII in the studied argon matrix could not be safely established. 
Experimentally, the IR spectrum of 82b isolated in solid argon can be fairly well 
reproduced by the calculated spectrum of conformer I alone (Figure 3.12).  
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Figure 3.12 – IR spectrum of the as-deposited argon matrix of 82b (top) and calculated spectrum 
(B3LYP/6-311++G(d,p)) for conformer 82bI. 
Annealing of the matrix up to about 40 K led to small, but perceptible changes in 
the relative band intensities, indicating that conformer 82bII could have partially survived 
to matrix deposition and had been converted into 82bI upon the annealing.  
The proposed assignments for the bands observed in the experimental spectrum 
(at 15 K) are summarized in Table S2 (Appendix 3). In this table, the theoretical 
wavenumbers and IR intensities for both conformers 82bI and 82bII are also provided. 
It is worth mentioning that no traces of 82c or 82d tautomers were found in the 
experimental IR spectra, revealing that the species resulting from sublimation of the used 
hydrochloride salt (82b.HCl) are solely HCl and 82b, i.e., the tautomeric species of the 
compound present in the crystalline solid did not convert to other tautomers upon 
sublimation (see Appendix 3 - Figure S22). 
We prepared the quinolone form, 82c, by alkaline washing of the salt, 82b.HCl. 
Matrix isolation studies on this sample show that, during sublimation the keto form 82c 
converts extensively to the most stable hydroxy-quinoline form (82b). In fact, the infrared 
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spectrum of matrix-deposited 82c is identical to that obtained upon deposition of the 
unwashed 82b.HCl sample. 
3.2.5. Evaluation of photostability; UV-induced photochemistry of matrix-
isolated 82b 
The photostability of monomeric 82b was assessed through an investigation of its 
UV-induced matrix photochemistry. Continuous broadband irradiation (λ > 220 nm; 130 
min) of the matrix led to only partial photodecomposition of 82b (consumption of about 
1/3 of the original compound), giving rise to an open-ring ketene isomeric species. The 
number of new bands detected in the spectra of the photolysed matrix was very small 
(Figure 3.13), indicating the formation of CO2
168, CO and ketene species.169–172 Formation 
of ketenes has been observed for similar compounds isolated in matrices and subjected to 
similar irradiation conditions, for example, methyl p-hydroxybenzoic acid (methyl 
paraben) and triclosan.173,174 The results obtained in the performed photochemical 
experiments indicate that 82b appears to be relatively photostable. 
 
Figure 3.13 – Fragment of the IR spectra showing photolysis (λ > 220 nm; 130 min) of 82b in 
argon matrix; in black: IR spectrum obtained prior to irradiation; in purple: IR spectrum obtained 
after irradiation; bands due to CO, CO2 and ketene species are identified. 
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3.3. Investigation of 4-oxo/4-hydroxy-quinoline tautomerism using the 
unsubstituted 4-oxo-quinoline (92a) as model 
To build a deeper understanding of the oxo-quinoline/hydroxy-quinoline 
tautomerism it was decided to study the unsubstituted quinolone core structure devoid of 
substituents, so as to exclude possible substituent effects on the tautomeric equilibrium. 
It is noteworthy that the ester substituent in position 3 of the quinolone structure affects 
the quinoline-hydroxyquinoline tautomerism in quinolone 3-esters and introduces the 
possibility of another tautomeric form. We intended to conduct a brief structural study of 
quinolone core in order to gather information regarding its tautomeric equilibrium and 
those preferences, using contemporary computational methods, by performing molecular 
orbital calculations.  
The quinolone scaffold 92a (4-oxo-quinoline) was thus considered and its 
tautomeric equilibrium studied theoretically (Figure 3.14), using DFT methods. 
 
 
Figure 3.14 – Structural representation of the possible tautomers of 4-oxo-quinoline (92a) 
considered in the theoretical investigation (B3LYP/6-311++G(d,p)). 
Considering the planarity relatively of the quinolone core, the presence of 
conformers for tautomer 92a and 92c was not considered in this study. As represented in 
Figure 3.15, from rotation of the hydroxyl in compound 92b, two conformational minima 
were calculated (H-O-C-C dihedral equal to 0º or to 180º). 
 
Figure 3.15 – Structural representation of the two conformational minima, 92b180 and 92b0, 
calculated from the scanning for conformational evaluation of 92b (B3LYP/6-311++G(d,p)). 
180º   
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The minima energies for optimized structures of 92a, 92b180, 92b0 and 92c were 
determined by using different functional and basis functions (selected from a study about 
theoretical structure and vibrational spectra of ciprofloxacin).175 Results obtained with 
the various levels of theory proved to follow a similar trend, with the quinolone 92a as 
the most stable structure, while 92c is the most unstable (with an average of relative 
energy of about 265.92 kJ mol-1). The absence of an ester carbonyl at position 3 of the 
quinolone core abrogates the advantageous stabilization of the hydroxyl group of 92b, 
when compared with the more stable form, the tautomer 92a. However, the two minima 
of 92b show energies relatively close together and also relatively close to 92a (∆E = 44.76 
kJ mol-1 for 92b0; and ∆E = 34.44 kJ mol-1 for 92b180, in average). Thus, all these three 
forms, tautomer 92a and both conformers of 92b, can coexist and contribute to the 
equilibrium populations at room temperature. 
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3.4. Summary and conclusions 
The low intrinsic solubility of 4-oxo-quinoline 3-esters drove us to consider the 
synthesis of 4-chloroquinoline derivatives (for example compound 56) as intermediate 
compounds. 4-Chloroquinolines derivatives steamed as versatile building blocks for the 
preparation of 4-oxo-quinolines, with the possibility of introducing chemical diversity at 
positions 4, 6 and/or 7 of the quinoline core structure. Theoretical calculations 
((B3LYP/6-311++G(d,p)) predicted four different conformers of 4-chloroquinoline 56, at 
room temperature. These conformers are related with the ester moiety but show low 
predicted barriers for conformational interconversion. The same four conformers were 
found in the as-deposited argon-matrix of the compound, in relative amounts close to 
those predicted by theory.  
Structure-activity relationship studies on the quinolone 3-ester chemotype and 
docking studies performed in silico at the yeast Qo site of the bc1 protein complex of P. 
falciparum indicated that both the 4-oxo-quinoline and the ethyl ester moieties are 
relevant for activity. The present work shows that the barriers predicted for 
conformational isomerization around the ethyl ester moiety are low and this may be 
important to facilitate structural adjustments of the ethyl ester moiety in the enzyme 
pocket, so as to maximize drug-target interactions, thereby improving the 
pharmacodynamic profile. 
Conventional quinolones (e.g. nalidixic acid, ciprofloxacin and norfloxacin) that 
are widely used in medicine as antibacterial agents are N-alkyl substituted, and the N-
substituent hinders the possibility of tautomerism. However, this strategy cannot be 
applied in the development of quinolones antimalarials directed to the bc1 protein 
complex, since the docking studies indicated that the 4-oxo and N−H groups in the 
quinolone core appear to be important to the antimalarial activity of quinolone 3-esters. 
Hence, the possibility of tautomerism between 4-oxo-quinoline and 4-hydroxy-quinoline 
forms should not be neglected. Tautomerization translates in an alteration of chemical 
and physical properties, with consequences for pharmacokinetic and pharmacodynamic 
profiles.  
For the compounds in study (82 series), calculations show a difference between 
the lowest energy hydroxy-quinoline and quinolone forms of 27 and 38 kJ mol−1, for 5-
substituted and 7-substituted compounds, respectively. The preference for the hydroxy-
quinoline form can be correlated with the presence in these forms of a O−H···O(ester 
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carbonyl) stabilizing intramolecular H-bond interaction. Calculations of aromaticity for 
the two rings of each compound in study by HOMA and BI indexes afford results that are 
in keeping with the observed preference for the enol forms, and the aromaticity can thus 
be considered a relevant factor in defining structural preferences. 
Sublimation of the hydroxy-quinoline salt followed by its deposition to form a 
cryogenic matrix and analysis by FTIR spectroscopy allowed collection of data showing 
that the tautomeric species of the compound present in the crystalline solid (hydroxy-
quinoline) did not convert to another tautomer upon sublimation. On the contrary, when 
the solid 4-oxo-quinoline (keto) form was used as starting material in the matrix isolation 
experiments, extensive tautomerization of the compound was observed, resulting in the 
sole observation of the 4-hydroxy-quinoline tautomeric form.  
To understand the effect of the 3-ester substituent on the quinolone structure, a 
brief computational study was conducted on the quinolone scaffold (92 series), 
calculating the structure and energy of its tautomeric equilibrium species. The results 
obtained highlighted the keto form as the most stable compound, in the unsubstituted 4-
oxo-quinoline, since the absence of an ester carbonyl at position 3 of the quinolone core 
abrogates the possibility of advantageous stabilization of the hydroxyl group at position 
4. However, the energy barriers between the 4-hydroxy-quinoline and 4-oxo-quinoline 
forms are relatively close together and all these tautomers can coexist and contribute to 
the equilibrium populations. 
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3.5. Experimental 
X-ray diffraction studies 
The single crystal X-ray diffraction (XRD) study was performed at room 
temperature on a Bruker APEXII diffractometer using graphite monochromatized Mo Kα 
radiation (λ = 0.71073 Å). Bond lengths and angles are within the expected range of 
values. The crystal structure have been deposited at the Cambridge Crystallographic Data 
Centre (deposition numbers: CCDC 1406711 for 56 and 1039599 for 82b.HCl) and 
further details on data collection, structure refinement and full tables of interatomic 
distances, valence and torsion angles are available therein. 
Matrix preparation, IR spectroscopy and photostability studied 
Isolation of the compound in solid argon was achieved by sublimating the solid 
compound in a specialized thermoelectrically-heatable mini-oven assembled inside the 
cryostat, and co-depositing its vapors with argon (N60, supplied by Air Liquide), coming 
out from a separate line, onto a CsI window kept at 15 K. The obtained matrices were 
enough diluted (matrix:sample ratio >1000), so that they contain only monomers of the 
compound. Annealing of the matrices was undertaken in steps of 1 degree, until 
evaporation of the argon host (at 40-43 K), and in steps of 5 degrees, after that 
temperature.  
Evaporation of the host matrix atoms allowed obtaining an amorphous solid, 
which could later be crystallized at a temperature of ~233-243 K. The crystal was then 
re-cooled down to 17 K and its infrared spectrum collected. 
The low temperature set up used includes, as main component, an APD 
Cryogenics closed-cycle helium refrigeration system, with a DE-202A expander. The 
temperature was measured directly at the sample holder, using a silicon diode sensor 
connected to a digital temperature controller (Scientiﬁc Instruments, Model 9650-1), 
which provides accuracy of 0.1 degree. 
The IR spectra were recorded in the 4000-400 cm-1 range with 0.5 cm-1 resolution, 
on a Thermo Nicolet 6700 Fourier-transform infrared (FTIR) spectrometer, equipped 
with a deuterated triglycine sulfate (DTGS) detector and a KBr beamsplitter. 
UV-irradiation of the matrices was done through the outer quartz window of the 
cryostat, using a HBO200 high-pressure Hg(Xe) lamp. 
The ATR-FTIR spectra were obtained using a germanium crystal in a Nicolet 
iN10 MX infrared system with a MCT-A detector and a KBr/Germanium optics. The 
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spectral resolution used was 2 cm-1, with an aperture of 80 and number of scans of and 
64.  
Theoretical calculations 
The quantum chemical calculations were performed using Gaussian 09.176 
Geometries were fully optimized at the DFT/B3LYP level of approximation.177–179  
The potential energy profiles for internal rotation were calculated with the driving 
coordinate incrementally fixed and all the other geometrical parameters optimized. 
The harmonic vibrational wavenumbers were obtained at the same level of theory 
and scaled by 0.978, to correct them for the shortcomings of the applied methodology 
(mainly for anharmonicity). The scaled calculated frequencies, together with the 
calculated intensities, were used to produce the simulated spectra.  
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4.1. Lipophilicity/solubility evaluation – CLogP calculation 
To reach its target, a drug must pass through several membranes, beginning with 
the absorption in the stomach and small and large intestine, if orally administered. To 
pass across most membranes, the drug must be relatively non polar. However the drug 
must be solubilized in biological media and, for that, it should possess some polar 
characteristics. The polarity of a substance is measured by its partition coefficient in a 
two phase system consisting of 1-octanol (mimicking the cell membrane) and water 
(mimicking the extracellular fluid), where P is the ratio between the amount of drug in 
octanol and the amount in water. Usually, in medicinal chemistry, the logarithm of the 
partition coefficient (LogP) is used to assess the drug-likeness of a given molecule, as it 
is a well-established measure for the compound’s hydrophilicity and/or 
hydrophobicity.180 
Partition coefficients have a strong influence on pharmacokinetic properties of 
drugs and are thus useful to estimate the absorption and distribution of drugs within the 
body and also to predict how rapidly they are metabolized and excreted. For a drug to be 
orally absorbed, it normally must first pass through lipid bilayers in the intestinal 
epithelium and must be hydrophobic enough (high LogP values), but not so hydrophobic 
since the drug must be previously dissolved, and once it is in the bilayer should not 
partition out again.181 On the other hand, in terms of pharmacodynamic profile, 
hydrophobic drugs tend to be more toxic because, in general, they are retained for longer 
periods and have a wider distribution within the body.182  
However, LogP is not an accurate determinant of lipophilicity for ionisable 
compounds, because it only describes the partition coefficient of neutral molecules. This 
limitation can affect the research, since approximately 80% of the drugs are ionisable and 
are subject to the changing pH environments in the body.180–182 
Nowadays, there are computer programs available to calculate the LogP (CLogP) 
values from the structure of compounds. In this work we have used ALog PS 2.1 
(available from Virtual Computation Chemistry Laboratory – 
www.vcclab.org/lab/alogps/), considered to be the most accurate program to predict 
lipophilicity and aqueous solubility of molecules. 
Christopher Lipinski developed the “Rule of five” based on the observation that 
most orally administered drugs are relatively small (with molecular weight of less than or 
equal to 500 g mol-1), not too polar (five or fewer hydrogen-bond donors and up to 10 
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hydrogen-bond acceptors) and are moderately lipophilic (not too hydrophobic nor too 
hydrophilic), with an intermediate LogP value (between 2 and 5).183  
4.1.1. Evaluation of CLogP 
As pointed out in the previous chapter, changes in the structure of 4-oxo-quinoline 
3-esters (due for example to tautomeric and conformational preferences) will translate in 
changes of chemical and physical properties (like solubility) and may have impact on 
pharmacokinetic and pharmacodynamic profiles. Considering the possibility of keto-enol 
tautomerism in the chemotype investigated162 and also the fact that, in some cases, an 
isomeric mixture (5 and 7-substituted) was obtained from the cyclisation step  due to the 
possibility of various aromatic substitution patterns, the LogP values were calculated for 
the library of quinolones studied and for the corresponding tautomers and isomers (Table 
4.1).  
Table 4.1 - CLogP values for ethyl 4-oxo-quinoline-3-carboxylates, substituted at positions 5 or 
7, and for the corresponding tautomers. (a) calculated by ALog PS2.1. 
  CLogP value(a) 
Compound Substituent 
Position 7, 
keto form 
Position 5, 
keto form 
Position 7, 
enol form 
Position 5, 
enol form 
13 Benzoyloxy- 2.95±0.39 3.04±0.42 3.88±0.42 3.91±0.40 
14 Benzyloxy- 3.02±0.45 3.12±0.39 4.02±0.61 4.01±0.61 
31 Benzysothiazoloxy- 2.40±0.67 2.53±0.60 3.41±0.95 3.38±0.96 
33 Hydroxyl- 1.11±0.49 1.50±0.41 1.96±0.28 2.09±0.37 
43 Fluorine- 1.69±0.43 1.80±0.32 2.67±0.44 2.68±0.44 
46 Iodine- 2.44±0.41 2.54±0.35 3.41±0.60 3.40±0.60 
60 
4-morpholino 
methyl-phenyl 
2.70±0.45 2.75±0.44 3.62±0.61 3.61±0.61 
79 Acetyl- 1.40±0.44 1.56±0.32 2.32±0.42 2.22±0.37 
80 Nitro- 1.44±0.41 1.52±0.31 2.40±0.41 2.31±0.34 
81 Nitrile- 1.31±0.41 1.36±0.29 2.23±0.39 2.23±0.39 
82 Methyl- 1.90±0.40 1.99±0.31 2.88±0.51 2.87±0.51 
83 Trifluoromethyl- 2.47±0.46 2.56±0.33 3.34±0.51 3.35±0.50 
84 Methoxy- 1.56±0.34 1.54±0.38 2.37±0.40 2.48±0.63 
Analysis of Table 4.1 shows that the keto forms have a lower CLogP than the 
corresponding enol forms for all the examples investigated, predicting a higher aqueous 
solubility for 4-oxo-quinolines, but also a reduced lipophilicity that can lead to a decrease 
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in the passage through biological membranes. Thus, the CLogP values exhibited by the 
4-hydroxy-quinoline derivatives appear more adequate from a bioavailability viewpoint 
(higher than 2 and lower than 5). 
On the other hand, the presence of the substituent at positions 7 or 5 does not 
appear to affect significantly the CLogP value, predicting that the pattern of substitution 
on the carboxylic part of the quinolone structure may not interfere significantly with the 
pharmacokinetic profile for the range of substituents considered in this work. 
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4.2. Biological activity 
Following Lipinski’s rule (Rule of 5), the lipophilicity/solubility of the 
synthesized quinoline derivatives (expressed by their CLogP values), molecular weight 
(in g mol-1) and the number of hydrogen-bond donors and acceptors were considered as 
part of a preliminary test for the drug-likeness of the compounds (see number of violations 
of Lipinski’s rule at column Rof5 violations in Table 4.2). Considering the results, it 
appears clear that, in general, the quinolones synthesized do not violate the parameters of 
Lipinski’s rule. The exception is compound 45b that presents a molecular weight higher 
than 500 g/mol and a CLogP value higher than 5 (2 violations).  
The soluble quinolines were evaluated for their activities against laboratory-
adapted chloroquine and mefloquine-resistant Plasmodium falciparum Dd2 and/or for 
3D7 chloroquine sensitive strains (Table 4.2). Compounds 45a and 87 demonstrated the 
best antiplasmodial activities, showing IC50 values for sensitive strains of 323 nM and 
398 nM, respectively. For chloroquine/mefloquine-resistant strains it is noteworthy the 
IC50 value of compound 87 (335 nM). 
Since compounds 14, 43, 46, 83 and 86 were not soluble in DMSO, they could 
not be tested against 3D7 and Dd2 strains and their potential as antimalarial drugs could 
not be evaluated. Also, the poor solubility of some of the quinolones synthesized (for 
example compounds 31 and 32b) may have influenced results obtained for biological 
activities. In the case of quinolone 31 the biological test has failed and it was not possible 
to obtain an optimal curve to determine an IC50 value. Compound 32b was tested in 
duplicate (contrary to the other compounds in study, which were tested in triplicate) and 
the results were not coherent, since the biological activity (measured in terms of IC50 
values) of 32b against 3D7 strain in the first assay was 2.7 μM while in the second one 
was around 16.2 μM, resulting in the large standard deviation observed for this compound 
(9.476 ± 9.525 μM). 
Quinolones 13 and 60 showed weak activity against the sensitive strain of 
Plasmodium (8.7 μM and 5.4 μM, respectively) and, therefore, these compounds were 
not tested against the resistant strain Dd2.
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Table 4.2 – Final step yield, drug-likeness properties (MW, CLogP values, number of hydrogen-bond donors and acceptors atoms in each structure and number 
of violations to the Rule of 5) and in vitro antimalarial activity for chloroquine and mefloquine and for synthesized quinolines. (a) calculated by ALog PS2.1. 
Compound Structural representation 
Yield 
(%) 
MW 
(g/mol) 
CLogP(a)± SD 
D
o
n
o
rs
 
A
cc
ep
to
rs
 
R
o
f5
 
(v
io
la
ti
o
n
s)
 Antiplasmodial activity 
(IC50; μM) 
Average ± SD 
3D7 Dd2 
Chloroquine Chloroquine n.a. 319.87 5.28±0.68 1 3 1 0.023±0.006 0.270±0.071 
Mefloquine Mefloquine n.a. 378.31 3.10±0.41 2 9 0 0.030±0.012 0.094±0.004 
13 
 
73 337.33 2.95±0.39 1 6 0 8.715±1.691 n.d. 
14 
 
17 323.34 3.02±0.45 1 5 0 Not soluble Not soluble 
31 
 
48 398.39 2.40±0.67 1 8 0 
Poor 
solubility 
n.d. 
32b 
 
22 349.34 3.30±0.45 1 7 0 
9.476±9.525 
(Poor 
solubility) 
n.d. 
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43 
 
44 235.21 1.69±0.43 1 5 0 Not soluble Not soluble 
45a 
 
62 357.14 2.79±0.37 1 4 0 0.323±0.060 1.013±0.088 
45b 
 
12 573.16 6.18±0.79 0 4 2 0.743±0.124 1.553±0.201 
46 
 
44 343.12 2.44±0.41 1 4 0 Not soluble Not soluble 
60 
 
13 392.45 2.70±0.45 1 6 0 5.396±1.065 n.d. 
82a 
 
12 231.25 1.90±0.40 1 4 0 n.d. 3.034±0.347 
82b 
 
22 231.25 2.87±0.51 1 4 0 n.d. 5.891±1.542 
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83 
 
35 285.22 2.47±0.46 1 7 0 Not soluble Not soluble 
86 
 
18 242.23 1.41±0.39 1 5 0 Not soluble Not soluble 
87 
 
13 245.27 2.33±0.46 1 4 0 0.398±0.155 0.335±0.058 
90 
 
31 217.22 1.51±0.40 1 4 0 3.423±0.274 n.d. 
91 
 
75 189.17 0.89±0.47 2 4 0 4.844±0.849 n.d. 
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Considering the results from docking studies performed for 4-oxo-quinoline 3-
esters on Qo site
120 and the evidence of tautomerism in some cases,162 it could be expected 
that the 4-oxo-quinoline 3-ester form, with the N–H and 4-oxo groups involved in 
important interactions inside the enzyme pocket, presents a much better pharmacological 
profile as P. falciparum bc1 inhibitor than its  
4-hydroxy-quinoline 3-ester tautomer. From the chemical diversity of our library of 
compounds, we could evaluate and compare the in vitro activities of 4-oxo-quinoline and 
of its derivatives without the N-H and 4-oxo groups (45a vs 45b; and 82a vs 82b).  
  
  
The 4-hydroxy-quinoline 82b exhibited activity against P. falciparum Dd2 at 
micromolar concentrations, with an IC50 of 5.891 μM (against Dd2 strain), while its 
isomer, 4-oxo-quinoline 82a, showed antiplasmodial Dd2 activity slightly higher than 
82b (IC50 of 3.034 μM) - Table 4.2. Isomers 82a and 82b are not true tautomers. However, 
since it was not possible to isolate the 4-hydroxy-quinoline of 82a and the 4-oxo-
quinoline of 82b, we compared the antimalarial activities for these two compounds 
although they bear the methyl substituent at different positions. The activity results may 
look somewhat surprising if we consider published results from docking studies: the 
activity profile of 82b as inhibitor of the P. falciparum bc1 complex is expected to be less 
favourable and a bigger difference in its activity was expected, comparing with 82a.  
We could presuppose that the better pharmacodynamic performance of 82a may 
be offset by its poor bioavailability, considering the lower value of CLogP for 82a 
compared to 82b. However, we consider that further investigations are required to 
understand the micromolar activity of 82b.  
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Similar results were obtained to 45a and 45b. These compounds demonstrated 
slightly different antimalarial activities against the multiresistant strain Dd2, with IC50 
values of 1.013 μM and 1.553 μM respectively. 
In order to test the importance of the ethyl ester group at position 3 of the 
quinolone core, the ethyl ester of compound 90 was hydrolysed to afford the 
corresponding carboxylic acid 91. The antimalarial results support the idea that 
compounds with an ethyl ester group have slightly increased potency in vitro relatively 
to the analogues with a carboxylic acid at the same position (IC50 for 90 against 3D7 is 
around 3.4 μM, while for 91 is around 4.8 μM). 
  
Chapter 4 - Docking studies, CLogP calculations and evaluation of antimalarial activity 
 
 
166 
4.3. Docking simulations – binding of 4-oxo-quinolines to the Qi site of 
cytochrome bc1 complex 
The Q-cycle requires two distinct binding sites for the reduction of ubiquinone 
and the oxidation of ubiquinol. Both sites are located within cytochrome b: the Qo site 
acts to oxidize ubiquinol near the intermembrane space and the Qi site reduces 
ubiquinone near the mitochondrial matrix.50 
Atovaquone binds to cytochrome bc1 at the Qo site. However, several mutations 
have been reported, giving rise to atovaquone-resistant strains of P. falciparum. These 
mutations arise in the Qo pocket and prevent atovaquone from binding.  
Many different classes of compounds have been investigated as potential drugs 
and much work has focused on the inhibition of the Qo site.
85 Among these, selected 
quinolones have been investigated, in view of finding suitable inhibitors targeting the Qo 
site of P. falciparum. Although exhibiting activity at low nanomolar concentrations, some 
of these compounds have clearly not avoided the issues that resulted in atovaquone 
resistance, demonstrating some cross resistance with atovaquone. However, when tested 
in atovaquone resistant strains, only a 92 fold drop in potency was observed, representing 
a distinct improvement over the 760-fold decrease in potency observed for atovaquone in 
the same atovaquone-resistant parasite strain. These results may indicate a mode of action 
different from the intended Qo inhibition.
59,120,184 
Also, the results described in the previous section, concerning the antimalarial 
activity exhibited by the 4-oxo-quinoline/4-hydroxy-quinoline pair, prompted us to 
hypothesize that the quinolone chemotype may bind to the Qi site of the bc1 complex. 
Taken together, the evidence exposed above encouraged us to investigate the 
possibility of drug-target interactions with the Qi site of the bc1 complex, using docking 
studies. An additional stimulus comes from the fact that the Qi site of cytochrome bc1 has 
been far less explored than the Qo site in the search for antimalarial compounds and only 
the binding of a few compounds has been visualized directly.67,185,186  
The 4(1H)-pyridone chemotype has been optimized for antiplasmodial activity. 
From this effort, compounds GW844520 and GSK932121 (Figure 4.1), produced by 
GSK, emerged as promising leads, exhibiting excellent antimalarial properties, even 
against atovaquone-resistant parasites. However, these compounds had to be withdrawn 
from development due to unexpected toxicity, attributed to cardiotoxicity and possibly 
due to the inhibition of the mammalian bc1 complex.
55,73,85 
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Figure 4.1 – Representation of the chemical structures of 4(1H)-pyridones GW844520 and 
GSK932121 docked for the Qi site of cytochrome bc1 in a previous study. 
Co-crystallization of the cytochrome bc1 complex with compounds GSK932121 
and GW844520 revealed that these inhibitors do not bind at the Qo site but, instead, bind 
at the Qi site, providing a molecular explanation for the cardiotoxicity and for the ability 
of this class to overcome parasite Qo-based atovaquone resistance.
85,102,103 
In our docking simulations, we will investigate the hypothesis that some of the 
quinolones from our library bind to the Qi site, as observed for the 4(1H)-pyridones. 
4.3.1. Software available for protein-ligand docking 
Computational chemistry has greatly improved, providing various tools that may 
be successfully applied in strategies for drug design and optimization. Ligand docking is 
nowadays a standard method for exploring the way in which small molecules bind to 
specific sites of proteins or other biological macromolecular targets. It is possible to 
determine the structures that would lead to optimized interactions (virtual screening) or 
rationalize the results obtained from random screening of compounds previously 
synthesized, helping the analysis of structure-activity relationships required to lead 
optimization. 
There are several options of available docking software, including the GOLD 
(Genetic Optimization for Ligand Docking) suite of programs elected for this study. 
GOLD performs molecular docking using a genetic algorithm in which the molecules to 
be docked are modeled and the strength of binding is predicted according to the non-
covalent interactions observed between the ligand and the protein.187–189 Predicted poses 
are scored (GoldScore) according to factors such as hydrogen bonding and van der Waals 
energies, ligand strain and steric clashes, to generate a figure intending to show the 
optimal ligand-protein pose and demonstrating the most probable docking pose for a 
given protein-ligand complex. The reported pose with the highest GoldScore is 
considered to be the more favorable pose for the results of that search.188,190 
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All molecular docking simulations conducted in the work described herein were 
performed using GOLD docking suite version 5.2. A genetic algorithm (GA) using 
piecewise linear potential (PLP) as the fitness function was used for all docking 
calculations. Ten independent GA runs were performed for each ligand. Default settings 
were used, except the “allow early termination” setting, that was turned off. 
4.3.2. Protein – Co-crystallized structure of bovine bc1 
Since an atomic structure for P. falciparum bc1 is not available, the compounds 
selected for this study were modeled in silico using the coordinates of the crystal structure 
of bovine heart cytochrome bc1 protein (Protein Data Bank accession code 4D6U), where 
the ligand GSK932121 is bound in the Qi site. Using GOLD, this ligand can be removed 
and other compounds docked into the Qi site.
85 
Although not identical to the parasite bc1 complex, the protein sequence alignment 
of bovine, human and P. falciparum cytochrome b shows a fairly conserved Qi binding 
site. However, some differences are shown between the mammalian and Plasmodium 
proteins, especially in the N-terminal region of cytochrome bc1 (Figure 4.2).
85  
 
Figure 4.2 – Representation of protein sequence alignments of bovine (B. taurus), human (H. 
sapiens), S. cerevisiae, P. falciparum and T. gondii, showing conservation in the Qi binding site. 
The scale at the top is numbered according to the bovine sequence. Residues fully conserved are 
colored in deep blue, partially conserved in light blue and unconserved in white.85 
4.3.3. Binding of pyridone GSK932121 to the Qi site of cytochrome bc1 
The binding modes of the antimalarial 4(1H)-pyridones to the Qi site of 
cytochrome bc1 have been previously published (Figure 4.3).
85 The pyridone ring of 
GSK932121 is oriented in a way to place the amine of the pyridone and the N of His201 
on helix D within bonding range (separated by 3.3 Å). The same study has demonstrated 
that the carbonyl of this compound was within 3.5 Å of both Ser35 on loop A and Asp228 
on loop E, to allow formation of hydrogen bonds. The formation of hydrogen bonds 
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between several residues and the head group indicates that this pyridone is strongly bound 
at the Qi site. 
 
Figure 4.3 – Representation of interactions between the Qi binding site and compounds 
GSK932121 (in the foreground) and GW844520 (in gray, in the rear). Carbons are colored in 
black, oxygens in red, nitrogens in blue and halogens in green.85 
Additionally, the trifluoromethyl tail group is positioned between Met190 and 
Met194. The residues Phe18, Leu21 and Leu197 form a hydrophobic pocket around the 
aromatic rings of the pyridone tail, while Phe220 forms a stacking interaction with the 
head group (hydrophobic interactions provide a large part of the binding energy). These 
stacking interactions may help to fix the pyridone compounds in place, as opposed to the 
ubiquinone, explaining the increased strength of binding to the pyridones, compared with 
ubiquinone. 
These data indicate that the Qi site of the bc1 complex may be a target for a number 
of ubiquinone-mimicking antimalarials that are not cross-resistant with atovaquone. 
4.3.4. Selection of quinolone ligands 
From some papers published by the groups of Roman Manetsch191 and Paul 
O’Neill118 and considering the structure of 3-aryl substituted 4(1H)-pyridones 
GSK932121 and GW844520, a library of 25 quinolones (compound 93 to 117) with 
antimalarial activity was selected for docking studies. This selection includes aryl 
substitution at positions 2 or 3 of the quinolone core (Table 4.3 and Table 4.4, respectively) 
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and, for each group, compounds with IC50 values ranging from 1nM to more than 1µM 
are included. 
Table 4.3 – Structural representations of 2-aryl substituted quinolones selected for docking and 
corresponding in vitro activities against the P. falciparum strains 3D7 and C2B. 
Compound Structural representation 
Antiplasmodial activity 
(IC50; nM)
a 
3D7 C2B 
93 
 
26 92 
94 
 
73 274 
95 
 
212 n.d. 
96 
 
408 n.d. 
97 
 
465 n.d. 
98 
 
139 n.d. 
99 
 
105 552 
100 
 
24 n.d. 
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101 
 
8.4 31 
102 
 
8 n.d. 
103 
 
664 n.d. 
104 
 
36 178 
105 
 
+1000 n.d. 
106 
 
752 n.d. 
a Values extracted from the literature.118 
 
Table 4.4 - Structural representations of 3-aryl substituted quinolones selected for docking and 
corresponding in vitro activities against the P. falciparum strains W2 and C2B. 
Compound Structural representation 
Antiplasmodial activity 
(IC50; nM)
a 
W2 C2B 
107 
 
24.5 7.33 
108 
 
6.65 2.67 
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109 
 
61.7 160 
110 
 
1.30 0.638 
111 
 
10.6 1.28 
112 
 
5400 829 
113 
 
154 93.9 
114 
 
258 277 
115 
 
517 73.1 
116 
 
777 48.4 
117 
 
2860 467 
a Values extracted from the literature.191 
The minimum energy structures of ligands were determined using Merck 
molecular force field (MMFF) 94, within the SPARTAN ’08.192 The files were then 
Chapter 4 - Docking studies, CLogP calculations and evaluation of antimalarial activity 
 
173 
uploaded to the GOLD protein-ligand docking suite and docked into the Qi site using the 
protein configuration previously described (where compound GSK932121 was docked). 
For each ligand docked, 10 independent results of GoldScore and distinct poses were 
registered, for visual comparison and analysis. 
4.3.5. Docking of selected compounds – GoldScore vs IC50 correlation 
From the docking results obtained for 2-aryl (Table 4.5) and 3-aryl substituted 
(Table 4.6) quinolones it is possible to conclude that the 2-aryl substituted compounds 
exhibit a higher GoldScore range (64.4-80.8) than their 3-aryl substituted counterparts 
(53.5-67.8). However, these results only describe the predicted strengths of interaction 
between the protein and the compound for a given docking pose, not accounting for many 
other factors that influence the activity of the compounds, such as membrane 
permeability, solubility or plasma half-life. These factors must also be considered when 
predicting how efficacious a compound is. Furthermore, in the docking simulation the 
receptor model of the protein is a rigid system with the amino acid fixed in the crystallized 
position, while in a biological setting the protein is a flexible structure that can adapt to 
its environment.188,189,192,193 Thus, although important, results from docking must be 
cautiously interpreted and, for the present case, one cannot assume that 2-aryl substituted 
quinolones are more antimalarially active than their 3-aryl substituted analogues on the 
sole basis of results from docking simulations.  
 
 
 
 
 
 
 
 
Chapter 4 - Docking studies, CLogP calculations and evaluation of antimalarial activity 
 
 
174 
Table 4.5 – GoldScore results obtained from the docking of 2-aryl substituted quinolones to the 
Qi site of P. falciparum bc1 complex.  
 GoldScore 
Ligand Highest Average ± SD GS/nonH 
93 79,9 71,8 ± 6,5 2,052569 
94 78,6 77,9 ± 0,6 2,513118 
95 75,8 67,9 ± 4,8  1,995819 
96 70,7 69,2 ± 0,9 2,036004 
97 75,3 73,5 ± 1,2 2,371305 
98 76,7 75,0 ± 0,7 2,418851 
99 78,9 77,8 ± 0,8 2,881419 
100 82,5 79,5 ± 1,6 2,483531 
101 82,7 80,3 ± 2,1 2,589522 
102 80,1 79,0 ± 0,6 2,469841 
103 83,5 80,8 ± 2,0 2,524687 
104 78,7 77,1 ± 1,3 2,486014 
105 65,5 64,4 ± 0,7 2,801977 
106 65,2 64,8 ± 0,4 2,945663 
Table 4.6 – GoldScore results obtained from the docking of 3-aryl substituted quinolones to the 
Qi site of P. falciparum bc1 complex. 
 GoldScore 
Ligand Highest Average ± SD GS/nonH 
107 55,2 53,7 ± 0,8 2,441261 
108 59,8 57,9 ± 1,8 2,412066 
109 57,5 55,1 ± 1,8 2,396792 
110 71,6 67,8 ± 1,7 2,336793 
111 70,4 66,5 ± 1,8 2,291618 
112 59,4 58,6 ± 0,6 2,548302 
113 59,9 57,7 ± 1,6 2,507608 
114 60,9 58,9 ± 2,0 2,563028 
115 57,3 56,0 ± 0,7 2,334175 
116 58,7 56,7 ± 1,4 2,364318 
117 57,1 53,5 ± 1,3 2,430855 
In an attempt to examine if there is a correlation between GoldScore and 
antimalarial activity (expressed as IC50) for the 2 sets of compounds, the values of log 
(1/IC50) were plotted against the GoldScore average or against a parameter that considers 
Chapter 4 - Docking studies, CLogP calculations and evaluation of antimalarial activity 
 
175 
the molecular size (GS/nonH – division of GoldScore by the number of non-hydrogen 
atoms). When considering the molecular size (GS/nonH), for 2- and 3-aryl substituted 
derivatives, and the GoldScore average for 3-aryl substituted derivatives (Chart 4.1), the 
correlation with the antimalarial activities were somewhat deviated from linearity. 
However, some correlation between the GoldScore average and log (1/IC50) values for 
the 2-aryl series could be observed (Chart 4.2), when considering the antimalarial 
activities against the 3D7 strain. 
Chart 4.1 - Correlation between the GoldScore average and log(1/IC50), for 3-aryl substituted 
ligands selected, considering their antimalarial activities against the 3D7 strain. See Table 4.4, for 
structures and corresponding activities, and Table 4.6, for GoldScore average values. 
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Chart 4.2 - Correlation between the GoldScore average and log(1/IC50), for 2-aryl substituted 
ligands selected, considering the antimalarial activities against the 3D7 strain. R2 = 0.7668. 
Compound 103 was not included, as it is an outlier and it is the only compound of the 2-aryl series 
with a methoxy group at position 5. See Table 4.3, for structures and corresponding activities, and 
Table 4.5, for GoldScore average values. 
 
These evidence of possible or no correlation between the GoldScore and the 
antimalarial activity has to be interpreted taking in consideration that the GoldScore only 
gives indication of the predicted strength of protein-ligand interaction 
(pharmacodynamics), not taking in account other variables adjacent to the 
pharmacological activity and also the possibility of multiple-targets which give the 
phenotypic readout.188,189,192,193 
4.3.6. Docking pose of selected quinolones in the Qi site 
Compound 110 exhibited the highest in vitro activities against W2 and C2B strains 
of P. falciparum and has also shown the highest GoldScore average among selected 
members of the 3-aryl series. Therefore, 110 can be considered of most importance with 
regard to modeling interpretation. However, comparison of the docking poses results 
shows that other 3-aryl substituted compounds studied in this project exhibit similar 
results, with the key structural features located in the similar positions for all ligands 
docked. The differences are only observed in their precise alignment with the protein 
residues, orientating the compounds such that the quinolone “head” and the phenyl ring 
of the tail are in a similar position along the series (Figure 4.4).  
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Figure 4.4 - Image of the Qi site showing the highest scoring docking pose for each of the 3-aryl 
substituted compounds studied. 
The GoldScore results for 110 across the 10 distinct docking poses vary by less 
than 6 units (Table 4.7) and this compound is orientated in a similar manner to the 
reference ligand (GSK932121) in the Qi binding pocket.
85 Between all the 10 distinct 
docking poses of 110, only small differences are visible in the position assumed by the 
aryl tail in position 3 (related to a slow alignment with the protein residues). 
Table 4.7 – Results for docking of 110 in the Qi site, expressed as GoldScore. 
Docking pose 1 2 3 4 5 6 7 8 9 10 
GoldScore 65,9 65,9 67,1 68,9 71,6 67,0 66,3 69,1 67,5 69,1 
 
The orientation of the quinolone core of 110 promotes the formation of key 
hydrogen-bonds between the inhibitor and the amino acids Asp228/Ser205 and His201 
(Figure 4.5). The quinolone N1 forms a hydrogen bond with the Nε2 of His201 and the 
two atoms are separated by 2.4Å, while Ser205 and Asp228 on helix E are 2.7Å and 3.3Å, 
respectively, apart from the carbonyl group, allowing formation of hydrogen bonds. 
Phe220 appears to form a stacking interaction with the aromatic quinolone core, while 
residues Phe18, Leu21, Leu197, Ile42, Leu41, Met190 and Met194 form a tight 
hydrophobic pocket around the aromatic rings of the quinolone tail (Figure 4.5), 
suggesting that these hydrophobic interactions provide a contribution to the binding 
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energy. A stacking interaction between the phenyl rings of the tail and Phe18 can also be 
perceived, which may help to fix the quinolone 3-aryl substituted compounds in place.  
The same residues were also found to interact directly with the head of the 
reference ligands GSK932121 and GW844520, with antimycin (compound known to 
bind to the Qi site) and with ubiquinone (natural substrate of Qi site), which lie in a similar 
position deep within this cavity.67,85,185,186 Considering that the stacking interaction 
described between Phe18 and the tail of our compound was not seen in ubiquinone-bound 
structures,67 due to the absence of an aryl substituent in this natural substrate, it may be 
postulated that this difference contributes to an increased strength of binding in the 
quinolones compared with ubiquinone.  
 
Figure 4.5 – Image representing the Qi site interactions with the quinolone core of compound 
110. The key protein residues are highlighted and the potential H-bond interactions indicated in 
black. H-bond lengths indicated are expressed in Å. Molecules are rendered as sticks colored by 
atom type (ligand structure, cyan; hydrogens, white; protein residues, green; oxygens, red; 
nitrogens, blue; and sulphurs, yellow). 
Among the compounds of the 2-aryl series selected, compound 102 exhibited the 
highest in vitro activity against 3D7 strain and also one of the highest GoldScore values. 
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Results across the 10 distinct docking poses for 102 vary by less than 3 units (Table 4.8). 
The other 2-aryl substituted compounds studied in this project have shown similar results, 
i.e. similar positions for protein-interactions, with only minor deviations. 
Table 4.8 – Results for docking of 102 in the Qi site, expressed as GoldScore. 
Docking pose 1 2 3 4 5 6 7 8 9 10 
GoldScore 79,1 79,1 78,3 79,6 78,0 80,1 79,4 79,2 78,5 79,1 
 
When comparing the orientation of the 2-aryl  substituted quinolones with that 
exhibited by the 3-aryl substituted analogues and the reference ligand GSK932121,85 an 
inversion of the quinolone core in the Qi binding pocket is easily perceived. This inversion 
of the quinolone core in the 2-aryl substituted quinolones may enable an increase in 
strength of interaction between the protein and the compound for a given docking pose, 
and may explain the higher GoldScore results observed, compared to the 3-aryl series 
(64.4-80.8 for the 2-aryl series vs 53.5-67.8 for the 3-aryl series). 
For the 3-aryl substituted quinolones, the quinolone core promotes the formation 
of hydrogen bonds between quinolone-N1 and His201 and also between the C4 carbonyl 
oxygen and Ser205/Asp228. However, for example for 102 it is possible to observe that 
the quinolone-N1 hydrogen binds to Ser205 and Asp228 on helix E, with donor and 
acceptor separated by 2.1Å and 2.3Å, respectively, while the C4 carbonyl oxygen 
interacts with the Nε2 of His201, with donor and acceptor separated by 3.0Å (Figure 4.6). 
Between all the 10 distinct docking poses of 102, only minor differences are 
perceived in the position of the 2-aryl tail (related to a slow alignment with the protein 
residues). The aromatic rings of the quinolone tail may force the inversion of the 
quinolone core, to keep the interactions between the ligand and the hydrophobic pocket. 
Considering that 102 bears an aromatic tail at the position 2, inversion of the quinolone 
core places the aromatic ring in position for optimized stacking interaction with Phe18, 
while favoring other hydrophobic interactions with the residues Leu21, Leu197, Ile42, 
Leu41, Met190 and Met194 that form a hydrophobic pocket around the aromatic rings of 
the quinolone tail (Figure 4.6). These interactions between the tail and the hydrophobic 
channel can also be observed for the reference ligand GSK932121.85 
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Figure 4.6 - Image representing the Qi site interactions with the quinolone core of compound 102. 
The key protein residues are highlighted and the potential H-bond interactions indicated in black. 
H-bond lengths indicated are expressed in Å. Molecules are rendered as sticks colored by atom 
type (ligand structure, lilac; hydrogens, white; protein residues, green; oxygens, red; nitrogens, 
blue; and sulphurs, yellow). 
Also, as evidenced for compounds of the 3-aryl series, GSK932121, GW844520, 
antimycin and ubiquinone,67,85,185,186 in the 2-aryl series Phe220 appears to form a 
stacking interaction with the aromatic core, suggesting that the hydrophobic interactions 
contribute substantially to the binding energy. 
From these docking results, it may be extracted that the residues that intervene in 
the binding ligand-protein and that are non-conserved (Phe18, Leu21 and Leu197) are 
from the hydrophobic pocket around the aromatic tail of the quinolones in study (these 
are replaced with Leu, Tyr and Ile, respectively, in P. falciparum). The residues involved 
in interactions with the quinolone core, by hydrogen bonds and by stacking (His201, 
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Asp228, Ser205 and Phe220), are mainly conserved across cytochrome b sequences.85 
The differences observed between the bovine heart bc1 and the P. falciparum bc1 
sequences also may contribute to the observed fragility in the correlations between 
GoldScore and IC50 values. 
Along with the docking simulations carried out for 2- and 3-aryl substituted 
quinolone derivatives, ten independent GA runs were performed for atovaquone binding 
at the Qi site. However, atovaquone did not produce consistent docking poses at the Qi 
site. No similarities were observed when overlapping the figure pose for all the 10 runs. 
These results are consistent with some previous studies reported85 and support the idea 
that atovaquone binds to the Qo, not binding to Qi site and, consequently, not overcoming 
the phenomenon of parasite resistance associated to Qo-mutations. 
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4.4. Summary, conclusions and future work 
It is generally accepted that changes in the structure of compounds (for example 
by tautomeric and conformational preferences) may translate in changes of chemical and 
physical properties (like solubility). In drugs, those changes may impact on the 
pharmacokinetic and pharmacodynamic profiles. 
For the range of 4-oxo-quinoline 3-esters prepared in this work, the possibility of 
keto-enol tautomerism and the different patterns of aromatic substitution obtained during 
the synthesis of quinolone derivatives, led us to calculate the ClogP values as an 
estimation of solubility. Results indicate that the pattern of substitution on the quinoline 
core structure (substituent at position 7 or 5) does not appear to alter the ClogP values 
(thus, possibly with a minor impact on the pharmacokinetic profile). However, regarding 
tautomerism, the differences are substantial, with the 4-hydroxy-quinoline derivatives 
demonstrating CLogP values that appear more adequate from a bioavailability viewpoint. 
In fact, the keto forms have a consistently lower CLogP than their enol isomers, predicting 
a higher aqueous solubility for 4-oxo-quinolines, but also have a lower lipophilicity that 
can translate in a decrease in the passage through biological membranes.  
On the side of pharmacodynamics, the 4-oxo-quinoline 3-ester forms were 
expected to present a much better pharmacological profile as P. falciparum bc1 inhibitors 
than their 4-hydroxy-quinoline 3-ester isomers, with the N–H and 4-oxo groups involved 
in important interactions inside the enzyme pocket. However, the 4-oxo-quinoline 
derivatives studied have shown to be only slightly more active than their 4-hydroxy-
quinoline isomers. 
Then, we may conclude that the better pharmacodynamic performance of 
quinolone derivatives may be offset by their poorer bioavailability (considering the lower 
value of CLogP). Alternatively, it may be postulated that 4-hydroxy-quinoline 3-esters 
bind differently to the same site (Qo) or switch to the Qi site of the bc1 complex. 
Other factors supporting the hypothesis of binding to Qi site are the capacity 
exhibited by selected quinolone derivatives to partially overcome the atovaquone 
resistance (no cross-resistance observed) and the evidence that 4(1H)-pyridones bind to 
this site. 
The docking studies performed in this project demonstrated that the 2-aryl and 3-
aryl selected compounds can bind at the Qi site, as observed for 4(1H)-pyridones, which 
may explain the ability of some of them overcome parasite Qo-based atovaquone 
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resistance. Results indicate that the 2-aryl and 3-aryl substituted compounds occupy 
similar positions in the protein-site, keeping the hydrophobic interactions. The quinolone 
core establishes key H-bonding interactions with the residues His201, Ser205 and Asp228 
and these are conserved along the range of compounds studied. 
However, attempts to establish a correlation between GoldScore results and 
observed antimalarial activities did no yield good results, probably due to the following 
reasons: GoldScore data reflects the mode and strength of ligand-protein interactions; the 
study only considered one target (the compounds studied may bind to Qi and Qo); the 
docking results do not account for many conditions influencing the activity of the 
compounds (such as membrane permeability or solubility); the receptor model of the 
protein is a rigid system with the amino acid residues fixed in a crystallized position 
(while in a biological setting the protein is a flexible structure that can adapt to its 
environment); and there are differences between the bovine heart bc1 (protein used for 
this study) and the P. falciparum bc1, especially in the hydrophobic pocket. Compounds 
of the 2-aryl series demonstrated higher GoldScore results (64.4-80.8) than those of the 
3-aryl series (53.5-67.8), indicating a stronger interaction between the protein and the 
compound at the Qi pocket. However, this may not mean that the 2-aryl substituted 
compounds tested are more active as antimalarial agents than their 3-aryl analogues. 
Future work should be performed to optimize a homology model of P. falciparum 
bc1 (Qi site) and the inhibition may be evaluated directly in the complex (not only 
accounting the in vivo antimalarial activity in specific strains) to provide a better 
correlation between the GoldScore and the IC50. Considering the cardiotoxicity revealed 
for 4(1H)-pyridones and the possibility that some of the quinolone derivatives tested bind 
to the same site pocket, additional studies regarding the cardiotoxicity of these 
compounds should be performed.  
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4.5. Experimental 
CLogP calculations 
CLogP calculations were performed using ALog PS2.1, available in 
http://www.vcclab.org/lab/alogps/. 
Biological activity 
Laboratory-adapted chloroquine and mefloquine-resistant Plasmodium 
falciparum Dd2 and chloroquine sensitive P. falciparum 3D7 were continuously cultured. 
Staging and parasitaemia were determined by light microscopy of Giemsa-stained thin 
blood smears. Antimalarial activity of the compounds was determined using the SYBR 
Green I assay with modifications. Briefly, early ring stage parasites (> 90% of rings, 3% 
haematocrit and 1% parasitaemia) were tested in triplicate in a 96-well plate and 
incubated with the compounds for 48h (37 ºC, 5% CO2), parasite growth was assessed 
with SYBR Green I. Each compound was tested at concentrations ranging from 10-0.002 
µM. Fluorescence intensity was measured with a multi-mode microplate reader (Dynex 
Triad, Alfagene), with excitation and emission wavelengths of 485 and 535 nm, 
respectively, and analysed by nonlinear regression using GraphPad Prism 5 demo version 
to determine IC50. 
Docking simulations 
Compounds for docking simulations were selected from published papers by the 
groups of Roman Manetsch191 and Paul O’Neill118. The structures were built in 
ChemDraw and the three-dimensional minimum energy structures were created via 
energy minimization using the Merck molecular force field (MMFF) 94, within the 
SPARTAN ’08.192  
Each compound was modelled in silico using the crystal structure of bovine heart 
cytochrome bc1 protein (Protein Data Bank accession code 4D6U). The structure of 
GSK932121, bound in the Qi site of protein 4D6U, was removed using GOLD and the 
compound in study was then docked. 
All molecular docking experiments were performed by GOLD docking suite 
version 5.2 using piecewise linear potential (PLP) as the fitness function. Ten independent 
GA runs were performed for each ligand. Default settings were used, except the “allow 
early termination” setting (in the “fitness and search option”) that was “turned off”.  
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5.1. Tuberculosis and malaria co-infection 
Tuberculosis (TB) and some parasitic diseases in humans, such as malaria, exhibit 
an extensive distribution and are endemic in many regions of the world, especially in 
developing countries, and the co-infection with the two pathogens is common. Some 
studies have showed that the immune response in the co-infection situation is modified, 
resulting in increased complexity of control and prevention of tuberculosis and of 
malaria.194,195 
TB is an infectious bacterial disease caused by Mycobacterium tuberculosis that 
most commonly affects the lungs causing cough (sometimes with sputum or blood), chest 
pain, weakness, weight loss, fever and night sweats. Despite available treatments for this 
disease, the tuberculosis treatment is a global health problem since the pathogen agent 
has demonstrated an increased prevalence of multi and extensive drug-resistant strains 
(MDR and XDR, respectively). The resistance phenomenon may result, mostly, from the 
misuse of current antituberculosis chemotherapeutic regimens. These involve the use of 
combinations of, at least, three different drugs, must be taken for six months or longer 
and possess some characteristic side effects. So, the development of new and effective 
antimycobacterial agents, able to shorten the treatment duration and to treat MDR and 
XDR tuberculosis infections, is a priority.117,196 
Over the past years, several subclasses of quinoline derivatives, incorporating 
various substituents in the structure of the quinoline core, have demonstrated diverse 
bioactivities, including high activity against bacterial pathogens. Among these studies, 
one publication on some quinolone derivatives as promising scaffolds for the 
development of new antituberculosis agents came to light117 encourageding us to explore 
further the quinolone chemotype in the context of TB chemotherapeutics. 
Thus, in parallel to the study of quinolone 3-esters directed to the plasmodial 
cytochrome bc1 of P. falciparum, the author of this thesis was involved in a research 
project, in cooperation with members of the O’Neill research group, directed to the 
synthesis of a small library of quinolones with potential activity against M. tuberculosis, 
acting as inhibitors of the mitochondrial electron transport chain of this bacillus.  
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5.2. Quinolones with potential antituberculosis activity 
Based in the structure of previously synthesized quinolones targeting the 
therapeutic target PfNDH2
118,119, a similar template structure was considered and the 
synthetic routes were adapted for the synthesis of compound 128. 
 
Some results of this investigation were included in a publication submitted to 
Journal of Medicinal Chemistry: 
Nixon, G. L.; Gibbons, P. D.; Leung, S. C.; Hong, W. D.; Amewu, R.;  Stocks, P. 
A.; Stachulski, A.; Horta, P.; Cristiano, M. L. S.; Shone, A. E.; Moss, D.; Ardrey, A.; 
Sharma, R.; Warman, A. J.; Bedingfield, P.; Fisher, N. E.; Aljayyoussi, G.; Mead, S.; 
Caws, M.; Berry, N. G.; Ward, S. A.; Biagini, G. A.; O’Neill, P. M.: “Rational design, 
synthesis and biological evaluation of heterocyclic quinolones; targeting the respiratory 
chain of Mycobacterium Tuberculosis”, April (2016). 
5.2.1. Synthesis of quinolone 128 and of its prodrug 129 
The proposed retrosynthetic approach to quinolone 128 is depicted in Scheme 5.1. 
Considering a convergent synthesis, the preparation of the two main blocks, ketone 122 
(Scheme 5.2) and oxazoline derivative 127 (Scheme 5.3), was undertaken. Thereafter, 
these two blocks were coupled through a cyclisation reaction, to afford the desired 
quinolone scaffold 128 (Scheme 5.4). The versatility of the starting materials enable the 
possibility to incorporate different functionalities (Y and X), allowing for the synthesis 
of several other quinolone derivatives, based on structure 128. 
Scheme 5.1 – Retrosynthetic analysis of quinolone derivative 128. 
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Scheme 5.2 – Preparation of synthetic block 1. Representation of the synthetic approach followed 
to afford ketone 122. Conditions: (a) CuI, TMEDA, Cs2CO3, DMSO, 110 ºC, 24 hours; (b) Dry 
diethyl ether, n-BuLi (2.5M in hexane), -78 ºC to room temperature, 3 hours. 
 
Scheme 5.3 – Preparation of synthetic block 2. Representation of the synthetic approach followed 
to afford oxazoline 127. Conditions: (a) THF:H2O (1:1), 0 ºC to room temperature, 3 hours; (b) 
Chlorobenzene, ZnCl2, 140 ºC, 18 hours. 
 
Scheme 5.4 – Representation of the synthetic approach to the preparation of quinolone 128 and 
of its prodrug 129. Conditions: (a) TFSA, n-butanol, 130 ºC, 2 days; (b) tButOK, dry THF, acetyl 
chloride, room temperature, 90 minutes. 
The reaction conditions for coupling the phenol derivative 119 to 2,5-
dibromopyridine 118 were improved, from an yield of around 17%, using sodium hydride 
and DMF (where some quantities of a side product from the reaction between 118 and 
DMF has resulted) to an yield of around 90%. This improvement was achieved following 
the Ullmann reaction (Scheme 5.5), a copper-catalysed coupling between an aryl iodide 
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or bromide (118) and a phenol (119) to afford diaryl ether (120). Most copper salts are 
insoluble in organic solvents and the reactions require higher temperatures (125–220 ºC), 
limiting the utility of this methodology. Hence, new methods have been developed to 
synthesize diaryl ethers under relatively mild reaction conditions (110–120 ºC), for 
example by adding a base (Cs2CO3) and/or a ligand for metal ions (TMEDA - 
tetramethylethylenediamine) that forms stable and soluble complexes in organic 
solvents.197,198 
 
Scheme 5.5 – Schematic representation of the mechanism proposed for the coupling reaction, 
following the Ullmann methodology.197,198  
Ketone 122 was then synthesized, in good yield (59%), by first treating 120 with 
n-BuLi to generate an aryl-lithium intermediate, which further reacted with N,N-
dimethylpropionamide. Henry Gilman found an important organolithium transformation 
and described the lithium-halogen exchange199,200 that may explain the formation of the 
intermediate 5-lithio-2-(4-(trifluoromethoxy)phenoxy)pyridine. However, the 
mechanism for the formation of the lithium intermediate is not fully understood. As for 
Grignard reagents, aryl-lithium compounds, are rarely isolated (they are formed in 
solution and used immediately in the desired reaction). The organometallic compound 
formed from 120 has a strongly polarized carbon-metal bond (Cδ--Liδ+), turning the 
carbon from an electrophilic carbon into a nucleophilic centre that can attack the carbonyl 
carbon of the N,N-dimethylpropionamide 121.153 The mechanism proposed for this step 
is represented in Scheme 5.6. 
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Scheme 5.6 – Schematic representation of the mechanism proposed for the synthesis of ketone 
122, from the bromide derivative 120.153,199,200 
Oxazoline 127 was synthesised (76% yield) from the isatoic anhydride 125, 
previously obtained from 4-methoxy anthranilic acid 123 (85% yield). Isatoic anhydride 
is a very useful intermediate in synthesis and there are different methodologies commonly 
used for its preparation. Among them, the cyclisation of anthranilic acid with a carbonic 
acid derivative (e.g. ethyl chloroformate, phosgene or phosgene derivatives) was chosen 
for this project. Diphosgene is related to phosgene (a chemical weapon during World War 
I) and is comparably toxic. Although its handling required the observation of several 
safety measures, diphosgene is more conveniently handled than phosgene, since it is a 
liquid whereas phosgene is a gas. The reaction of an anthranilic acid derivative with 
phosgene is well documented in the literature and can be adapted for the reaction with 
diphosgene.201 From the isatoic anhydride synthesized, and in the presence of anhydrous 
zinc chloride (a moderate-strength Lewis acid) in dry chlorobenzene, formation of the 
desired oxazoline 127 occurred, following the mechanism proposed in Scheme 5.7.202 
 
Scheme 5.7 – Schematic representation of the mechanism proposed for the synthesis of isatoic 
anhydride 125 and for its conversion into the oxazoline derivative 127.201,202 
The strategy followed for the coupling of the synthetic blocks 1 (122) and 2 (127), 
to afford the target quinolone derivative 128, is an adaptation of Friedländer synthesis, an 
acid-catalysed reaction (using trifluoromethanesulfonic acid – TFSA). Quinolone 128 
was recovered with a yield of 39%. Several mechanisms were proposed to describe this 
reaction.135,203 Scheme 5.8 presents one of these mechanisms. It is proposed that, initially, 
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the oxazoline 127 is protonated twice in TFSA and the resulting intermediate undergoes 
a ring-opening reaction to produce a reactive dicationic species that further reacts with 
the ketone 122, or more specifically with its enol form, following the Friedländer 
methodology.204 
 
Scheme 5.8 – Schematic representation of the mechanism proposed for the synthesis of quinolone 
derivative 128.135,201–204 
Due to the poor solubility of 128 and considering some biological results 
(discussed below), an acetate prodrug of 128 (129) was synthesized by esterification of 
acetyl chloride with the keto/enol form of quinolone 128, in 56% yield (Scheme 5.4). 
5.2.2. Investigation of antituberculotic activity 
At the Liverpool School of Tropical Medicine, the quinolone 128 was tested in 
vitro against Mycobacterium tuberculosis (H37Rv strain) and its pharmacokinetic profile 
was evaluated in vivo (Wistar rats). The antituberculotic activity of 128 was screened 
using the mycobacteria growth indicator tube (MGIT) assay, where a specific compound 
is converted to a fluorescent compound in presence of M. tuberculosis. 
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The MGIT assay result for compound 128 (Figure 5.2) was compared to those 
exhibited by isoniazid and rifampicin (antituberculostatic drugs), under the same 
conditions. From the analysis, it was possible to conclude that quinolone 128 has 
demonstrated an activity profile that overlaps with the “no drug” assay. This data could 
mean that the quinolone 128 is not active against M. tuberculosis or, alternatively, the 
apparent lack of activity could result from solubility problems. Another quinolone 
derivative (130, MTC420, Figure 5.1) synthesized by a member of Paul O’Neill’s group, 
was tested in the same conditions and demonstrated much better activity with potency 
approaching that of isoniazid.   
 
Figure 5.1 – Structural representation of quinolone derivative (130), synthesized by a member of 
Paul O’Neill’s group and screened for antituberculotic activity together with compounds 128 and 
129. 
Therefore, the project was directed to the synthesis and optimisation of analogues 
of 130. The synthetic approach to compound 130 is present in Scheme 5.9. 
For the synthesis of 130, 4-bromopropiophenone 131 was first converted to a 
more reactive 4-iodopropiophenone 132 by an aromatic substitution catalysed by 
copper(I) iodide in combination with N,N-dimethyl-1,2-diaminoethane. The amination of 
132 was performed following the Buchwald-Hartwig methodology, using 
tris(dibenzylidene-acetone)dipalladium(0) [(Pd2(dba)3] and Xantphos (4,5-
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bis(diphenylphosphino)-9,9-dimethylxanthene) to afford the ketone side chain 134. 
Oxazoline 135 was synthesized following the methodology used for the synthesis of 127. 
The strategy followed for the coupling of 134 and 135, to afford the target quinolone 
derivative 130, is similar to that one used for the synthesis of 128 (Friedländer synthesis 
– see Scheme 5.8 as example). 
 
Scheme 5.9 – Representation of the synthetic approach to the preparation of quinolone 130. 
Conditions: (a) CuI, N,N-dimethyl-1,2-diaminoethane, NaI, 1,4-dioxane, 110oC, 24 hours; (b) 
Pd2(dba)3, Xantphos, NaOtBu, 1,4-dioxane, 110oC, 24 hours; (c) CF3SO3H, n-BuOH, N2, 130 oC, 
24 hours. 
 
 
Figure 5.2 – Results of the MGIT assay for quinolones 128 and 130. 
Isoniazid 
Rifampicin 
Quinolone 128 
Quinolone 128 + 2% DMSO 
Quinolone 130 
Quinolone 130 + 2% DMSO 
No Mtb 
No drug 
No drug + 2% DMSO 
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Additionally, the antiplasmodial activities of 128 and its prodrug (129) were also 
evaluated and the results are promising, both against sensitive and 
chloroquine/mefloquine-resistant strains (see Table 5.1). 
Table 5.1 - In vitro antimalarial activities for quinolone 128 (parent quinolone) and for its 
acetate prodrug 129. 
Compound 
Antiplasmodial activity (IC50; μM); Average ± SD 
3D7 Dd2 
128 0.018±0.009 0.017±0.002 
129 0.070±0.046 0.048±0.002 
 
In addition to the solubility issues exhibited by quinolone 128, pharmacokinetic 
analysis shown in Figure 5.3 shows that an increasing dose of 128 (from 10 mg/kg to 50 
mg/kg) did not translate into increase of exposure. However, a 10-fold increase was 
observed when using the acetate prodrug 129 at 10 mg/kg and an increase of over 30-fold 
at 50 mg/kg, compared to the exposure of 128. The exposure has increased 5-6 times on 
increasing the dose of 129 from 10 mg/kg to 50 mg/kg. 
 
Figure 5.3 – Pharmacokinetic profiles of quinolone 128 (parent quinolone) and of its acetate 
prodrug 129. 
The CYP450 inhibition by compounds 128 and 130 was also tested, using an assay 
where a substrate for each P450 is provided and the oxidation (metabolism) of this 
substrate results in the formation of a fluorescent metabolite. For each CYP450 isoform 
assay study, only one specific isoform is expressed. The results were compared with the 
data obtained for the incubation with the vehicle control (where maximum fluorescence 
intensity is observed) and for the positive controls using 10 μM ketoconazole (a known 
CYP3A4 inhibitor - Figure 5.4 and Figure 5.5), 30 µM sulfaphenazole (a known CYP2C9 
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inhibitor - Figure 5.6 and Figure 5.7) and 10 μM montelukast (a known CYP2C8 inhibitor 
- Figure 5.8 and Figure 5.9). 
 The results (Figure 5.4 and Figure 5.5) indicate that 128 and 130 did not lead to 
inhibition of CYP3A4 at the three concentrations in study. The fluorescence measured 
for both compounds is higher than for the vehicle controls and these results are not well 
understood since the pre-incubation of the drugs showed no inherent compound 
fluorescence. These compounds did not exhibited inhibition for CYP3A5 (results not 
shown). 
 
Figure 5.4 – CYP3A4 inhibition assay for quinolone 128 at 0.1 μM, 1 μM and 10 μM (here 
defined as RKA259), considering ketocozanole (10 μM) as positive control. 
 
Figure 5.5 – CYP3A4 inhibition assay for quinolone 130 at 0.1 μM, 1 μM and 10 μM (here 
defined as MTC420), considering ketocozanole (10 μM) as positive control. 
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 The quinolone 130 resulted in little or no inhibition of CYP2C9 (Figure 5.7), while 
128 exhibited an inhibitory capacity dependent on dose, decreasing the activity of this 
isoform by 43% at 10 µM concentration (Figure 5.6). 
  
 
 
Figure 5.6 – CYP2C9 inhibition assay for quinolone 128 at 0.1 μM, 1 μM and 10 μM (here 
defined as RKA259), considering sulfaphenazole (30 μM) as positive control. 
 
Figure 5.7 – CYP2C9 inhibition assay for quinolone 130 at 0.1 μM, 1 μM and 10 μM (here 
defined as MTC420), considering sulfaphenazole (30 μM) as positive control. 
 While 128 showed strong inhibitory capacity (Figure 5.8), 130 only exhibited 
moderate inhibition on CYP2C8 (Figure 5.9), reducing the activity of this isoform in 60% 
at 10 µM of 128 and in 39% at 10 µM of 130. In contrast, atovaquone (10 µM) did not 
evidence inhibition capacity towards CYP2C8. 
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Figure 5.8 – CYP2C8 inhibition assay for quinolone 128 at 1 μM, 10 μM and 100 μM (here 
defined as RKA259), and for atovaquone (10 μM), considering montelukast (10 μM) as positive 
control. 
 
Figure 5.9 – CYP2C8 inhibition assay for quinolone 130 at 1 μM, 10 μM and 100 μM (here 
defined as MTC420), and for atovaquone (10 μM), considering montelukast (10 μM) as positive 
control.   
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5.3. Summary, conclusions and future work 
In general, the reaction conditions followed in the synthetic steps required for the 
preparation of quinolone derivatives 128 and 129 (with potential activity against M. 
tuberculosis) were optimized. However, considering the hazards inherent to some 
reagents used on these synthetic routes, some alternatives should be considered. 
As described for many of the quinolone 3-esters discussed in the previous chapter, 
also the quinolones proposed in this section have demonstrated solubility problems and 
these may contribute to the negligible activity of compound 128. Quinolone derivative 
130 has activity close to isoniazid versus M. tuberculosis and, therefore, synthesis of some 
derivatives should be considered, in view of selecting analogues with improved properties 
for development. 
The solubility liabilities demonstrated for quinolone 128 reflected in a poor 
pharmacokinetic profile, but this problem was solved with the synthesis and use of the 
acetate prodrug 129. 
Quinolone 128 did not inhibit CYP3A4 and CYP3A5, but exhibited some 
potential inhibitory capacity towards CYP2C9 and strong inhibitory capacity towards 
CYP2C8, while 130 did not inhibit CYP3A4, CYP3A5 and CYP2C9 but exhibited 
moderate inhibitory capacity towards CYP2C8. 
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5.4.Experimental 
Solvents, reagents and other compounds; Monitoring and purification; 
Spectroscopic analysis; and other analysis 
These specifications are found in the experimental section of the previous chapter 
(Synthesis of quinolone 3-esters with potential activity against P. falciparum). 
Preparation of the synthetic block 1: synthesis of ketone 122 
5-Bromo-2-(4-(trifluoromethoxy)phenoxy)pyridine (120) 
  
2,5-dibromopyridine 118 (2.00 g; 8.44 mmol; 1 eq.), 4-(trifluoromethoxy)-phenol 
119 (1 eq.), copper (II) iodide (0.1 eq.), tetramethylethylenediamine (0.1 eq.) and cesium 
carbonate were mixed in DMSO (15 mL), under a nitrogen atmosphere. The reaction was 
stirred at 110 ºC for 24 hours. The mixture was cooled to room temperature and filtered 
by using Celite to remove the inorganic residues. From the extraction in DCM and brine, 
the organic layer was dried under MgSO4 anhydrous, filtered, concentrated under vacuum 
and purified by column chromatography in silica gel (eluting with 30% of DCM in 
hexane), to afford the desired product as a yellow oil (2.55 g; 7.63 mmol; 90%). 
1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.80 (d, 1H), 7.24 (d, 2H), 7.15 (dd, 
2H), 6.89 (d, 1H); 13C NMR (101 MHz, CDCl3) δ 162.45, 152.38, 148.68 (2C), 142.58, 
122.80 (2C), 122.72 (2C), 114.38, 113.71 (2C); MS m/z (ES) [M + H]+ C12H8NO2F3Br 
requires 333.9690, found 333.9689. 
1-(6-(4-(trifluoromethoxy)phenoxy)pyridin-3-yl)propan-1-one (122) 
  
To a solution of 5-bromo-2-(4-(trifluoromethoxy)phenoxy)pyridine 120 (2.00 g; 
5.99 mmol) in dry diethyl ether (40 mL), at -78 ºC, and under nitrogen atmosphere, was 
added, slowly, a 2.5M solution of n-butyl lithium in hexane (2.88 mL; 1.2 eq.). After 1 
hour, at -78 ºC, N,N-dimethylpropionamide 121 (1.2 eq) was added and the reaction 
temperature was allowed to rise to room temperature, under stirring, for 2 hours. The 
reaction mixture was quenched with saturate NH4Cl solution, the organic layer was 
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separated and the aqueous layer extracted with diethyl ether (2 x 30 mL). The organic 
layers were combined, washed with brine and dried over MgSO4, filtered and 
concentrated under vacuum. The crude product was purified by column chromatography 
(eluting with 70% of DCM in hexane) to give the pure product as yellow oil (1.10 g; 3.55 
mmol; 59%). 
1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.30 (d, 1H), 7.32 – 7.27 (m, 2H), 
7.22 – 7.17 (m, 2H), 7.00 (d, 1H), 2.96 (q, CH3CH2CO), 1.23 (t, CH3CH2CO); 13C NMR 
(101 MHz, CDCl3) δ 198.50 (CH3CH2CO), 166.09, 151.89, 149.24 (2C), 139.75, 128.62, 
123.17 (2C), 122.78 (2C), 111.91 (2C), 32.21 (CH3CH2CO), 8.36 (CH3CH2CO); MS m/z 
(ES) [M + H]+ C15H13F3NO3 requires 312.0848, found 312.0857. 
Preparation of the synthetic block 2: synthesis of oxazoline 127 
4-Methoxy-isatoic anhydride (125) 
  
4-methoxy anthranilic acid 123 (3.00 g; 17.95 mmol) was dissolved in a mixture 
of THF:H2O (1:1; 60mL), under stirring, at 0 ºC. Trichloromethyl chloroformate 124 (1.5 
eq.) was added drop-by-drop, very carefully and slowly. The reaction temperature was 
allowed to rise to room temperature and the mixture was kept stirring for 3 hours. The 
organic solvent was carefully removed under reduced pressure to leave the water solution 
and some precipitate, that was filtrated, carefully washed with water and dried under 
vacuum to give the product as an off-white solid (2.94 g; 15.20 mmol; 85%). 
1H NMR (400 MHz, (CD3)2SO) δ 7.84 (d, 1H), 6.84 (d, 1H), 6.59 (s, 1H), 3.86 (s, 
OCH3); 
13C NMR (101 MHz, (CD3)2SO) δ 166.23, 159.29, 147.79, 143.99, 131.41, 
112.00, 103.25, 98.87, 56.27 (OCH3); MS m/z (CI) [M + H + NH3]
+ C9H11N2O4 requires 
211.0718, found 211.0820. 
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2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-5-methoxyaniline (127) 
  
4-methoxy-isatoic anhydride 125 (2.31 g; 11.98 mmol) was suspended in 
chlorobenzene (30 mL), under nitrogen, and stirred for 15 minutes. 2-amino-2-
methylpropan-1-ol 126 (1.4 eq) was added to the suspension via a syringe, followed by 
zinc chloride (0.1 eq). The mixture was refluxed at 140 °C for 18 hours. The solvent was 
removed under reduced pressure and the residue extracted with ethyl acetate (2 x 25 mL), 
washed with brine, dried over MgSO4, filtered and concentrated under vacuum. 
Purification by column chromatography, eluting with 15% of ethyl acetate in hexane, 
gave the desired oxazoline 127 as a white solid (2.00 g; 9.06 mmol; 76%). 
1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 6.26 (d, 1H), 6.17 (d, 1H), 4.00 (s, 
CH2), 3.79 (s, OCH3), 1.37 (s, C(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 163.09, 162.29, 
150.43 (CNH2), 131.50, 103.97, 103.05, 99.69 (2C), 67.88, 55.53 (OCH3), 29.12 (2C); 
MS m/z (CI) [M + H]+ C12H17N2O2 requires 221.1290, found 221.1281. 
Coupling of synthetic blocks 1 and 2: cyclisation reaction to give the desired 
quinolone scaffold 128 
7-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenoxy)pyridin-3-yl)-4-oxo-quinoline 
(128) 
  
2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-5-methoxyaniline (oxazoline 127; 0.82 
g; 3.72 mmol) was added to a solution of ketone 122 (1 eq.) and trifluoromethanesulfonic 
acid (TFSA, 1.4 eq.) in n-butanol (10 mL). The reaction mixture was heated to 130 °C, 
under nitrogen, and stirred for 2 days. The solvent was removed under reduced pressure 
and water (20 mL) was added. The aqueous solution was extracted with ethyl acetate (3 
× 20 mL), dried over MgSO4, filtered and concentrated under vacuum. The product was 
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purified by column chromatography (eluting with 75% of ethyl acetate in hexane) to give 
the desired quinolone 128 as a white solid (0.64 g; 1.45 mmol; 39%). 
1H NMR (400 MHz, (CD3)2SO) δ 11.49 (s, NH), 8.36 (d, 1H), 8.10 (d, 1H), 8.02 
(d, 1H), 7.48 (d, 2H), 7.36 (d, 1H), 7.35 (d, 1H), 7.30 (d, 1H), 6.96 (d, 1H), 6.91 (d, 1H), 
3.83 (s, OCH3), 2.51 (s, CH3); 
13C NMR data not obtained due to poor solubility in all 
available deuterated solvents; MS m/z (ES) [M + Na]+ C23H17F3N2O4Na requires 
465.1038, found 415.1036; CHN for C23H17F3N2O4 requires C 62.43%, H 3.88%, N 
6.33%, found C 62.24%, H 3.96%, N 6.32%. 
Acetate 7-methoxy-3-methyl-2-(6-(4-(trifluoromethoxy)phenoxy)pyridin-3-yl)-4-yl-
quinoline (129) 
  
A mixture of quinolone 128 (0.40 g; 0.90 mmol) and potassium tert-butoxide 
(1.25 eq.) in anhydrous THF (30 mL) was stirred for 1 hour at room temperature. Acetyl 
chloride (2.0 eq) was added and the mixture was stirred 30 min. The reaction was 
quenched with water (approximately 10 mL) and the mixture was concentrated under 
reduced pressure. Water (approximately 10 mL) was added to the residue and the product 
was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated. The resulting residue was purified by column 
chromatography (eluting with 40% of ethyl acetate in hexane) to give the desired ester as 
a white solid (0.24 g; 0.50 mmol; 56%). 
1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 7.68 (d, 1H), 7.31 – 7.26 (m, 4H), 
7.26 – 7.20 (m, 3H), 7.10 (d, 1H), 3.96 (s, , OCH3), 2.53 (s, CH3), 2.28 (s, COCH3); 13C 
NMR data not obtained due to poor solubility in all available deuterated solvents; MS 
m/z (ES) [M + H]+ C25H20F3N2O5 requires 485.1324, found 485.1342; CHN for 
C25H19F3N2O5 requires C 61.71%, H 4.35%, N 5.76%, found C 62.36%, H 4.15%, N 
5.80%. 
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Preparation and characterization of 2-(4-(3,3-difluoropyrrolidin-1-yl)phenyl)-
5,7-difluoro-3-methyl-4-oxo-quinoline (130) 
 
For the synthesis of 130, 4-bromopropiophenone 131 was first converted to a 
more reactive 4-iodopropiophenone 132 by an aromatic reaction catalysed by copper(I) 
iodide in combination with N,N-dimethyl-1,2-diaminoethane. The amination of 132 was 
performed following the Buchwald-Hartwig methodology using tris(dibenzylidene-
acetone)dipalladium(0) [(Pd2(dba)3] and Xantphos (4,5-bis(diphenylphosphino)-9,9-
dimethylxanthene) to afford the ketone side chain 134. 
Oxazoline 135 (1 eq.), previously synthesized following the same methodology 
than the used for the synthesis of 127, was added to a solution of ketone 134 (1 eq.) and 
trifluoromethanesulfonic acid (TFSA, 0.2 eq.) in anhydrous n-butanol (10 mL). The 
reaction mixture was heated to 130 °C, under nitrogen, and stirred for 24 hours. The final 
mixture was cooled and the solvent removed under reduced pressure. Saturated NaHCO3 
solution was added and the resulting aqueous solution was extracted with ethyl acetate (3 
× 20 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered and concentrated under vacuum. The product was purified by trituration to give 
the desired quinolone 130 as a white solid (56%). 
Melting range: 316-317 °C; 1H NMR (400 MHz, (CD3)2SO) δ 7.41 (d, 2H), 7.17 
(d, 1H), 7.01 (m, 1H), 6.78 (d, 2H), 3.79 (t, 1H), 3.56 (t, 1H), 2.59 (tt, 1H), 1.87 (s, 1H); 
13C NMR (101 MHz, (CD3)2SO) δ 175.38, 164.09, 148.09, 147.72, 142.82, 130.34, 
129.16, 126.71, 122.79, 116.32, 111.98, 111.61, 99.37, 98.82, 54.96, 45.75, 33.72, 12.54; 
MS m/z (ES) [M + H]+ C20H16F4N2ONa requires 399.1096, found 399.1093. 
Biological activity – Mycobacteria growth indicator tube 
Cultures of M. tuberculosis H37Rv were continuously cultured until a mid-log 
growth phase was reached, in a liquid growth medium specially used for culture of 
Mycobacterium (Middlebrook 7H9 Broth) with addition of 10% albumin–dextrose–
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catalase solution (Becton Dickinson), glycerol and Tween 80. The antituberculotic 
activity was determined using the mycobacteria growth indicator tube (MGIT) assay, 
where a specific compound is converted to a fluorescent compound in presence of M. 
tuberculosis. Each compound was tested at concentrations ranging from 10 µM to 0.08 
µM and was co-incubated with replicating Mycobacterium tuberculosis (7 days, 37°C) 
using a microplate Alarmarblue assay (MABA). Measurements of well absorbance at 570 
and 600 nm recorded using an Opsys MR plate reader were determined to calculate IC50 
values for the compounds tested. 
In vitro CYP450 inhibition 
CYP450 VIVID® inhibition kits were purchased from Invitrogen Life 
Technologies™.  Briefly, compounds were tested at a final concentration of 10, 1 and 0.1 
µM alongside with a relevant positive control for the isoform of interest and a solvent 
control.  The assay utilised a substrate, specific to the isoform, which produced a 
fluorescent metabolite as it underwent oxidation by the P450 enzyme.  Inhibition of the 
enzyme led to reduced fluorescent output.  The assay was carried out in kinetics mode, 
with readings taken every minute, during 1 hour. 
Pharmacokinetic studies in Male Wistar rats 
Male Wistar rats (180 – 250 g) (n=4) were purchased from Charles River 
Laboratories, UK and allowed to acclimatise for 1 week in controlled conditions 
(temperature 23 ± 3 °C; relative humidity 50 ± 10 %; light-dark cycle 12 h). The animals 
were provided with feed pellet and filtered water ad libitum. Each rat received an oral 
dose of the relevant compound (10 or 50 mg/kg) in PEG400 (100 %) (5 mL/kg) via 
gavage needle. At various time-points, the rats were anaesthetised using isoflurane and a 
blood sample (< 300 µL) was taken from a superficial vein in the tail. The blood was 
properly treated, an aliquot of plasma was removed (100 µL) and then the plasma 
concentration of drug was determined. 
 
 
 
  
Chapter 5 - Synthesis of quinolone derivatives and evaluation of activity against M. tuberculosis 
 
 
206 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
  
Conclusions 
 
 
208 
  
Conclusions 
 
209 
Conclusions 
 
General synthetic approaches to afford quinolone 3-esters with chemical diversity 
were devised and optimized, generally using nitro arenes as starting compounds. Reaction 
conditions for the reduction of nitro arenes (ortho and/or meta substituted) and for the 
coupling of the corresponding anilines with DEEMM were optimized to give high yield 
of the desired products (anilines and α,β-unsaturated ester, respectively). 
The cyclisation step of the enamine derivatives to afford the quinolone scaffolds, 
following the thermally driven Gould-Jacobs intramolecular cyclisation methodology, 
posed some problems. The yields of this step varied from 3% to 62% and for some of the 
enamines derivatives no product was recovered. The reaction proved to be dependent on 
concentration. The poor solubility of the quinolone derivatives rendered difficult their 
isolation, purification and characterization. The high temperatures required for this step 
and the high boiling point of the solvent (Dowtherm A) may lead to the degradation of 
susceptible groups and to side reactions, as well as to difficulties in the removal of the 
solvent. 
To overcome those problems, the synthesis of 4-chloroquinoline derivatives (with 
improved solubility) mediated by POCl3 was considered. However, as for the Gould-
Jacob methodology, the possibility of obtaining a mixture of structural isomers from the 
cyclisation reaction of the enamine, due to different patterns of aromatic substitution, and 
to the possibility of oxo-quinoline/hydroxy-quinoline tautomerism should not be 
neglected. 
4-Chloroquinoline derivatives steamed as versatile building blocks for the 
preparation of 4-oxo-quinolines, enabling the introduction of chemical diversity at 
positions 6 and/or 7 of the quinoline prior to conversion into the corresponding quinolone 
structure. The structure of a 4-chloroquinoline derivative (compound 56) was elucidated. 
Four conformers were predicted by theoretical calculations and found in the as-deposited 
argon-matrix. These conformers, related to rotations in the ester moiety, show low 
predicted barriers for conformational interconversion what may facilitate structural 
adjustments of the ethyl ester moiety in the enzyme pocket, maximizing drug-target 
interactions and improving the pharmacodynamic profile. 
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Considering that the quinolone derivatives studied in this thesis are not N1 
substituted (contrary to the conventional quinolone antibacterials – ciprofloxacin, 
norfloxacin and levofloxacin), the possibility of tautomerization is a reality. In the 
compounds under investigation tautomerism may translate in alteration of chemical and 
physical properties, with consequences for pharmacokinetic and pharmacodynamic 
profiles, especially because the N-H and 4-oxo groups are believed to be involved in 
important interactions inside the Qo site of the enzyme pocket. 
 From a detailed study of tautomerism in the 82 series (quinolone 3-esters with a 
methyl group at position 7 or 5), the preference for the hydroxy-quinoline form was 
evident. The lower energy of the hydroxy-quinoline form is related to the presence of an 
intramolecular H-bond interaction, O−H···O(ester carbonyl), and to the highest aromatic 
character exhibited by the heterocyclic ring of quinoline in the enol form. When 
evaluating compound without a 3-ester group (92 series), the keto form was considered 
as the most stable form but the energy barriers between the 4-hydroxy-quinoline and 4-
oxo-quinoline forms were found to be relatively close together, so these tautomers can 
coexist and contribute to the equilibrium populations. 
While the substitution pattern on the carbocyclic part of the quinolone bicyclic 
structure (7- or 5-substituted derivatives) does not appear to interfere with the 
lipophilicity/solubility profile within the range of compounds studied, tautomerism does 
interfere. The 4-hydroxy-quinoline forms appear more adequate from a bioavailability 
viewpoint but, on the other side, it is expected that the 4-oxo-quinoline 3-ester forms 
present a much better pharmacological profile as P. falciparum bc1 inhibitors acting at 
the Qo site. However, the activity results showed that the 4-oxo-quinoline derivatives 
were only slightly more active than their 4-hydroxy-quinoline analogues. 
These results may support the hypothesis of quinolone binding to another site (for 
example to Qi site). It was reported that some quinolones partially overcome the 
atovaquone resistance and, additionally, reports that selected 4(1H)-pyridones (with 
similar structure to quinolone derivative) bind to Qi site also came to light. The docking 
simulation performed during our studies demonstrated that the quinolones selected can 
bind at the Qi site, as observed for 4(1H)-pyridones. The quinolone core appears to be 
positioned to enable formation of key hydrogen bonds with the residues His201, Ser205 
and Asp228. 
2-Aryl quinolones were synthesized and tested against M. tuberculosis. The 
solubility liabilities demonstrated for quinolone 128 reflected in a poor pharmacokinetic 
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profile, which was solved through the synthesis of its acetate prodrug (compound 129). 
Although promising, quinolone 130 demonstrated to be as active as isoniazid against M. 
tuberculosis and, therefore, synthesis of some derivatives should be considered, in view 
of identifying optimised leads. In general, 128 and 130 did not evidence inhibitory 
capacity towards cytochromes P450 isoforms, the exception being the CYP2C8 isoform 
(with strong and moderate inhibitory capacity observed for 128 and 130, respectively). 
Quinolone derivative 130 has activity close to isoniazid versus M. tuberculosis 
and, therefore, synthesis of some derivatives should be considered, in view of selecting 
analogues with improved properties for development. 
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Appendix 2 – Chemical characterization of compounds synthesized in 
this project and described in Chapter two. 
 
Figure S1 – Mass spectrum of ethyl 7-benzoyloxy-4-oxo-quinoline-3-carboxylate (13). 
 
 
Figure S2 – 1H-NMR spectrum of ethyl 7-benzoyloxy-4-oxo-quinoline-3-carboxylate (13) (400 
MHz; D6-DMSO) and structural representation of the compound showing the chemical shifts 
(ppm) predicted for 1H-NMR, obtained using MestReNova software. 
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Figure S3 – 13C-NMR spectrum of ethyl 7-benzoyloxy-4-oxo-quinoline-3-carboxylate (13) (101 
MHz; D6-DMSO) and structural representation of the compound showing the chemical shifts 
(ppm) predicted for 13C-NMR, obtained using MestReNova software. 
 
Figure S4 – 1H-NMR spectra (range of chemical shifts for aromatic protons) of ethyl 7-
benzysothiazoloxy-4-oxo-quinoline-3-carboxylate (31) and Dowtherm A, superimposed (400 
MHz; D6-DMSO). Structural representation of 31 showing the chemical shifts (ppm) predicted 
for 1H-NMR, obtained using MestReNova software. 
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Figure S5 – Mass spectrum (by EI) of ethyl 7-(1-phenyl-1H-diazirin-3-yl)oxy-4-oxo-quinoline-
3-carboxylate (32b). 
 
Figure S6 – 13C-NMR spectrum (from 165 to 100 ppm) of ethyl 7-(1-phenyl-1H-diazirin-3-
yl)oxy-4-oxo-quinoline-3-carboxylate (32b) (101 MHz; D6-DMSO). Structural representations of 
32b and 32c showing the chemical shifts (ppm) predicted for 13C-NMR, obtained using 
MestReNova software. 
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Figure S7 – ORTEPII plot of ethyl 3-((3,4-difluorophenyl)amino)-2-((3,4-
difluorophenyl)carbamoyl) acrylate (44b), in the crystal (from single crystal XRD data). Atoms 
F2# and F3# are, approximately, 20% of F2 and F3 atoms and 80% of H atoms. Fluorinated 
benzene rings have rotational through dihedrals C10-C11-N2-C14 and C7-N1-C8-C12. 
 
Figure S8 – ORTEPII plot of 1,3-bis(3,4-difluorophenyl)urea (44c), in the crystal (from single 
crystal XRD data). 
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Figure S9 – Mass spectra of 1-methyl-5-aminotetrazole (52) – top frame – and 2-methyl-5-
aminotetrazole (53) – bottom frame – with a representation of the fragmentation patterns. 
 
Figure S10 – 13C-NMR spectrum of the isomeric mixture of ethyl 7-methoxy-4-oxo-quinoline-
3-carboxylate (84a) and ethyl 5-methoxy-4-oxo-quinoline-3-carboxylate (84b) (101 MHz; D6-
DMSO). Structural representations of 84a and 84b showing the chemical shifts (ppm) predicted 
for 13C-NMR, obtained using MestReNova software. 
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Appendix 3 – Structural investigation of selected quinolone derivatives, 
as discussed in Chapter three. 
 
 
Figure S11 - B3LYP/LANL2DZ+cc-pVDZ calculated relaxed potential energy proﬁles for 
internal rotation around the C–O ester bond of 56, showing interconversion pathways between 
conformers aa and ag± (top), and between sa and sg± (bottom). 
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Figure S12 - B3LYP/LANL2DZ+cc-pVDZ calculated relaxed potential energy profiles for 
internal rotation around the C–C bond connecting the ester substituent to the ring system of 56, 
showing the interconversion pathways between conformers aa and sa (top), and between ag+ and 
sg+ (bottom). A similar potential energy profile to this latter exists for the interconversion between 
ag- and sg-. 
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Table S1 - Assignment of the infrared spectra for matrix isolated 56 (15 K), as well as for the neat solid glassy state and crystalline compound. a 
Approximate Experimental      Calculated          
Description b Ar matrix (15 K)  Glass (43 K)  Crystal (17 K) c sa   aa   sg   ag  
        IIR   IIR   IIR   IIR 
CH s Ph 3098.4  3097.4  3105.0  3157.2 1.1  3156.5 1.2  3157.6 1.1  3157.7 0.7 
CH Ph 3098.4  3097.4  3105.0  3153.0 0.3  3155.0 0.3  3154.3 0.3  3155.6 0.8 
CH as Ph 3071.7  3068.8  3088.1  3140.0 1.2  3138.0 1.1  3141.1 1.2  3139.6 1.0 
CH Py 3071.7  3068.8  3088.1  3132.9 2.3  3119.6 0.5  3132.7 2.2  3118.3 0.5 
CH as" 3003.4  2984.3          3074.2 21.5  3075.1 19.5 
 2998.3  2984.3  2991.0  3057.9 31.3  3060.5 29.5       
CH as'  2991.8  2984.3  2980.3  3051.8 22.8  3052.8 23.1  3054.4 6.9  3055.0 5.8 
CH as 2991.8  2984.3          3045.0 23.3  3046.0 23.4 
 2967.4  2945.2  2938.8  3025.7 7.0  3028.4 6.9       
CH s 2950.8  2945.2          3007.0 32.1  3007.5 27.4 
 2940.0  2932.4  2928.0  2985.8 18.5  2987.6 18.0       
CH s 2920.5  2908.9  2913.1  2975.1 17.2          
 2917.0  2908.9       2976.6 15.3  2973.8 17.8  2974.1 17.8 
C=O 1754.8/1749.0/1747.4  1743.8          1759.0 216.4    
 1753.4/1744.8/1740.7/1738.3 1732.7  1733.9/1727.8 1760.7 224.5          
 1732.6/1723.9/1720.2  1715.2       1734.7 280.2     1733.4 270.2 
C=C Ph 1602.1  1597.2       1603.8 151.9  1604.2 160.0  1604.0 152.9 
 1595.8/1590.0  1591.5  1597.8/1590.1 1604.2 160.4          
C=N Py 1599.6  1582.8       1596.6 63.2  1590.9 111.0  1596.3 66.4 
 1581.4  1582.8  1584.4/1577.4 1590.9 107.5          
C=C Ph 1551.8  1548.9  1552.0/1548.7 1551.2 59.7  1550.1 60.8  1551.1 59.4  1550.0 60.8 
C=C Py 1484.0  1479.8       1464.9 59.3     1464.9 55.3 
 1471.3  1471.0  1466.1  1466.3 104.4     1465.9 114.6    
CH 1460.5  1471.0  1456.2  1459.8 13.7  1459.3 2.4       
 1455.7  1448.0          1447.6 7.2  1448.2 15.4 
CH as' 1448.2  1438.5  1436.6  1438.3 6.9  1438.5 1.2  1429.5 13.1  1436.6 33.4 
CC Ph 1448.2  1438.5  1436.6  1437.3 3.3  1436.1 28.1  1437.1 8.6  1429.0 15.1 
CH as" 1438.9  n.obs  1430.7  1424.8 6.3  1424.5 6.5  1424.8 10.6  1424.4 11.4 
C=C Ph 1401.4  1395.0       1399.8 88.3     1398.7 87.7 
 1397.1  1389.7  1391.0  1396.7 15.2     1396.4 15.8    
CH s 1387.8  1389.7  1385.0  1383.7 3.6  1383.6 8.7       
 1383.6  1389.7          1380.3 10.0  1379.3 4.8 
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CH Ph 1374.1  1372.2  1372.0/1370.0 1365.1 53.4     1363.6 43.6    
 1371.4  1372.2       1360.1 3.1     1358.7 12.6 
 1361.5  1359.9       1351.3 68.0  1350.4 13.6  1353.3 54.1 
wCH2 1359.7  1359.9  1357.2/1353.8 1345.7 20.4          
CH Py 1340.9  1339.2  1337.9  1335.5 39.1     1335.7 45.2    
 1337.0  1321.7       1329.2 10.5     1329.6 14.0 
CC Py 1322.4  1321.7       1314.9 280.2     1317.1 248.4 
 1297.8  1299.6  1302.3/1291.1 1298.7 15.1     1300.5 14.7    
tw CH2 1287.9  1299.6          1292.2 15.3  1290.7 15.4 
C-O 1270.3  1282.8       1259.6 305.7     1258.1 253.8 
tw CH2 n.obs.  n.obs.  n.obs.  1252.6 1.1  1253.1 1.1       
CH Ph 1266.7  1271.3  1271.7/1262.6 1248.5 321.3     1249.5 267.3    
CH2 Ph 1235.8  1232.0 d  1228.2/1217.1 1221.1 208.9     1220.8 172.6    
 1232.1         1218.4 154.4     1216.8 149.6 
CH2 Ph 1206.5         1205.1 3.0     1204.9 14.4 
C-O 1201.6/1195.5  1199.1  1197.9  1191.8 240.6          
 1196.0/1192.3  1199.1          1189.6 202.3    
CH2 1164.7  1174.2          1164.0 127.5  1161.9 65.7 
CH2 Ph 1163.0  1162.7 d  1165.8  1156.8 184.5          
 1157.9         1150.1 118.8  1146.7 66.5  1144.8 49.1 
CH2 1143.4  1160.1  1161.2  1139.6 4.0  1138.6 4.5       
CC Ph 1140.0  1135.1 d  1142.2  1137.9 16.4          
 1129.0         1132.5 95.7  1133.3 76.1    
 1119.6               1129.1 149.2 
C-CH3 1117.6  1116.5  1118.2  1104.5 20.9  1106.4 21.7       
 1097.4  1095.9          1086.0 35.7  1085.7 17.7 
CC Ph 1058.2  1059.7  1063.8  1048.6 29.4  1048.3 22.1  1049.2 27.1  1048.5 22.5 
O-C 1042.5  1033.7 d  1034.3  1036.3 93.5          
 1040.7            1031.2 80.4    
 1031.6         1024.3 54.0       
 1025.4               1018.7 37.0 
ring Py 1011.7  1009.8  1012.8  992.2 35.2  994.0 11.3       
 999.9  1009.8          982.0 31.4  982.8 15.7 
CH2 as Ph 963.1  998.5  1005.8  969.9 0.6  971.2 3.9  969.7 0.6  969.4 3.5 
CH Py 951.0  998.5       965.0 0.6     963.9 1.7 
 949.1  944.6  940.4  953.9 3.5     954.4 3.5    
C-C(=O) 921.6  922.4  922.4  908.1 42.3          
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CH Ph 917.9  915.8  917.0  904.9 5.9  905.7 6.2  905.5 5.8  905.8 6.1 
C-C(=O) 911.1  910.0       900.9 40.5       
 889.0  885.8          896.7 49.4  895.9 40.8 
CH3' 872.0  885.8       866.2 9.2       
 857.8  854.6  856.0  861.1 0.5          
 855.2  846.9          853.3 1.7  856.9 9.4 
C-Cl 819.7  825.0  838.4/824.6  836.9 48.9     836.6 47.5    
 817.1  819.5/816.2       835.7 52.9     835.6 52.4 
CH2 s Ph 811.9  812.8  812.8  831.0 10.4  829.1 10.7  830.8 10.4  828.9 10.6 
OCC 790.0  785.5  790.8  799.6 57.8  805.3 38.8  809.2 30.5  813.7 22.5 
CH3" 783.9  774.5  788.7  792.2 7.9  792.8 3.8       
ring Ph 776.0  759.7  760.1  786.3 11.6  785.7 16.0  789.1 18.5  787.5 19.9 
ring Ph 760.0  755.9          759.1 17.3  760.9 18.4 
C=O   755.9  741.5  756.9 3.9  757.6 4.5  756.8 9.1  758.3 4.3 
ring Py 699.2  698.3       691.4 30.4     688.5 27.5 
 691.7  689.5  689.4  683.3 23.6     683.5 22.9    
                 
                 
ring Ph 634.1  635.1  635.1  632.8 3.2  634.5 3.5  633.3 2.9  635.4 3.3 
C-I n. obs.  631.5  631.5  621.2 2.7  627.6 2.1  622.6 3.4  627.1 1.6 
CCl 595.6  593.5  593.4/589.5  596.3 1.8  595.0 1.8  596.4 2.2  595.7 2.3 
CC=O 573.6  n.obs.  579.3  567.4 7.6     564.9 7.9    
 567.0  n.obs.       556.9 2.7     557.6 2.2 
CCl 532.0  534.6  534.6  527.0 5.0  525.5 4.2  525.4 4.6  526.2 3.7 
a Wavenumbers () in cm–1; calculated intensities (IIR) in km mol–1; the calculated wavenumbers were scaled by 0.978.  b , stretching; , bending; , rocking; 
w, wagging; tw, twisting; , torsion; Py, pyridine ring; Ph, Phenyl ring; s, symmetric; as, anti-symmetric. c Assignments refer to the sa conformer, which 
constitutes the molecular unit in the crystal. d Bands observed for the glassy phase at 1232.0, 1162.7, 1135.1 and 1033.7 cm–1 exhibit very broad profiles and 
shall correspond to superposition of several bands belonging to different conformers present in this phase (in the Table the frequencies of these bands are 
presented in the first row of the set of rows to which they correspond, to avoid extensive repetition). 
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Figure S13 - ORTEP drawing of 56, showing the atom numbering scheme. Ellipsoids were drawn 
at the 50% probability level. 
 
 
Figure S14 - Projection of the crystal structure along the c-axis, showing the molecular packing 
diagram (top), and along the a-axis (bottom), highlighting the layered nature of the molecular 
packing.  
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Figure S15 - ORTEPII plot of ethyl 4-hydroxy-5-methyl quinolinium chloride 3-carboxylate 
(82b.HCl) in the crystal of the compound, showing the anisotropic displacement ellipsoids drawn 
at the 50% probability level. For clarity, only the major component of the disordered ethyl group 
is shown. 
 
 
Figure S16 - 1H-NMR spectrum of ethyl 7-methyl-4-oxo-quinoline-3-carboxylate (82a) (400 
MHz; D6-DMSO). Atoms identification (A) and predicted chemical shifts (ppm) for 1H-NMR 
(B), obtained using MestReNova software and considering the literature, are shown.205 
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Figure S17 - 13C-NMR spectrum of ethyl 7-methyl-4-oxo-quinoline-3-carboxylate (82a) (101 
MHz; D6-DMSO). Atoms identification (A) and predicted chemical shifts (ppm) for 13C-NMR 
(B), obtained using MestReNova software, are shown. 
 
Figure S18 - 1H-NMR spectrum of ethyl 7-methyl-4-oxo-quinoline-3-carboxylate (82a) (400 
MHz; D-Chloroform). H1 was observed around 12.20, but after calibration by TMS it was not 
possible to show this peak. 
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Figure S19 - 1H-NMR spectrum of ethyl 4-hydroxy-5-methylquinoline-3-carboxylate (82b) (400 
MHz; D6-DMSO). Atoms identification (A) and predicted chemical shifts (ppm) for 1H-NMR 
(B), obtained using MestReNova software and considering the literature, are shown.205 
 
Figure S20 - 13C-NMR spectrum of ethyl 4-hydroxy-5-methylquinoline-3-carboxylate (82b) (101 
MHz; D6-DMSO). Atoms identification (A) and predicted chemical shifts (ppm) for 13C-NMR 
(B), obtained using MestReNova software, are shown.  
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Figure S21 - 1H-NMR spectrum of ethyl 4-hydroxy-5-methylquinoline-3-carboxylate (82b) (400 
MHz; D-Chloroform).
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Table S2 - Observed IR frequencies for 82b in argon matrix (15 K) and B3LYP/6-
311++G(d,p) calculated frequencies and IR intensities for conformers 82bI and 82bII. a 
 
 
Table 3. Observed IR frequencies for 5Me-EHMQ in argon matrix (15 K) and B3LYP/6-
311++G(d,p) calculated frequencies and IR intensities for conformers I and II. 
a
 
Observed 
(Ar matrix; 15 K) 
Conformer I  Conformer II  Approximate 
  I
IR  I
IR Description b 
b 3208 555 3209 560 OH 
3068 3132 8 3132 8 CH r1 
3040 3109 19 3109 19 CH r1 
3032 
3100 4 3101 4 CH r2 
3094 9 3094 8 CH r1 
2994 
3051 34 3068 18 CH3 as et 
3043 23 3043 3 CH3 as 
3037 25 3043 28 CH3 as et 
3035 10 3035 10 CH3 as 
3026 1 3033 31 CH2 as 
2943 
2991 14 3010 23 CH2 s 
2977 22 2977 23 CH3 s 
2972 17 2970 18 CH3 s et 
1669/ 1665 1651 337 1650 321 C=O 
1624/ 1616 1611 282 1611 289 CC r2, COH 
1607 1606 12 1606 6 CC r1 
1596/ 1583/ 1573 1574 99 1574 97 CC r1,r2 
1504/ 1498 1496 84 1495 81 CC r1,r2 
1482 1485 6 1473 23 CH2 
1468 
1465 3 1465 19 CH3 as et 
1465 17 1459 11 CH3 as 
1458 1453 8 1455 11 CH3 as et 
1451/ 1448 1450 8 1450 8 CH3 as 
1441 1443 31 1442 28 CC r1,r2, CH r1 
1427/ 1422 1424 68 1423 72 COH 
1411 1406 25 1405 20 CH r2 
1406/ 1401 1400 73 1395 85 wCH2 
1396 1392 12 1391 11 CH3 s 
1387/ 1382 
1378 154 1377 140 CH3 s et 
1370 26 1370 24 CH r1 
1357/ 1349 1348 149 1349 162 CC r2, wCH2 
1330/ 1320 1309 83 1310 76 CC r1,r2 
1283/ 1277 
1271 424 1303 10 CC(=O), CH r2 
1269 1 1271 354 twCH2 
1245 1258 16 1257 12 CH r1 
1229 1221 16 1219 8 CC(H3), CC r2 
1208 1206 287 1204 269 CN, C-O 
1162 1157 93 1169 43 CH r1 
1151 1149 4 1155 53 CH3 et, CH2 
1136/ 1132 1133 97 1125 124 CC(=O), C-O(H) 
1117/ 1115/ 1108/ 1099 1107 13 1089 33 CH3 et 
1085 1083 3 1081 2 CC r1, CH3 
1041 1038 2 1038 2 CH3 
1040 1034 13 1034 13 CH3 
1031/ 1027/ 1021/ 1010 1013 89 1004 74 CC et 
n.obs. 978 1 979 1 CH r1 
977/ 974 968 22 965 21 CC r1, CH3 
950/ 949 941 7 943 7 CH r2 
932 923 17 909 16 r1,r2 
899 896 0.3 897 0.3 CH r1 
869 858 2 849 1 OC et 
842/ 839 825 108 828 105 OH 
823 814 32 817 24 r2 
813/ 810 806 12 807 15 CH r1 
807 796 0.4 803 5 r2 
804 795 5 782 16 CH2 
789 780 14 761 5 CH r1 
769 754 12 754 12 CC(=O) 
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676 
670 0.1 670 0.2 r1,r2 
666 1 667 1 r1 
613 621 1 622 1 r1 
595 604 2 601 3 r2 
575 563 0.4 564 0.1 r2 
526 522 2 521 2 r1 
n.obs. 489 0.1 490 0.2 r1 
489 484 2 483 3 wC(CH3) 
n.i. 
472 1 476 1 tr1,r2 
453 2 458 12 wC(C=O)O) 
401 34 404 4 CC=O 
360 1 387 30 CCO 
334 1 356 0.1 CCC et 
283 7 307 5 C=O, CH3 et 
277 6 271 4 COC 
255 3 255 3 r1,r2 (butterfly) 
247 0.3 249 0.4 CH3 et 
223 1 225 1 CH3 
213 2 220 2 OCC et 
192 0.04 190 0.03 r1,r2 
119 1 136 2 C-O 
113 0.1 113 0.1 C-O et 
93 1 95 0.1 COC, OCC et 
71 0.2 73 0.2 r2 
57 2 43 0.2 C(C(=O)O) 
16 0.4 41 2 O-C et 
a
 Wavenumbers () in cm-1; IR intensities (IIR) in km mol-1. b Assignments and approximate descriptions are 
specific for conformer I; , stretching; , in-plane-bending; , out-of-plane rocking; , torsion; w, wagging; tw, 
twisting; r1 and r2 refers to the benzene and heteroaromatic ring, respectively; et, ethyl group; s, symmetric; as, 
anti-symmetric; n.obs., non-observed; n.i., not investigated. 
b
 As it is common when the molecule contains a 
very strong intramolecular H-bond, the OH band is very broad and difficult to distinguish from the baseline. 
Moreover, in the present case the spectral region when it is expected to occur is quite congested due to the 
presence of the bands due to the CH stretching modes and also those due to the stretching vibration of the co-
deposited H-Cl (see experimental description). Under these circumstances, we let opened to investigation the 
precise assignment of this vibration.  
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Figure S22 - Comparison of the B3LYP/6-311++G(d,p) calculated IR spectra of the most stable 
conformers of 82b, 82c and 82d, with the experimental IR spectrum of compound 82b, obtained 
in argon matrix (15 K). 
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